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CHAPTER 1
THE GUILLAIN-BARRÉ SYNDROME, AN INTRODUCTION
Adapted from
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
P.A. van Doorn, L.Ruts, B.C. Jacobs
Lancet Neurology 2008;7:939-950 (review) 
Autonome dysfuncti e bij pati ënten met het Guillain-Barré syndroom 
L. Ruts, B.C. Jacobs, J.P. Blankevoort, P.A. van Doorn
Tijdschrift  Neurologie & Neurochirurgie 2008;109:118-124
Transient hypertrichosis in a pati ent with Guillain-Barré syndrome
L. Ruts, J.P. Blankevoort, E.P. Prens, P.A. van Doorn
J Peripher Nerv Syst. 2007;12:290-292
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AIMS ΈCASEͳILLUSTRATEDΉ
The Guillain-Barré syndrome (GBS) is an immune-mediated polyneuropathy. Unti l now, 
GBS remains a descripti ve diagnosis for which there are no specifi c diagnosti c tests. 
The combinati on of rapidly progressive symmetrical weakness in arms and legs with or 
without sensory disturbances, hypo- or arefl exia, in the absence of a cerebrospinal fl uid 
(CSF) cellular reacti on, remains the hallmark for the clinical diagnosis of GBS (1,2). 
 In GBS, there is a broad spectrum of clinical symptoms and severity in the acute phase. 
During the subsequent course of disease, the presence and severity of residual symptoms 
is highly variable. In most treatment studies only severely aff ected pati ents (those being 
unable to walk without assistance; GBS disability scale grade 3-5) have been included. 
Because progressive paralysis is the most striking and alarming symptom of GBS, most 
att enti on generally is given to the rapid progression and severity of weakness in the acute 
phase. There are however some underexposed but important issues in GBS like residual 
fi ndings in parti cular in pati ents which limited weakness (mildly aff ected pati ents), 
a fl uctuati ng course aft er initi al improvement (treatment related fl uctuati ons (TRF)), 
the transiti on to chronic infl ammatory demyelinati ng polyneuropathy (CIDP) and the 
frequency and nature of pain and autonomic dysfuncti on that have been studied limited 
so far. These issues have formed the basis of the studies described in this thesis. 
 The following cases illustrate the importance of these underexposed issues. 
Case | Residual fi ndings in mildly aff ected pati ents
A 52-years-old man, without signifi cant medical history, was admitt ed because of distal 
limb weakness, numbness and ti ngling in his toes. He was diagnosed with GBS. Maximal 
weakness was reached 12 days aft er onset. At that moment he was sti ll able to walk 
unaided, but unable to run (‘mildly aff ected pateint’ with GBS disability scale grade 2). Six 
months later he visited the outpati ent clinic. Rather unexpected for the pati ent and his 
neurologist, he was sti ll unable to run, suff ered from severe fati gue and had burning pain 
in his feet.
Case | GBS with a fl uctuati ng course
A 60-years-old man, without signifi cant medical history, was admitt ed with rapidly 
progressive limb weakness and ti ngling in the lower limbs. GBS was diagnosed. He was 
treated with intravenous immunoglobulins (IVIg). Maximal weakness was reached 18 days 
aft er onset. At that moment he could walk with support (GBS disability scale grade 3). 
Aft er nadir, he improved in strength and aft er one week he was able to walk unaided. 
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However, at day 25 aft er onset the pati ent deteriorated again and needed support to 
walk again. This raised doubt about the diagnosis GBS. It was considered that (aft er all) 
the diagnosis of CIDP with an acute onset (A-CIDP) could also be possible. For treatment 
strategy and the prognosis it was relevant to disti nguish between GBS with treatment 
related fl uctuati ons (GBS-TRF) and A-CIDP as soon as possible. It was decided to retreat 
the pati ent again with IVIg, whereaft er the pati ent improved and was able to walk unaided 
again. Unexpectedly, the pati ent deteriorated again at day 42 aft er onset. The diagnosis 
A-CIDP was suggested again and the third IVIg treatment course was given. Aft er one year 
the pati ent visited the outpati ent clinic. He was recovered completely, and he had had no 
further deteriorati ons. In retrospect, the diagnosis GBS-TRF was more likely than A-CIDP.
Case | Pain
A 25-years-old man, without signifi cant medical history, was admitt ed because of rapidly 
progressive limb weakness, numbness and ti ngling in the lower limbs. GBS was diagnosed. 
Shortly aft er admission, he became bedridden and required mechanical venti lati on (GBS 
disability scale grade 5) despite IVIg treatment. During the period at the intensive care 
unit (ICU), he had severe pain in the extremiti es. Due to the mechanical venti lati on, it was 
diffi  cult to communicate. Aft er extubati on and discharge from the ICU he stressed that 
the pain he suff ered from was one of the most severe symptoms of GBS and a traumati c 
experience. Three years later, aft er rehabilitati on, he visited the outpati ent clinic. He was 
able to walk unaided and doing his previous job. However, he sti ll suff ered from burning 
pain in his feet. 
Cases | Autonomic dysfuncti on 
Autonomic dysfuncti on occurs in GBS. GBS pati ents can even die from unpredictable 
(sudden) autonomic dysfuncti on (heart rhythm disturbances). Four GBS pati ents with 
autonomic dysfuncti on are described into more detail.
 
  A 56-years old man with GBS became bedridden and needed arti fi cial venti lati on (GBS 
disability scale grade 5). Besides severe weakness in the extremiti es and a bilateral facial 
palsy he developed a ptosis, miosis and anhidrosis on the right side (Horner’s syndrome) 
(fi gure 1). Also severe blood pressure oscillati ons and episodic tachycardia did occur (3).
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Figure 1 | GBS pati ent with unilateral anhidrosis (right side) in the acute phase due to autonomic 
(sympatheti c) failure (with permission from the pati ent)
  A 47-years-old woman with severe GBS, bedridden and venti lated (GBS disability scale 
grade 5), developed light-reacti ve dilatati on of the right pupil with normal extra-ocular 
eye movements and without ptosis (fi gure 2). Also severe blood pressure oscillati ons 
and episodic tachycardia did occur (3).
Figure 2 | GBS pati ent with pupil dilatati on (right side) in the acute phase due to failure of the 
parasympatheti c branch of the oculomotor nerve (with permission from the pati ent).
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  A 58-years-old woman with GBS and diabetes and hypertension in medical history 
became bedridden and needed arti fi cial venti lati on (GBS disability scale grade 5). She 
had three ti mes a cardiac asystole and was reanimated successfully. She later visited the 
outpati ent clinic with very limited residual defi cit (3).
  A 20-years-old woman with GBS, without relevant medical history, became bedridden 
and needed arti fi cial venti lati on (GBS disability scale grade 5). She developed excessive 
hair growth on parts of her body (limbs, trunk, back) defi ned as hypertrichosis (fi gure 
3a). She also had excessive sweati ng, blood pressure fl uctuati ons, hypertension, heart 
rate fl uctuati ons, tachycardia and long-lasti ng diarrhoea. These fi ndings (including the 
excessive hair growth) are highly suggesti ve for widespread autonomic dysfuncti on. 
At 6-month follow-up, she had no residual motor or sensory defi cits and no further 
symptoms of autonomic dysfuncti on. Her hair growth had normalised (fi gure 3b) (3,4).
Figure 3 | GBS pati ent (women) with hypertrichosis in the acute phase (A) and normalised hair 
patt ern aft er 6 months (B) possibly due to involvement of the small nerve fi bres in the skin (with 
permission from the pati ent)
 These cases illustrate the need to study into more detail the outcome in GBS subgroups 
like mildly and severely aff ected GBS pati ents, the disti ncti on between GBS-TRF and A-CIDP 
and the understanding and treatment of pain and autonomic dysfuncti on in GBS. These 
issues were the basis of this thesis. 
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The aims of this thesis were:
  To provide more insight in the course of disease, the presence and severity of residual 
fi ndings and the frequency and nature of pain and autonomic dysfuncti on in GBS;
  To study involvement of small diameter nerve fi bres in GBS, because these fi bres play a 
key role in pain conducti on and autonomic functi ons;
  To delineate subgroups of GBS pati ents having a high chance to develop A-CIDP, pain or 
autonomic dysfuncti on;
  To identi fy possible (new) factors related to outcome in subgroups of GBS.
Before describing the objecti ves and outline of this thesis, some background informati on 
is provided about the clinical manifestati ons, diagnosis, pathogenesis and treatment of 
GBS in a general introducti on.
GENERAL INTRODUCTION
Diagnosis
GBS is most commonly a post-infecti ous disorder that usually occurs in otherwise healthy 
people, not typically associated with an autoimmune or other systemic disorder. The 
incidence of GBS is reported to be 1.2-2.3/100.000/year (5-11). Most studies found 
that the incidence increases linearly with age and that men are about 1.5 ti mes more 
frequently aff ected than women (6,7,9). The main features of GBS are rapidly progressive 
bilateral and relati vely symmetric weakness of the limbs with or without involvement of 
respiratory or cranial-nerve-innervated muscles (1,2). Diagnosti c criteria for typical GBS 
are shown in table 1. Weakness might equally aff ect all limb muscles, or predominantly 
the distal or proximal muscles in arms or legs. Pati ents have decreased or absent deep-
tendon refl exes, at least in the aff ected limbs. A lumbar puncture is almost always done in 
pati ents suspected to have GBS. CSF examinati on typically shows an increased protein with 
normal CSF white-cell count. An increased CSF protein however may be absent especially 
in the fi rst week aft er onset of weakness. Electromyography can be helpful to confi rm 
the diagnosis in clinically diffi  cult cases such as in pati ents who have extreme pain, and 
in parti cular is needed for subclassifying GBS into the subgroups of acute infl ammatory 
demyelinati ng polyneuropathy (AIDP) being the most frequently occurring form of GBS in 
the Western-world; and in acute motor axonal neuropathy (AMAN) (12). Some features 
that could raise doubt about a diagnosis of GBS are listed in table 1. 
 Clinical manifestati ons of GBS can vary, and an extensive number of other disorders 
could cause similar features of acute neuromuscular paresis (table 2). The diagnosis of 
GBS can be diffi  cult, parti cularly in pati ents with asymmetric weakness, in those with 
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weakness initi ally only in the arms, in pati ents with rapidly progressive deteriorati on in 
pulmonary functi on with relati ve preservati on of muscle force in the extremiti es, and in 
pati ents with prominent pain or autonomic dysfuncti on as the presenti ng symptom (13). 
Table 1 | Diagnosis of typical GBS, table adapted from Asbury (1) 
Features required for diagnosis
  Progressive weakness in both arms and both legs (might start with weakness only in the legs)
  Arefl exia (or decreased tendon refl exes)
Features strongly supporti ng diagnosis
  Progression of symptoms over days to 4 weeks
  Relati ve symmetry of symptoms
  Mild sensory symptoms or signs
  Cranial nerve involvement, especially bilateral weakness of facial muscles
  Autonomic dysfuncti on
  Pain (oft en present)
  High concentrati on of protein in CSF
  Typical electrodiagnosti c features
Features that should raise doubt about the diagnosis
  Severe pulmonary dysfuncti on with limited limb weakness at onset
  Severe sensory signs with limited weakness at onset
  Bladder or bowel dysfunti on at onset
  Fever at onset
  Sharp sensory level
  Slow progression with limited weakness without respiratory involvement 
(consider subacture infl ammatory demyelinati ng polyneuropathy or CIDP)
  Marked persistent asymmetry of weakness
  Persistent bladder or bowel dysfuncti on
  Increased number of monouclear cells in CSF (> 50x106/l)
  Polmorphonuclear cells in CSF
CIDP = chronic infl ammatory demyelinati ng polyneuropathy
 About two-third of pati ents have symptoms of an infecti on in the three weeks prior 
to the onset of weakness. One Japanese study found that the most frequent antecedent 
symptoms in GBS and related disorders were fever (52%), cough (48%), sore throat (39%), 
nasal discharge (30%), and diarrhoea (27%) (14). In most GBS studies symptoms of a 
preceding infecti on of the upper respiratory tract or gastrointesti nal tract predominate, 
although many other types of infecti ons have been reported. Furthermore, an argument 
for the post-infecti ous nature of GBS is the usually typical monophasic clinical course of 
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the disease. The most frequently identi fi ed cause of infecti on is Campylobacter jejuni. 
Other well defi ned types of infecti on related to GBS are cytomegalovirus (CMV), Epstein-
Barr virus (EBV), Mycoplasma pneumoniae, and Haemophilus infl uenzae (15-17). 
Table 2 | Diff erenti al diagnosis of GBS
Intracranial/spinal cord abnormaliti es
  Brain stem encephaliti s, meningti s carcinomatosis/lymphomatosis, transverse myeliti s, cord 
compression
Anterior horn cells abnormaliti es
  Poliomyeliti s, West-Nile virus
Spinal nerve roots
  Compression, infl ammati on (e.g. cytomegalovirus), leptomeningeal malignancy
Peripheral nerves abnormaliti es
  CIDP, drug-induced neuropathy, porhyria, criti cal illness polyneuropathy, vasculiti s, diphteria, 
vitamin B1 defi ciency (beri-beri), heavy metal or drug intoxicati on, ti ck paralysis, metabolic 
disturbances (hypokalaemia, hypophosphataemia, hypermagnesaemia, hypoglycaemia)
Neuromuscular juncti on abnormaliti es
  Myasthenia gravis, botulism, organophosphate poisoning
 Muscular abnormaliti es
  Criti cal illness polyneuromyopathy, polymyositi s, dermatomyositi s, acute rhabdomyolysis
CIDP = chronic infl ammatory demyelinati ng polyneuropathy
Pathogenesis
Studies in pati ents and  animals have provided convincing evidence that GBS, at least in 
some cases, is caused by an infecti on-induced aberrant immune response that damages 
peripheral nerves (18-25). Four key factors have been identi fi ed that control this process 
(fi gure 4). 
Anti ganglioside anti bodies 
In about half of the pati ents with GBS, serum anti bodies to various gangliosides have be 
found in human peripheral nerves, including LM1, GM1, GM1b, GM2, GD1a, GalNAc-
GD1a, GD1b, GD2, GD3, GT1a, and GQ1b (21,23,26-36). Other anti bodies might bind to 
mixtures or complexes of diff erent gangliosides instead of individual gangliosides (37-
40). These gangliosides have a specifi c ti ssue distributi on in peripheral nerves and are 
organised in specialised functi onal microdomains called ‘lipid raft s’, and play a part in the 
maintenance of the cell membrane structure (41). Interesti ngly, most of these anti bodies 
are specifi c to defi ned subgroups of GBS. Anti bodies to GM1, GM1b, GD1a and GalNAc-
GD1a are associated with the pure motor or axonal variants of GBS, whereas anti bodies 
to GD3, GT1a and GQ1b are related to ophthalmoplegia and Miller Fisher syndrome (MFS) 
(table 3) (6,21,31,42). 
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Figure 4 | Immunobiology of GBS (with permission from Lancet Neurology) 
AP = anti gen presenti ng cell; PC =  plasma cell; B = B-cell; T = T-cell
Legend: Infecti ons (eg, with Campylobacter jejuni) might induce an immune response that fi nally leads to GBS. 
The immune response depends on certain bacterial factors, such as the specifi city of lipo-oligosaccharide (LOS), 
and on the pati ent-related (host) factors. Geneti c polymorphisms in the pati ent might parti ally determine the 
severity of GBS. Anti bodies to LOS can cross-react with specifi c nerve gangliosides and can acti vate complement. 
The extent of nerve damage depends on several factors. Nerve dysfuncti on leads to weakness and might cause 
sensory disturbances. The outcome in pati ents with GBS varies. Clinical prognosti c factors are: age, severity at 
onset and diarrhoea.
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Table 3 | Spectrum of GBS and serum anti -ganglioside anti bodies
GBS subgroup Anti bodies
Acute infl ammatory demyelinati ng polyradiculoneuropathy 
(AIDP)
Unknown
Acute motor (and sensory) axonal neuropathy (AMAN or 
AMSAN)
GM1, GM 1b, GD1a, GalNAc-GD1a
Miller Fisher syndrom (MFS) and GBS overlap syndrome GD3, GT1a, GQ1b
Although there is a relati on between the presence of these anti bodies and the clinical 
symptoms and severity of GBS, the pathological signifi cance of some of these anti bodies 
has yet to be established. Anti bodies to other glycolipids, and even anti bodies and T-cells 
to peripheral nerve proteins, have also been found in pati ents with GBS. Despite intensive 
research over the past two decades, the immune target is sti ll unknown in a substanti al 
group of pati ents with GBS. This is parti cularly the case in pati ents with the sensory-motor 
AIDP, the most frequent variant in developed countries.
Molecular mimicry and cross-reacti vity
Campylobacter jejuni isolates from pati ents express lipo-oligosaccharides (LOS) that mimic 
the carbohydrates of gangliosides (43-45). The type of ganglioside mimic in Campylobacter 
jejuni seems to determine the specifi city of the anti ganglioside anti bodies and the 
associated variant of GBS. Campylobacter jejuni isolates from pati ents with pure motor or 
axonal GBS frequently express a GM1-like and GD1a-like LOS, whereas those isolated from 
pati ents with ophthalmoplegia or MFS usually express a GD3-like, GT1a-like or GD1c-like 
LOS (40,46,47). Anti bodies in these pati ents are usually cross-reacti ve, and recognise LOS 
as well as gangliosides or gangliosides complexes (40). GBS, at least in Campylobacter-
associated GM1-related cases, is thought to be a true case of molecular-mimicry-related 
disease (42,48). Molecular mimicry and cross-reacti ve immune responses have also been 
identi fi ed aft er some types of preceding infecti on, including Haemophilus infl uenzae (49). 
Complement acti vati on 
Post-mortem studies have shown that local complement acti vati on occurs at the side 
of nerve damage, such as the axolemma in pati ents with AMAN and the Schwann-cell 
membrane in pati ents with AIDP (50-52). 
Host factors
Less than 1 in 1000 pati ents with a Campylobacter jejuni infecti on will develop GBS (53). 
Epidemics or outbreaks of GBS have not been reported, not even in families infected with 
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a gangliosides-mimicking variant of Campylobacter jejuni (54). Host factors may infl uence 
the suscepti bility to GBS, or the extent of nerve damage and outcome. 
CLINICAL SPECTRUM AND OUTCOME
The extent and distributi on of weakness, sensory involvement and the neurophysiological 
characteristi cs varies tremendously between individuals with GBS. The most common 
subtype of GBS in Europe and North America is the sensory-motor form, AIDP (6). In Europe 
and North America fewer than 5 to 10% of pati ents have one of the axonal subtypes – 
AMAN or acute motor and sensory axonal neuropathy (AMSAN) (12,55-57). Facial nerve 
palsy is the most common form of cranial nerve involvement in GBS, occurring in at least 
70% of pati ents. Bulbar and oculomotor nerves are less oft en aff ected, except in pati ents 
with the anti GQ1b anti body syndromes (58). MFS is a cranial nerve variant of GBS. These 
pati ents typically have the triad of ophthalmoplegia, ataxia and arefl exia (31,42,59). MFS 
and overlapping syndromes involving cranial nerve dysfuncti on and limb weakness are 
probably more common in Japan than in Europe. The GBS varieti es have related and 
someti mes specifi c anti ganglioside anti bodies (21,23,26-28,31,32,34,35,42,60,61) (table 
3).
 Bickerstaff  brainstem encephaliti s is another overlapping syndrome that generally starts 
with cranial or peripheral nerve involvement, and can later progress to severe disturbances 
of consciousness and can even coma (58). Recogniti on of Bickerstaff  brainstem encephaliti s 
is important, because this disorder might improve aft er plasma exchange (PE), a treatment 
that despite the absence of a randomised controlled trial (RCT), could be off ered in this 
severe conditi on (58).
 Rapidly progressive weakness is the core clinical feature of GBS. By defi niti on, maximum 
weakness is reached within four weeks, but most pati ents have already reached their 
maximum weakness within two weeks (1,2). Pati ents then have a plateau phase of varying 
durati on, which ranges from days to several weeks or months. This phase is followed by 
a usually much slower recovery phase of varying durati on. In Europe about a quarter of 
pati ents with GBS remain able to walk without aid (mildly aff ected pati ents; GBS disability 
scale grade 1-2 ) (7,62,63). In pati ents with GBS who are admitt ed to hospital and are 
unable to walk unaided (severe aff ected pati ents; GBS disability scale grade 3-5), about 
25% need arti fi cial venti lati on predominantly because of weakness of the respiratory 
muscles. 
 RCTs that have investi gated the eff ect of IVIg or PE in pati ents who were unable to 
walk have concluded that about 20% of pati ents remained unable to walk unaided aft er 
6 months (64). Moreover, many pati ents remain otherwise disabled or severely fati gued 
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(65). Even 3-6 years aft er onset, GBS had great impact on social life and the ability to 
perform acti viti es (66-68). Therefore, GBS oft en remains a severe disease for which bett er 
treatment is required, at least in a proporti on of pati ents. The severity of GBS seems to be 
determined already in an early phase of the disease (69). 
 Detailed informati on about signs and symptoms in the acute phase, course of disease 
and outcome in the diff erent GBS subgroups as described above, could be helpful for 
clinical decision-making like whether and at which point of ti me there is an indicati on 
to start treatment and to guide the prognosis. It also may add to the pathophysiological 
understanding of GBS and fi nally to the insti tuti on of a bett er treatment. Diff erent GBS 
subgroups (MFS, mildly aff ected, severely aff ected pati ents) have been studied and the 
results are described in chapter 3.
 About 5-10% of pati ents with GBS deteriorate aft er initi al improvement or stabilisati on 
following IVIg treatment, a conditi on named ‘treatment-related fl uctuati on’ (TRF) (fi gure 5) 
(70). This oft en raises the questi on whether these pati ents might have CIDP with an acute 
onset (A-CIDP). The diff erence between GBS and CIDP is mainly based on the durati on of 
progressive weakness, which is less than 4 weeks in GBS, and, on the basis of research 
criteria, at least 8 weeks for CIDP (1,2,71). A subacute form between GBS and CIDP has 
been described (72). Some pati ents initi ally have a course like that of GBS, but fi nally turn 
out to have CIDP. 
Figure 5 | GBS, treatment related fl uctuati ons (TRF) and acute onset CIDP (A-CIDP)
Legend: IVIg=treatment with a course of IVIg (2g/kg bodyweight) over 2-5 days.
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 Studies that can help to disti nguish between GBS-TRF and A-CIDP in the early phase of 
disease haven been indicated because prognosis and treatment strategy largely diff er. We 
studied this into detail. The results are described in chapter 3.
PAIN
Pain is a common and severe symptom in pati ents with GBS. Recogniti on of pain is 
important, especially in pati ents unable to communicate due to intubati on. Pain as a 
presenti ng symptom before the onset of weakness might be confusing and can cause a 
delay in making a diagnosis of GBS. Pain has been described in up to 89% of pati ents with 
GBS (73-75). Diff erent symptoms of pain associated with GBS have been disti nguished 
during diff erent phases of disease: paraesthesia or dysaesthesiae, backache or root pain, 
meningism, muscle pain, joint pain and visceral pain (76). Pain in GBS can be very severe, and 
treatment is oft en far from successful. There are some reports on the eff ect of medicati on 
to relieve pain in GBS (77-83). Corti costeroids, opioids, gabapenti n, and carbamazepine 
are suggested to be eff ecti ve, although these reports are based on limited numbers of 
pati ents, mostly in open studies, and oft en all types of pain are included together. The 
likely origin of pain is multi factorial. Pain in the acute phase of GBS might be of nocicepti ve 
origin due to infl ammati on. Small-diameter nerves in the skin, among others responsible 
for nocicepti on, are aff ected in GBS. A reducti on of intraepidermal nerve fi bre density has 
been found in skin biopsies taken at the ankle from pati ents with GBS in the acute phase 
(84). Later in the course of disease, neuropathic pain might result from degenerati on and 
perhaps even regenerati on of sensory nerve fi bres. Recogniti on of the presence and type 
of pain is important because specifi c treatments can be off ered. Skin biopsies may be 
helpful to elucidate mechanisms that give rise to a painful neuropathy in GBS.
 The frequency and nature of the pain in GBS, however, needs to be further defi ned 
during the whole course of the disease in relati on to the clinical spectrum of GBS. This is 
of potenti al benefi t for the pati ent but also for the pathophysiological understanding of 
pain in GBS. All studies thus far conducted on pain in GBS included only a relati vely small 
number of cases with a limited set of clinical, electrophysiological and serological data. We 
studied pain in GBS extensively and the results are described in chapter 4. Skin biopsies 
have become an accepted tool for investi gati ng small nerve fi bres (85). We studied the 
number of intraepidermal nerve fi bres in skin biopsies from GBS pati ents in relati on pain, 
autonomic dysfuncti on and outcome, because small diameter nerve fi bres play a key role 
in pain conducti on and autonomic functi ons. The results are described in chapter 5.
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AUTONOMIC DYSFUNCTION
Autonomic dysfuncti on is a common complicati on in GBS and occurs in approximately 
two-thirds of pati ents (86-89). The extensive distributi on of autonomic nerves may result 
in an array of signs and symptoms due to sympatheti c and parasympatheti c failure or 
over-reacti vity. Symptoms include various types of cardiac arrhythmias, blood pressure 
fl uctuati ons, abnormal haemodynamic responses to drugs, sweati ng abnormaliti es, 
pupillary abnormaliti es, and bladder and bowel dysfuncti on. 
 Although autonomic dysfuncti on is usually of minor clinical importance, life-threatening 
cardiovascular complicati ons might develop. Three to 10% of pati ents with GBS die, and 
in some of these pati ents the cause is likely to be (sudden) autonomic dysfuncti on (88). 
Therefore, recogniti on of autonomic dysfuncti on is important. Predicti ng which pati ents 
will develop serious autonomic dysfuncti on and will therefore need conti nue monitoring 
is not yet possible. Potenti ally serious bradyarrhythmias, ranging from bradycardia to 
asystole, have been found in severely disabled pati ents, but also in pati ents who were 
sti ll able to walk (90). Frequent monitoring of autonomic dysfuncti on is recommended 
in all pati ents with GBS (91). In some cases, applicati on of a transcutaneous pacemaker 
is indicated or atropine has to be given. In general, vasoacti ve medicati on and morphine 
derivati ves should be used with cauti on. Autonomic nerve fi bres can be studied in skin 
biopsies, and a correlati on between reduced intraepidermal nerve fi bre density values in 
skin biopsies from pati ents with GBS who have clinical autonomic dysfuncti on has been 
described once (84). 
 Detailed informati on about autonomic functi ons in relati on to the clinical spectrum of 
GBS needs to be studied into more detail, since this is of potenti al benefi t for the pati ent 
but also for the pathophysiological understanding of autonomic dysfuncti on in GBS. We 
performed further studies on autonomic functi ons in diff erent GBS subgroups (MFS, 
mildly and severely aff ected pati ents) and on intraepidermal nerve fi bre density values in 
skin biopsies from GBS pati ents with or without autonomic dysfuncti on. The results are 
described in chapter 3 and 5.
CARE AND TREATMENT
Pati ents with GBS are in parti cularly need of excellent multi disciplinary care to prevent 
and manage potenti ally fatal complicati ons (91). Thus, pati ents need careful and regular 
monitoring of pulmonary functi on (at least vital capacity and respirati on frequency) and 
possible autonomic dysfuncti on (heart beat frequency, blood pressure), and infecti ons 
need to be prevented of (92). Among other issues that need att enti on already early in the 
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course of disease are prophylaxis for deep-vein thrombosis, other symptoms of autonomic 
dysfuncti on (ilieus, pupil light unresponsiveness), recogniti on and management of pain, 
physiotherapy, rehabilitati on and psychosocial support (91). Many pati ents and their 
relati ves benefi t from joining a pati ent organisati on (eg, GBS/ Chronic Infl ammatory 
Demyelinati ng Polyneuropathy [CIDP] Foundati on Internati onal (www.GBS-CIDP.org), the 
UK GBS Support Group (www.gbs.org.uk) or the Dutch Associati on of Muscle Diseases 
(www.vsn.nl).
 The fi rst large trial to show a positi ve eff ect of immunotherapy on GBS was the North-
American PE study (93). This positi ve eff ect was confi rmed by a large French PE trial 
(94,95). PE was benefi cial when applied within the fi rst 4 weeks of onset, but the largest 
eff ect was seen when started early (within the fi rst two weeks) (93,96). The usual regimen 
is a fi ve ti mes PE during 2 weeks, with a total exchange of about fi ve plasma volumes. The 
fi rst RCT on the use of IVIg was published in 1992, and showed that IVIg is as eff ecti ve as 
PE (97). Since the publicati on of these results, IVIg, in a regimen of 0.4 g/kg bodyweight/
day for 5 consecuti ve days, has replaced PE as the preferred treatment in many centres, 
mainly because of its greater convenience and availability. The Cochrane review on the 
use of IVIg in GBS contained four additi onal trials (98). No diff erence was found between 
IVIg and PE with respect to the improvement in disability grade aft er 4 weeks, the durati on 
of mechanical venti lati on, mortality, or residual disability (98). The combinati on of PE 
followed by IVIg was not signifi cantly bett er than PE or IVIg alone (99). Oral steroids or 
intravenous methylprednisolone (500 mg daily for 5 consecuti ve days) alone are not 
benefi cial in GBS (100,101). The combinati on of IVIg and intravenous methylprednisolone 
was not more eff ecti ve than IVIg alone, although there might be some indicati on a short-
term eff ect of this combined treatment when a correcti on was made for known prognosti c 
factors (64,102,103). The well defi ned lack of a more obvious eff ect of corti costeroids 
remains a puzzling issue in an infl ammatory neuropathy disorder such as GBS. Possible 
explanati ons could include the minor eff ect of steroids on the toxicity of anti ganglioside 
anti bodies and subsequent complement acti vati on, or an adverse eff ect on macrophages 
that clear myelin debris and thus hamper remyelinati on (104,105). We recently studied 
the additi onal eff ect of a 6-week course of mycophenolate mofeti l in GBS. In this pilot-
study, there seemed to be no positi ve eff ect of mycophenolate mofeti l (106). Although 
there defi nitely is a positi ve eff ect of immunotherapy on the course of GBS, new research 
into ways to improve the fi nal outcome of GBS are urgently needed (64).
 ‘Mildly aff ected’ is arbitrarily defi ned as being able to walk without assistance (GBS 
disability scale ≤ 2) at nadir. A retrospecti ve study showed that these pati ents oft en have 
residual disabiliti es (69). The RCTs that have assessed the eff ect of IVIg have not studied 
the eff ect in mildly aff ected pati ents (64). One large French randomised trial studied the 
eff ect of PE also in pati ents who could walk with or without aid, but not run (62). Onset 
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of motor recovery was faster in pati ents who received two PE sessions than in those who 
received no PE. On the basis of this study, there might be an indicati on to treat mildly 
aff ected pati ents who have GBS with PE, but it should be kept in mind that no randomised 
placebo-controlled trials have assessed the eff ect of PE or IVIg in these mildly aff ected 
pati ents with GBS.
 No RCTs have studied the eff ect of PE or IVIg in pati ents with MFS (107). Observati onal 
studies have suggested that the fi nal outcome in pati ents with MFS is generally good. In a 
large Japanese uncontrolled observati onal study, IVIg slightly hastened the ameliorati on of 
ophthalmoplegia and ataxia, but the ti mes to resoluti on of these symptoms were similar 
among the IVIg, PE and control groups (108). The investi gators concluded that IVIg and PE 
did not infl uence the outcome of pati ents with MFS, presumably because of good natural 
recovery. Some pati ents with MFS can be severely aff ected and could also have swallowing 
and respiratory problems; they might even have an overlapping syndrome with additi onal 
weakness in arms and legs. One could argue that parti cularly in these pati ents, or in 
pati ents with severe autonomic dysfuncti on, IVIg treatment might be indicated, although 
there is no positi ve evidence of a benefi t. 
 As described before, about fi ve to ten percent of GBS pati ents deteriorate aft er initi al 
improvement or stabilisati on following IVIg treatment, a conditi on named ‘treatment-
related fl uctuati on’ (TRF) (fi gure 5) (70). Although no RCTs have assessed the eff ect of a 
repeated IVIg dose in this conditi on, it is common practi ce to give a second IVIg course 
(2 g/kg in 2-5 days), because these pati ents are likely to improve aft er re-initi ati ng this 
treatment (64). These pati ents are thought to have a prolonged immune response that 
causes persistent nerve damage that needs treatment for a longer period of ti me (109). 
Some of these pati ents with GBS might even have several episodes of deteriorati on. This 
oft en raises the questi on of whether these pati ents might have CIDP with acute onset 
(A-CIDP). The diff erences between GBS-TRF and A-CIDP have been studied and the results 
are described in chapter 3.
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OBJECTIVES AND OUTLINE OF THIS THESIS
The need to study 1) the outcome in GBS subgroups in parti cular MFS pati ents and mildly 
aff ected GBS pati ents, 2) the disti ncti on between GBS-TRF and A-CIDP, and 3) pain and 
autonomic dysfuncti on, was recognised by the Erasmus MC GBS research group.
 As described and case-illustrated, the aims of this thesis were 1) to provide more insight 
in the course of disease, the presence and severity of residual fi ndings and the frequency 
and nature of pain and autonomic dysfuncti on in GBS, 2) to study the presence of small 
fi bre neuropathy in GBS, 3) to delineate subgroups of GBS pati ents having a high chance 
to develop A-CIDP, pain or autonomic dysfuncti on, and 4) to identi fy possible (new) factors 
related to outcome in subgroups of GBS. 
 Overall, the descripti on and recogniti on of diff erent clinical signs, symptoms, and 
courses of disease within the broad spectrum of GBS can give more insight into the 
aeti ology, pathogenesis, response to treatment and prognosis of GBS. This eventually 
could hopefully lead to a bett er treatment for pati ents with GBS.
 We did several retrospecti ve studies on these topics and designed the GRAPH (GBS 
Research about Pain and Heterogeneity) study. The GRAPH study is a nati onwide prospecti ve 
GBS follow-up study in an unselected Dutch GBS populati on that was conducted by the 
Dutch GBS Studygroup. In this thesis the results of both the retrospecti ve studies and the 
GRAPH study are described.
 An overview of the GRAPH study is given in chapter 2. In Chapter 3 the clinical spectrum of 
GBS and CIDP and its treatment are described. In chapter 3.1 prospecti ve informati on about 
the diff erences in preceding infecti ons, course of disease and outcome between GBS (non-
MFS) versus MFS and mildly versus severely aff ected GBS pati ents is presented. In chapter 
3.2 the diff erences between GBS-TRF and A-CIDP are described based on a retrospecti ve 
study. In chapter 3.3 the diff erences between GBS-TRF and A-CIDP are described into more 
detail based on the GRAPH study. In chapter 3.4 a review about the treatment of CIDP is 
given. Chapter 4 deals with the presence, diff erent locati ons, types, and intensity of pain 
in GBS. In chapter 4.1 these aspects of pain, as studied retrospecti vely in severely aff ected 
GBS pati ents, are described. In chapter 4.2 pain studied retrospecti vely in pure motor 
GBS pati ents is presented. In chapter 4.3 the presence and detailed aspects of pain are 
described, based on the GRAPH study. These results subsequently are related to other 
clinical symptoms of GBS. In chapter 5 the presence of small nerve fi bre neuropathy in GBS 
and its subgroups in the acute and chronic phase of disease are described. This has been 
investi gated in skin biopsies by quanti fi cati on of the intraepidermal nerve fi bre density 
(IENFD). Additi onally, the relati on between IENFD and pain, autonomic dysfuncti on and 
outcome is presented. Finally, in chapter 6 the results of the diff erent studies described in 
this thesis are summarized and discussed and suggesti ons for further research are given.
binnenwerk l ruts.indd   27 31-3-2010   11:54:16
Ch
ap
te
r 
1 
28 
REFERENCE LIST 
01. Asbury AK, Cornblath DR. Assessment of current diagnosti c criteria for Guillain-Barré syndrome. 
Ann Neurol 1990;27 Suppl:S21-24.
02. van der Meché FG, van Doorn PA, Meulstee J, Jennekens FG. Diagnosti c and classifi cati on criteria 
for the Guillain-Barré syndrome. Eur Neurol 2001;45(3):133-139.
03. Ruts L, Jacobs BC, Blankevoort JP, van Doorn PA. Autonome dysfuncti e bij pati ënten met het 
Guillain-Barré syndroom. Tijdschrift  Neurologie & Neurochirurgie 2008;109:118-124. 
04. Ruts L, van Doorn PA, Blankevoort JP, Prens EP. Transient hypertrichosis in a pati ent with Guillain-
Barré syndrome. J Peripher Nerv Syst 2007;12(4):290-292.
05. Hahn AF. Guillain-Barré syndrome. Lancet 1998;352(9128):635-641.
06. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366(9497):1653-1666.
07. van Koningsveld R, van Doorn PA, Schmitz PI, Ang CW, van der Meché FG. Mild forms of Guillain-
Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54(3):620-625.
08. Alshekhlee A, Hussain Z, Sultan B, Kati rji B. Guillain-Barré syndrome: incidence and mortality rates 
in US hospitals. Neurology 2008;70(18):1608-1613.
09. Bogliun G, Beghi E. Incidence and clinical features of acute infl ammatory polyradiculoneuropathy 
in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110(2):100-106.
10. Hauck LJ, White C, Feasby TE, Zochodne DW, Svenson LW, Hill MD. Incidence of Guillain-Barré 
syndrome in Alberta, Canada: an administrati ve data study. J Neurol Neurosurg Psychiatry 
2008;79(3):318-320.
11. Lehmann HC, Kohne A, zu Horste GM, Kieseier BC. Incidence of Guillain-Barré syndrome in 
Germany. J Peripher Nerv Syst 2007;12(4):285.
12. Ho TW, Li CY, Cornblath DR, et al. Patt erns of recovery in the Guillain-Barré syndromes. Neurology 
1997;48(3):695-700.
13. Nowe T, Hutt emann K, Engelhorn T, Schellinger PD, Kohrmann M. Paralyti c ileus as a presenti ng 
symptom of Guillain-Barré syndrome. J Neurol 2008;255:756-757.
14. Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain-Barré syndrome: an important indicator 
for clinical and serological subgroups. Acta Neurol Scand 2001;103(5):278-287.
15. Hadden RD, Karch H, Hartung HP, et al. Preceding infecti ons, immune factors, and outcome in 
Guillain-Barré syndrome. Neurology 2001;56(6):758-765.
16. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infecti ons in 
Guillain-Barré syndrome: a case-control study. Neurology 1998;51(4):1110-1115.
17. Guillain-Barré Syndrome Study Group. Guillain-Barré syndrome: an Italian multi centre case-control 
study. Neurol Sci 2000;21(4):229-234.
18. Ang CW, de Klerk MA, Endtz HP, et al. Guillain-Barré syndrome- and Miller Fisher syndrome-
associated Campylobacter jejuni lipopolysaccharides induce anti -GM1 and anti -GQ1b Anti bodies 
in rabbits. Infect Immun 2001;69(4):2462-2469.
19. Griffi  n JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann 
Neurol 1996;39(1):17-28.
20. Halstead SK, O’Hanlon GM, Humphreys PD, et al. Anti -disialoside anti bodies kill perisynapti c 
Schwann cells and damage motor nerve terminals via membrane att ack complex in a murine model 
of neuropathy. Brain 2004;127(Pt 9):2109-2123.
21. Willison HJ, Yuki N. Peripheral neuropathies and anti -glycolipid anti bodies. Brain 2002;125(Pt 
12):2591-2625.
binnenwerk l ruts.indd   28 31-3-2010   11:54:16
The Guillain-Barré syndrome, an introducti on 29
22. Yuki N, Yoshino H, Sato S, Ohno T, Miyatake T. An acute axonal form of Guillain- Barré syndrome with 
anti bodies against gangliosides GM1 and GD1b, a case report. Rinsho Shinkeigaku 1990;30(9):989-
993.
23. Yuki N. Anti -ganglioside anti body and neuropathy: review of our research. J Peripher Nerv Syst 
1998;3(1):3-18.
24. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by 
sensiti zati on with GM1 ganglioside. Ann Neurol 2001;49(6):712-720.
25. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and 
Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 
2004;101(31):11404-11409.
26. Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barré syndrome 
with anti -GalNAc-GD1a anti bodies. Neurology 1999;53(9):2122-2127.
27. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG anti body to ganglioside GQ1b is a possible 
marker of Miller Fisher syndrome. Ann Neurol 1992;31(6):677-679.
28. Ho TW, Willison HJ, Nachamkin I, et al. Anti -GD1a anti body is associated with axonal but not 
demyelinati ng forms of Guillain-Barré syndrome. Ann Neurol 1999;45(2):168-173.
29. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infecti ons and anti -GM1 anti bodies 
in Guillain-Barré syndrome. Ann Neurol 1996;40(2):181-187.
30. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of anti gen 
for serum anti body in Guillain-Barré syndrome. Neurology 1996;47(1):237-242.
31. Willison HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005;10(2):94-
112.
32. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti -GQ1b anti body in Fisher’s 
syndrome. Neurology 1993;43(2):414-417.
33. Yuki N, Taki T, Handa S. Anti body to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome 
subsequent to Campylobacter jejuni enteriti s. J Neuroimmunol 1996;71(1-2):155-161.
34. Yuki N, Ho TW, Tagawa Y, et al. Autoanti bodies to GM1b and GalNAc-GD1a: relati onship to 
Campylobacter jejuni infecti on and acute motor axonal neuropathy in China. J Neurol Sci 
1999;164(2):134-138.
35. Yuki N, Ang CW, Koga M, et al. Clinical features and response to treatment in Guillain-Barré 
syndrome associated with anti bodies to GM1b ganglioside. Ann Neurol 2000;47(3):314-321.
36. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007;35(6):691-711.
37. Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target anti gens in Guillain-Barré 
syndrome. Ann Neurol 2004;56(4):567-571.
38. Kaida K, Kanzaki M, Morita D, et al. Anti -ganglioside complex anti bodies in Miller Fisher syndrome. 
J Neurol Neurosurg Psychiatry 2006;77(9):1043-1046.
39. Kaida K, Morita D, Kanzaki M, et al. Anti -ganglioside complex anti bodies associated with severe 
disability in GBS. J Neuroimmunol 2007;182(1-2):212-218.
40. Kuijf ML, Godschalk PC, Gilbert M, et al. Origin of ganglioside complex anti bodies in Guillain-Barré 
syndrome. J Neuroimmunol 2007;188(1-2):69-73.
41. Ledeen RW. Gangliosides of the neuron. Trends Neurosci 1985;10:169-174.
42. Yuki N. Infecti ous origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet 
Infect Dis 2001;1(1):29-37.
43. Godschalk PC, Kuijf ML, Li J, et al. Structural characterizati on of Campylobacter jejuni 
lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes. Infect 
Immun 2007;75(3):1245-1254.
44. Houliston RS, Yuki N, Hirama T, et al. Recogniti on characteristi cs of monoclonal anti bodies that 
are cross-reacti ve with gangliosides and lipooligosaccharide from Campylobacter jejuni strains 
associated with Guillain-Barré and Fisher syndromes. Biochemistry 2007;46(1):36-44.
binnenwerk l ruts.indd   29 31-3-2010   11:54:16
Ch
ap
te
r 
1 
30 
45. Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk factors for the 
development of Guillain-Barré syndrome aft er Campylobacter jejuni enteriti s. J Infect Dis 
2006;193(4):547-555.
46. Kimoto K, Koga M, Odaka M, et al. Relati onship of bacterial strains to clinical syndromes of 
Campylobacter-associated neuropathies. Neurology 2006;67(10):1837-1843.
47. Koga M, Gilbert M, Li J, et al. Antecedent infecti ons in Fisher syndrome: a common pathogenesis of 
molecular mimicry. Neurology 2005;64(9):1605-1611.
48. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. 
Trends Immunol 2004;25(2):61-66.
49. Jacobs BC, Koga M, van RW, et al. Subclass IgG to motor gangliosides related to infecti on and 
clinical course in Guillain-Barré syndrome. J Neuroimmunol 2008;194(1-2):181-190.
50. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an anti body-mediated att ack 
on axolemma. Ann Neurol 1996;40(4):635-644.
51. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune att ack on the Schwann cell surface in acute 
infl ammatory demyelinati ng polyneuropathy. Ann Neurol 1996;39(5):625-635.
52. Houliston RS, Koga M, Li J, et al. A Haemophilus infl uenzae strain associated with Fisher syndrome 
expresses a novel disialylated ganglioside mimic. Biochemistry 2007;46(27):8164-8171.
53. Mishu B, Blaser MJ. Role of infecti on due to Campylobacter jejuni in the initi ati on of Guillain-Barré 
syndrome. Clin Infect Dis 1993;17(1):104-108.
54. Ang CW, van Doorn PA, Endtz HP, et al. A case of Guillain-Barré syndrome following a family 
outbreak of Campylobacter jejuni enteriti s. J Neuroimmunol 2000;111(1-2):229-233.
55. Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barré syndrome or chronic 
infl ammatory demyelinati ng polyradiculoneuropathy following immunisati on. J Neurol Neurosurg 
Psychiatry 2002;73(3):348-349.
56. McKhann GM, Cornblath DR, Griffi  n JW, et al. Acute motor axonal neuropathy: a frequent cause of 
acute fl accid paralysis in China. Ann Neurol 1993;33(4):333-342.
57. Griffi  n JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy patt ern 
of the Guillain-Barré syndrome. J Neurocytol 1996;25(1):33-51.
58. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff ’s brainstem encephaliti s and Fisher syndrome form a 
conti nuous spectrum : Clinical analysis of 581 cases. J Neurol 2008;255:674-682.
59. Willison HJ, O’Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 
1999;100(1-2):3-12.
60. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relati onship to 
Campylobacter jejuni infecti on and anti -glycolipid anti bodies. Brain 1995;118(Pt 3):597-605.
61. Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory 
axonal neuropathy share a common immunological profi le. J Neurol Sci 1999;168(2):121-126.
62. Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperati ve 
Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1997;41(3):298-306.
63. Korinthenberg R, Schessl J, Kirschner J. Clinical presentati on and course of childhood Guillain-Barré 
syndrome: a prospecti ve multi centre study. Neuropediatrics 2007;38(1):10-17.
64. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for 
Guillain-Barré syndrome: a systemati c review. Brain 2007;130:2245-2257.
65. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fati gue in immune-mediated 
polyneuropathies. European Infl ammatory Neuropathy Cause and Treatment (INCAT) Group. 
Neurology 1999;53(8):1648-1654.
66. Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Residual physical outcome and daily living 
3 to 6 years aft er Guillain-Barré syndrome. Neurology 1999;53(2):409-410.
binnenwerk l ruts.indd   30 31-3-2010   11:54:16
The Guillain-Barré syndrome, an introducti on 31
67. Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Long-term impact on work and private life 
aft er Guillain-Barré syndrome. J Neurol Sci 2002;201(1-2):13-17.
68. Dornonville de la CC, Jakobsen J. Residual neuropathy in long-term populati on-based follow-up of 
Guillain-Barré syndrome. Neurology 2005;64(2):246-253.
69. van Koningsveld R, Schmitz PI, Ang CW, et al. Infecti ons and course of disease in mild forms of 
Guillain-Barré syndrome. Neurology 2002;58(4):610-614.
70. Kleyweg RP, van der Meché FG. Treatment related fl uctuati ons in Guillain-Barré syndrome aft er 
high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991;54(11):957-
960.
71. American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic 
infl ammatory demyelinati ng polyneuropathy (CIDP). Report from an Ad Hoc Subcommitt ee of the 
American Academy of Neurology AIDS Task Force 1991;41(5):617-618.
72. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinati ng 
polyradiculoneuropathy. Arch Neurol 1992;49(6):612-616.
73. Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Widen HL. Impairment in Guillain-Barré 
syndrome during the fi rst 2 years aft er onset: a prospecti ve study. J Neurol Sci 2004;227(1):131-
138.
74. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology 
1997;48(2):328-331.
75. Ropper AH, Shahani BT. Pain in Guillain-Barré syndrome. Arch Neurol 1984;41(5):511-514.
76. Pentland B, Donald SM. Pain in the Guillain-Barré syndrome: a clinical review. Pain 1994;59(2):159-
164.
77. Connelly M, Shagrin J, Warfi eld C. Epidural opioids for the management of pain in a pati ent with 
the Guillain-Barré syndrome. Anesthesiology 1990;72(2):381-383.
78. Kabore R, Magy L, Boukhris S, Mabrouk T, Lacoste M, Vallat JM. Contributi on of corti costeroid to the 
treatment of pain in the acute phase of Guillain-Barré syndrome. Rev Neurol (Paris) 2004;160(8-
9):821-823.
79. Pandey CK, Bose N, Garg G, et al. Gabapenti n for the treatment of pain in Guillain-Barré syndrome: 
a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002;95(6):1719-1723.
80. Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK. The comparati ve evaluati on of 
gabapenti n and carbamazepine for pain management in Guillain-Barré syndrome pati ents in the 
intensive care unit. Anesth Analg 2005;101(1):220-225.
81. Rosenfeld B, Borel C, Hanley D. Epidural morphine treatment of pain in Guillain-Barré syndrome. 
Arch Neurol 1986;43(11):1194-1196.
82. Sánchez-Guerra M, Infante J, Pascual J, Berciano J. Severe backache in Guillain-Barré syndrome. 
Muscle Nerve 2002;25(3):468.
83. Tripathi M, Kaushik S. Carbamezapine for pain management in Guillain-Barré syndrome pati ents in 
the intensive care unit. Crit Care Med 2000;28(3):655-658.
84. Pan CL, Tseng TJ, Lin YH, Chiang MC, Lin WM, Hsieh ST. Cutaneous innervati on in Guillain-Barré 
syndrome: pathology and clinical correlati ons. Brain 2003;126(Pt 2):386-397.
85. England JD, Gronseth GS, Franklin G, et al. Practi ce Parameter: evaluati on of distal symmetric 
polyneuropathy: role of autonomic testi ng, nerve biopsy, and skin biopsy (an evidence-based 
review). Report of the American Academy of Neurology, American Associati on of Neuromuscular 
and Electrodiagnosti c Medicine, and American Academy of Physical Medicine and Rehabilitati on. 
Neurology 2009;72(2):177-184.
86. Singh NK, Jaiswal AK, Misra S, Srivastava PK. Assessment of autonomic dysfuncti on in Guillain-Barré 
syndrome and its prognosti c implicati ons. Acta Neurol Scand 1987;75(2):101-105.
binnenwerk l ruts.indd   31 31-3-2010   11:54:16
Ch
ap
te
r 
1 
32 
87. Winer JB, Hughes RA. Identi fi cati on of pati ents at risk of arrhythmia in the Guillain-Barré syndrome. 
Q J Med 1988;68(257):735-739.
88. Winer JB, Hughes RA, Osmond C. A prospecti ve study of acute idiopathic neuropathy. I. Clinical 
features and their prognosti c value. J Neurol Neurosurg Psychiatry 1988;51(5):605-612.
89. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 
1994;17(10):1145-1155.
90. Flachenecker P, Lem K, Mullges W, Reiners K. Detecti on of serious bradyarrhythmias in Guillain-
Barré syndrome: sensiti vity and specifi city of the 24-hour heart rate power spectrum. Clin Auton 
Res 2000;10(4):185-191.
91. Hughes RA, Wijdicks EF, Benson E, et al. Supporti ve care for pati ents with Guillain- Barré syndrome. 
Arch Neurol 2005;62(8):1194-1198.
92. Wijdicks EF, Henderson RD, McClelland RL. Emergency intubati on for respiratory failure in Guillain- 
Barré syndrome. Arch Neurol 2003;60(7):947-948.
93. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. 
Neurology 1985;35(8):1096-1104.
94. Effi  ciency of plasma exchange in Guillain-Barré syndrome: role of replacement fl uids. French 
Cooperati ve Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol 1987;22(6):753-
761.
95. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperati ve Group on 
Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1992;32(1):94-97.
96. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. 
Cochrane Database Syst Rev 2002;(2):CD001798.
97. van der Meché FG, Schmitz PI. A randomised trial comparing intravenous immune globulin and 
plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 
1992;326(17):1123-1129.
98. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré 
syndrome. Cochrane Database Syst Rev 2006;(1):CD002063.
99. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in 
Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. 
Lancet 1997;349(9047):225-230.
100. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré 
Syndrome Steroid Trial Group. Lancet 1993;341(8845):586-590.
101. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corti costeroids for Guillain-Barré syndrome. 
Cochrane Database Syst Rev 2006;(2):CD001446.
102. Susuki K, Yuki N. Eff ect of methylprednisolone in pati ents with Guillain-Barré syndrome. Lancet 
2004;363(9416):1236-1237.
103. van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, van Doorn PA. Eff ect 
of methylprednisolone when added to standard treatment with intravenous immunoglobulin for 
Guillain-Barré syndrome: randomised trial. Lancet 2004;363(9404):192-196.
104. Rich MM, Pinter MJ. Sodium channel inacti vati on in an animal model of acute quadriplegic 
myopathy. Ann Neurol 2001;50(1):26-33.
105. Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in an animal model of acute 
quadriplegic myopathy. Ann Neurol 1998;43(2):171-179.
106. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of Guillain-Barré syndrome with 
mycophenolate mofeti l: a pilot study. J Neurol Neurosurg Psychiatry 2007;78(9):1012-1013.
107. Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff ’s 
brainstem encephaliti s and related disorders. Cochrane Database Syst Rev 2007;(1):CD004761.
binnenwerk l ruts.indd   32 31-3-2010   11:54:16
The Guillain-Barré syndrome, an introducti on 33
108. Mori M, Kuwabara S, Fukutake T, Hatt ori T. Intravenous immunoglobulin therapy for Miller Fisher 
syndrome. Neurology 2007;68(14):1144-1146.
109. Visser LH, van der Meché FG, Meulstee J, van Doorn PA. Risk factors for treatment related clinical 
fl uctuati ons in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg 
Psychiatry 1998;64(2):242-244.
binnenwerk l ruts.indd   33 31-3-2010   11:54:16
binnenwerk l ruts.indd   34 31-3-2010   11:54:16
CHAPTER 2
GRAPH STUDY
GBS research about pain and heterogeneity
Nati onal Dutch prospecti ve one year lasti ng follow-up study 
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STUDY DESIGN
The GRAPH (GBS Research about Pain and Heterogeneity) study is a nati onal Du tch 
prospecti ve one year lasti ng follow-up study. This study formed the basis for part of the 
arti cles included in this thesis. Informati on was collected from pati ents with GBS or GBS 
variants to study pain, autonomic dysfuncti on, course of disease and outcome. Erasmus 
MC was the coordinati ng centre of this multi -centre study conducted by the Dutch GBS 
study group. The protocol initi ally was approved by the ethics committ ee of the Erasmus 
MC and subsequently by other 55 parti cipati ng Dutch centres. Pati ents were included in 
the GRAPH between February 2005 and October 2008. Aft er obtaining writt en informed 
consent, clinical data, biological material and electrophysiological data were collected 
systemati cally during one year follow-up (table 1).
Table 1 | Flow-chart GRAPH study
During hospital stay Week 
13 
Week 
26 
Week 
39 
Week 
52 
Questi onnaires 
  Medical history once 
  Initi al symptoms once 
  Pain weekly x  x x x 
  Autonomic (dys)functi on weekly x 
  Disability twice a week -weekly x x x x 
  Course twice a week -weekly x x x x 
  Fati gue x x x x 
Neurological exam twice a week -weekly x 
Blood x 
Cerebrospinal fl uid (CSF) x 
Faeces x 
Sputum x 
Electromyographic study x 
For pati ents admitt ed in hospital in region of Rott erdam 
Skin biopsy x x 
For pati ents admitt ed in Erasmus MC 
Second electromyographic study x 
Autonomic cardiovascular measurement x x 
Questi onaires about disability, course, and neurological exam were fi lled in twice a week (in stead of weekly) during 
the fi rst 3 weeks of hospital stay aft er inclusion in the GRAPH study and when the pati ent had a deteriorati on. 
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 Questi onnaires were fi lled in by the parti cipati ng neurologist twice a week in the fi rst 
three weeks aft er inclusion, weekly during the further hospital stay and once aft er 26 
weeks. The fi rst three weeks aft er inclusion was determined as the acute phase, because 
all included pati ents had their nadir within 3 weeks aft er inclusion.  When the pati ent was 
discharged from hospital, additi onally questi onnaires were fi lled in by the pati ent at 13, 
26, 39, and 52 weeks aft er inclusion. If the pati ent was not able to fi ll in the questi onnaire, 
relati ves were asked for help. 
 Pati ents included in the GRAPH study and admitt ed to one of the hospitals in region 
of Rott erdam were considered for taking skin biopsies. Pati ents included in this skin 
biopsy study (as part of the GRAPH study) and admitt ed to the Erasmus MC were also 
asked to parti cipate in a substudy on autonomic functi ons in GBS. They were considered 
for autonomic cardiovascular measurements, once in the acute phase and once aft er 6 
months. These pati ents also had a second EMG aft er 6 months.
PATIENTS 
Pati ents diagnosed with GBS or a GBS variant could be included in the GRAPH study. 
Exclusion criteria were: age below twelve and signifi cant co-morbidity with an expected 
worse prognosis (less than one year survival). In total, 170 pati ents were included. Table 
2 presents a schemati c overview of the number of pati ents included in the GRAPH study 
performed by the Dutch GBS Studygroup. 
 We defi ned pati ents as GBS or Miller Fisher syndrome (MFS) according to the diagnosti c 
criteria (1,2). Pati ents fi nally having a diff erent diagnosis (n=3: hernia nucleus pulposi, 
Morbus Sjögren, diff use white matt er disease), or accompanying myeliti s (n=1), or 
Bickerstaff  encephaliti s (n=2) were excluded aft erwards. Some pati ents initi ally diagnosed 
and included as having ‘GBS’, fi nally revealed to have a chronic relapsing and remitti  ng 
course (3). These pati ents were defi ned as CIDP with an acute onset (A-CIDP). In total 164 
pati ents (138 GBS, 18 MFS, 8 A-CIDP) were included in the studies as described in this 
thesis. 
 During one year follow-up some pati ents died (n=4), were lost to follow-up or 
refrained further parti cipati on (n=5) (fi gure 1). From 155 pati ents (95%) all the follow-up 
questi onnaires were sent back. If questi onnaires or answers to some questi ons appeared 
to be lacking, our research coordinator phoned the pati ents and asked them to complete 
and return the questi onnaires. If there remained some missing answers, the pati ents were 
not excluded from the analyses. 
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Table 2 | Pati ents included in the GRAPH study by the Dutch GBS Studygroup, classifi ed by the 
including hospital and responsible neurologist
Hospital City Responsible neurologist 
Erasmus MC Rott erdam L. Ruts & 
Prof.dr.P.A. Doorn (van) 
33 
Maasstad Ziekenhuis, locati e Clara & Zuider Rott erdam H.A.W. Sinnige 12 
Academisch Medisch Centrum Amsterdam Dr. A.J. Kooi (van der) 10 
Canisius-Wilhelmina Ziekenhuis Nijmegen Dr. G.W. Dijk (van) 10 
Sint Franciscus Gasthuis Rott erdam F.H. Vermeij 10 
Sti chti ng het van Weel-Bethesda ziekenhuis Middelharnis Dr. U.A. Badrising 8 
Onze Lieve Vrouwe Gasthuis Amsterdam Dr. I.N. Schaik (van) 7 
Vlietland Ziekenhuis Schiedam J.C.B. Verhey 7 
Hofpoort Ziekenhuis Woerden J.S. Straver 6 
Sint Lucas Andreas Ziekenhuis Amsterdam Dr. W.H.J.P. Linssen 5 
Ziekenhuis Rijnstate Arnhem E.G.J. Zandbergen 4 
Catharina Ziekenhuis Eindhoven Dr. M.C. Rijk (de) 4 
Universitair Medisch Centrum Utrecht Utrecht Dr. W.L. Pol (van der) 4 
Flevoziekenhuis Almere J.P. Blankevoort 3 
Wilhelmina Ziekenhuis Assen D.G. Oenema 3 
St. Lievensberg Ziekenhuis Bergen op Zoom B. Feenstra 3 
St. Jansdal Harderwijk D.J. Hofstee 3 
Atrium Medisch Centrum Heerlen Dr. R. Beekman 3 
Academisch Ziekenhuis Maastricht Maastricht Dr. C.G. Faber 3 
Jeroen Bosch Ziekenhuis, locati e Groot 
Ziekengasthuis 
Den Bosch Dr. R.A.J.A.M. Bernsen 3 
Meander Medisch Centrum, locati e Elisabeth Amersfoort W.G.H. Oerlemans 2 
Haga Ziekenhuis, locati e Leyenburg Den Haag Dr. R.W.M. Keunen 2 
Groene Hart Ziekenhuis Gouda G.H.M. Verheul 2 
Marti ni Ziekenhuis Groningen Dr. J.W. Snoek 2 
Westf ries Gasthuis Hoorn T.C. Ree (van der) 2 
Medisch Centrum Leeuwarden Leeuwarden W.J. Schuiling 2 
Ruwaard van Putt en Ziekenhuis Spijkenisse Dr. J.L.M. Jongen 2 
Sint Elisabeth Ziekenhuis Tilburg Dr. L.H. Visser 2 
VieCuri, Medisch Centrum voor Noord-Limburg Venlo G.M.J. Lassouw 2 
Slotervaartziekenhuis Amsterdam Dr. V.I.H. Kwa 1 
Delfzicht Ziekenhuis Delfzijl J.A. Don 1 
Medisch Centrum Haaglanden, locati e 
Westeinde 
Den Haag Prof. dr. M.J.B. Taphoorn 1 
Sti chti ng Oosterscheldeziekenhuizen Goes F. Visscher 1 
Rijnland Ziekenhuis, locati e Leiderdorp Leiderdorp R.J.W. Witt eveen 1 
Leids Universitair Medisch Centrum Leiden Dr. J.J.G.M. Verschuuren 1 
IJsselmeerzieuizen, locati e Lelystad Lelystad E.M. Leenders 1 
Laurenti us Ziekenhuis Roermond Roermond Dr. P.H.M.F. Domburg (van) 1 
Ikazia Ziekenhuis Rott erdam D.M.H. Zuidgeest 1 
Havenziekenhuis Rott erdam H.J. Vroon 1 
Lange Land Ziekenhuis Zoetermeer R.J. Groen 1 
TOTAL 170 
binnenwerk l ruts.indd   38 31-3-2010   11:54:28
GRAPH (GBS Research about Pain and Heterogeneity)  study 39
 Mildly (GBS disability score at nadir ≤ 2, table 6) as well as severely aff ected pati ents 
(GBS disability score at nadir ≥ 3, table 6) were included. At nadir, 4% (7/164) had a GBS 
disability score 1, 16% (26/164) a GBS disability score 2, 25% (41/164) a GBS disability 
score 3, 38% (62/164) a GBS disability score 4, and 17% (28/164) a GBS disability score 5. 
All 164 pati ents reached nadir of weakness within 29 days aft er onset of weakness (fi gure 
2). 
Figure 1 | Pati ents included in the GRAPH study and pati ents who died (n=4) or were lost to 
follow-up (n=5) during the one year follow-up ti me
Total paents n=170
 included
Excluded n=1 Also a myelis n=2 Bickerstaff encephalis n=3 Misdiagnosed
aerwards
Acute phase n=164 
in hospital 
n=18 MFS n=8 A-CIDP
Week 13 n=2 died n=18 MFS n=8 A-CIDP
n=1 lost 
Week 26 n=1 lost n=18 MFS n=8 A-CIDP
Week 39 n=1 died n=17 MFS n=1 died n=6 A-CIDP n=2 lost 
Week 52 n=1 lost n=17 MFS n=6 A-CIDP
n=155
n=138 GBS
n=135 GBS
n=134 GBS
n=133 GBS
n=132 GBS
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Figure 2 | Frequency histogram displaying the period (in number of days) from onset of 
weakness to the maximal weakness (nadir) related to the GBS disability score at nadir in 164 
pati ents included in the GRAPH study
QUESTIONNAIRES 
The topics addressed in the questi onnaires are shown point by point. All topics were asked 
for in each questi onnaire, unless otherwise indicated.
Baseline characteristi cs and medical history 
(only in the fi rst questi onnaire)
Pain
For all pain questi onnaires it was emphasized that it had to be a newly arisen pain, diff erent 
from any previous pain in medical history.
To determine the presence of pain we asked for the presence of pain:
  in the previous week 
  two weeks before the onset of weakness (only in the fi rst questi onnaire)
  in medical history before the onset of GBS (= chronic pain within three months back 
in ti me – without 2 weeks before onset of weakness -) (only in the fi rst questi onnaire) 
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To determine the severity of pain at all ti me-points, we used the 11-point numerical 
rati ng scale (NRS, in which 0 represents no pain and 10 represents extreme pain) (4). The 
following NRS scores were obtained:
  mean NRS of the severest pain in the previous week
  NRS at this moment 
  mean NRS in the previous week 
The locati on, character and type of pain were determined.
Opti ons to mark for the locati on of pain: 
  (low)back
  interscapular
  neck
  extremiti es
  trunk
Character of pain was obtained based on the simplifi ed version of the Dutch McGill Pain 
Questi onnaire (appendix) (5,6).
Opti ons to mark for the type of pain (only fi lled in by the neurologist) (7): 
  radicular pain
  meningism
  painful par/dysaesthesiae
  muscle pain
  joint pain
  other pain (with the possibility to explain) 
The use of daily analgesics or co-analgesics was obtained categorized based on the WHO’s 
pain ladder (8):
  none
  paracetamol or non-steroidal anti -infl ammatory drugs (NSAIDs)
  opioids
  anti -depressants or anti -convulsants
Neurological symptoms, signs, disability and impairment
Questi onnaires only fi lled in by the neurologist: 
  neurological symptoms (only in the fi rst questi onnaire)
  impairment scales 
  MRC sumscore, ranging from 0 ‘paralysis’ to 60 ‘normal strength’ (9) (table 4) 
  ‘INCAT’ sensory sumscore (table 5) (10,11)
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  disability scales 
  GBS disability score, ranging from 0 ‘no symptoms or signs’ to 6 ‘dead’ (table 6) (15)
  overall disability sumscore (ODSS), ranging from 0 ‘no signs of disability’ to 12 ‘most 
severe disability score’ (table 7) (10,12)
  spinal root and meningeal stretch signs, presence of allodynia, tendon refl exes
  treatment and course of disease (deteriorati on, improvement or stabilisati on)
Questi onnaires fi lled in by the pati ent aft er hospital discharge: 
  pain symptoms like above
  Fati gue Severity Scale (FSS) ranging from 1 ‘no signs of fati gue’ to 7 ‘most disabling 
fati gue’ (13;14) (table 8) (FSS in medical history before the onset of GBS = FSS within 
three months back in ti me was also obtained (only in the fi rst questi onnaire))
  disability scales like above (GBS disability score, ODSS) 
  course of disease (deteriorati on, improvement or stabilisati on)
Autonomic (dys)functi on 
Clinical autonomic dysfuncti on parameters were defi ned as follows: 
  hypertension (systolic blood pressure >140 and/or diastolic blood pressure >90 mmHg)
  hypotension (systolic blood pressure <90 mmHg)
  tachycardia (heart rate >100 bpm)
  bradycardia (heart rate <60 bpm)
  gastrointesti nal dysfuncti on (diarrhoea, consti pati on, inconti nence)
  bladder dysfuncti on (urine retenti on, inconti nence)
  other symptoms of autonomic dysfuncti on (for example Horner’s syndrome, pupil 
dilatati on, excessive sweati ng)
We asked for the presence of these items in the previous week.
Table 4 | Medical Research Council sumscore (9)
MRC grades 
0 = no movement 
1 = palpable contracti on, but no visible movement 
2 = movement but only with gravity eliminated 
3 = movement against gravity (more or less full range) 
4 = movement against resistance, but weaker than normal 
5 = normal power 
Range: 0 ‘total paralysis’ to 60 ‘normal strength’ ; Muscle strength was assessed of six muscle groups (arm 
abductors, forearm fl exors, wrist extensors, hip fl exors, knee extensors, foot dorsal fl exors) at both sides. The 
MRC scale was used to score each muscle group and the scores are given in full numbers (0-5) only (4-, 4+, 4½ =4).
binnenwerk l ruts.indd   42 31-3-2010   11:54:29
GRAPH (GBS Research about Pain and Heterogeneity)  study 43
Table 5 | INCAT sensory sumscore (10,11)
"INCAT"sensory sumscore 
Pinprick Sensati on Vibrati on Sensati on 2-point discriminati on 
Sites of examinati on + 
Corresponding grades 
Sites of examinati on + 
Corresponding grades 
Sites of examinati on + 
Corresponding grades 
Arms Legs Arms Legs Index fi ngerK 
0 = normal sense 
at index fi ngerA 
0 = normal sense 
at halluxF 
0 = normal sense at 
index fi ngerA 
0 = normal sense 
at halluxF 
0 = normal sense 
(= 4 millimetres) 
Abnormal sense Abnormal sense Abnormal sense Abnormal sense Abnormal sense 
1= at index fi ngerB 1 = at halluxG 1= at index fi ngerB 1 = at halluxG 1 = 5-9 mm 
2 = at wristC 2 = at ankleH 2 = at wristC 2 = at ankleH 2 = 10-14 mm 
3 = at elbowD 3 = at kneeI 3 = at elbowD 3 = at kneeI 3 = 15-19 mm 
4 = at shoulderE 4 = at groinJ 4 = at shoulderE 4 = at groinJ 4 = 20 mm or more 
Pinprick and vibrati on sense examinati on took place from distal to proximal and only the highest extension of 
dysfuncti on of the most aff ected arm and leg was recorded separately for both qualiti es.
Pinprick was tested using the sharp end of a sti ck. Pati ents were asked to indicate whether they experienced the 
pinprick as normal or abnormal. Paraesthesiae, dysaesthesiae or hyperaesthesiae were scored as abnormal. We 
seek for a normal reference point (e.g. sensati on at the face), if a pati ent was experiencing problems indicati ng 
whether the pinprick was abnormal or not.
Vibrati on was assessed using the RydelSeiff er graduated tuning fork and the obtained values were compared with 
the published normati ve vibrati on threshold values.
ISS compositi on: pinprick arm grade [range: 0-4] + vibrati on arm grade [range: 0-4] + pinprick leg grade [range: 
0-4] + vibrati on leg grade [range: 0-4] + 2-point discriminati on grade [range: 0-4]. Sites of examinati on: A & B=index 
fi nger (dorsum distal interphalangeal joint); C=ulnar styloid process; D=medial humerus epicondyle; E=acromio-
clavicular joint; F & G=hallux (dorsum distal interphalangeal joint); H=medial malleolus; I=patella; J=anterior superior 
iliac spine; K=index fi nger (ventral side; distal phalanx). 
ISS Range: 0 (‘no sensory defi cit’) to 20 (‘most severe defi cit’).
Table 6 | GBS disability score (F-score) (15)
GBS disability score Defi niti on 
0 = Normal; no symptoms or signs 
1 = Minor symptoms or signs and able to run 
2 = Able to walk at least 10 meters without walker or support, but unable to run 
3 = Able to walk 10 meters with a walker or support 
4 = Bedridden or chair bound (unable to walk 10 meters with a walker or 
support) 
5 = Requiring arti fi cial venti lati on for at least part of the day 
6 = Dead 
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Table 7 | Overall disability sumscore (ODSS) (10-12) 
Overall disability sumscore = Arm disability scale (range: 0-5) + Leg disability scale (range: 0-7) 
Arm disability scale Functi on checklist Not 
aff ected 
Aff ected 
but not 
prevented 
Prevented 
Dressing upper part of body (excluding butt ons/zips) o o o 
Washing and brushing hair o o o 
Turning a key in a lock o o o 
Using knife and fork (spoon: is applicable if the pati ent 
never uses knife and fork) 
o o o 
Doing/undoing butt ons and zips o o o 
Arm grade 
0 =  Normal 
1 =  Minor symptoms or signs in one or both arms but not aff ecti ng any of the functi ons listed 
2 =  Moderate symptoms or signs in one or both arms aff ecti ng but not preventi ng any of the 
functi ons listed 
3 =  Severe symptoms or signs in one or both arms preventi ng at least one but not all functi ons 
listed 
4 =  Severe symptoms or signs in both arms preventi ng all functi ons listed but some purposeful 
movements sti ll possible 
5 =  Severe symptoms and signs in both arms preventi ng all purposeful movements 
Leg disability scale - Functi on checklist No Yes Not 
applicable 
Do you have any problems with your walking o o o 
Do you use a walking aid o o o 
Ho do you do usually get around for about 10 meters 
Without aid o o o 
With one sti ck or crutch or holding to someone's arm o o o 
With two sti cks or crutches or one sti ck or crutch 
and holding to someone's arm
o o o 
With a wheelchair o o o 
If you use a wheelchair: can you stand and walk a few 
steps with help 
o o o 
If you are restricted to bed most of the ti me, are you able 
to make some purposeful movementso o o 
o o o 
Leg grade 
0 = Walking is not aff ected 
1 = Walking is aff ected but does not look abnormal 
2 = Walks independently but gait looks abnormal 
3 = Usually uses unilateral support to walk 10 meters (sti ck, single cutch, one arm -25 yards) 
4 = Usually uses bilateral support to walk 10 meters (sti cks, cutches, two arm - 25 yards) 
5 = Usually uses wheelchair to travel 10 meters (25 yards) 
6 =  Restricted to wheelchair, unable to stand and walk few steps with help but able to make some 
purposeful leg movements 
7 = Restricted to wheelchair or bed most of the day, preventi ng all purposeful movements of the 
legs (e.g. unable to repositi on the legs in bed) 
ODSS = Arm disability scale (range: 0-5) + Leg disability scale (range: 0-7)
Range: 0 (no signs of disability) to 12 (maximum disability)
For the arm disability scale: Allocate one arm grade only by completi ng the Functi on checklist. Indicate whether 
each functi on is ‘aff ected’, ‘aff ected but not prevented’ or ‘prevented’. For the leg disability scale: Allocate one leg 
grade only by completi ng the Functi onal questi ons.
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Table 8 | The Fati gue Severity Scale (FSS) (13,14) 
Fati gue Severity Scale (FSS)  
1=strongly disagree; 2=mainly disagree; 3= parti ally disagree; 4=do not agree / disagree; 5=parti ally 
agree; 6= mainly agree; 7=strongly agree (circle one answer per questi on)  
1. My moti vati on is lower when I am fati gued  1  2  3  4  5  6  7  
2. Exercise brings on my fati gue 1  2  3  4  5  6  7  
3. I am easily fati gued 1  2  3  4  5  6  7  
4. Fati gue interferes whith my physical functi oning 1  2  3  4  5  6  7  
5. Fati gue causes frequent problems for me 1  2  3  4  5  6  7  
6. My fati gue prevents sustained physical functi oning 1  2  3  4  5  6  7  
7. Fati gue interferes with carrying out certain duti es and responsibiliti es 1  2  3  4  5  6  7  
8. Fati gue is among mythree most disabling symptoms 1  2  3  4  5  6  7  
9. Fati gue interferes with my work, family, or social life 1  2  3  4  5  6  7  
The mean score of the 9 inquiries ranges from 1 (no signs of fati gue) to 7 (most disabling fati gue)
Treatment related fl uctuati ons or exacerbati ons 
To determine nadir, improvement, deteriorati on or stabilisati on during one year follow-
up, the GBS disability score (table 6) (15) and MRC sumscore (table 4) (9) were used. 
By defi niti on, the fi rst progressive phase needs to have its nadir within four weeks, in 
accordance with the criteria for GBS (1,16). Aft er the fi rst nadir, treatment related 
fl uctuati ons (TRFs) (in case of GBS-TRF) and exacerbati ons (in case of A-CIDP) could occur 
with their own nadir. Because only part of the exacerbati ons in A-CIDP is treatment related 
(especially during the later phase of disease), here we used the term exacerbati ons in 
stead of TRFs. 
 A TRF or exacerbati on was defi ned as: 1) Improvement in GBS disability score of at least 
one grade or improvement in MRC sumscore of more than fi ve points aft er completi on of 
therapy, followed by a worsening in GBS disability score of at least one grade or a decrease 
in MRC sumscore of more than fi ve points within the fi rst months aft er onset of disease or 
2) Stabilisati on of the clinical course for more than one week aft er completi on of therapy, 
followed by a worsening of at least one grade of the GBS disability score or more than fi ve 
points on the MRC sumscore (3,17).
Clinical subgroup defi niti ons
We defi ned the following subgroups:
  pure motor: when pinprick and vibrati on sense were both normal 
  having sensory disturbances: when pinprick or vibrati on sense were abnormal
  mildly aff ected: able to walk unaided at nadir = GBS disability score ≤ 2 
  severely aff ected: unable to walk unaided at nadir = GBS disability score ≥3 
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PRECEDING INFECTIONS 
Clinically
The following preceding infecti ons, judged clinically, were scored: respiratory tract infecti on 
or infl uenza (-like) and gastro-enteriti s or diarrhoea (18). These were considered positi ve 
when pati ents reported symptoms meeti ng the criteria for these infecti ons according to 
the Centre of Disease Control (CDC) defi niti ons for nosocomial infecti ons (18) and when 
they occurred within four weeks before onset of weakness.
Serology
From 156 pati ents (95%) pre-treatment serum samples could be obtained. Serum samples 
were tested to determine recent infecti on with Campylobacter jejuni, human adenoviruses, 
respiratory syncyti al virus (RSV), infl uenza A virus, infl uenza B virus, parainfl uenza virus 1, 
2, and 3, cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Mycoplasma pneumoniae 
using a standard assay (19-21). 
Cultures
Bacteriological and virological examinati on of the stool and throat specimens was 
performed by (cell) culture and PCR. From 110 pati ents (67%) stool and throat samples 
were obtained. 
 Campylobacter jejuni was cultured from the stools and Haemophilus infl uenzae was 
cultured from the throat specimens using a standard assay (22,23). Stool samples were 
analysed for the presence of human adenoviruses and enteroviruses by cell culture (24). 
Respiratory viruses were isolated by centrifuge-enhanced culture (20). All samples were 
tested for RSV, infl uenza viruses type A and B, parainfl uenza viruses 1, 2, 3, and 4, human 
adenoviruses, rhinovirus, and human metapneumovirus (HMPV) by routi ne diagnosti c 
immunofl uorescence (IF) assays 48 hr aft er inoculati on. 
Nucleic acid extracti on and real ti me amplifi cati on (PCR) 
The stool swabs were tested by means of real-ti me PCR for human adenoviruses, norovirus, 
enterovirus, parechovirus using a standard assay (24,25). The throat swabs were tested by 
real-ti me PCR for RSV types A and B, infl uenza virus types A and B, human adenoviruses, 
parainfl uenza virus types 1, 2, and 3, rhinovirus, herpes simplex virus (HSV) types 1 and 
2, human metapneumovirus (hMPV), and human coronavirus (hCoV) types 229E, OC43 
and NL63. Total nucleic acids were routi nely isolated at the MagnaPureLC Isolati on Stati on 
(Roche Applied Science, Penzberg, Germany). A universal internal control virus was used 
to monitor the whole process from nucleic acid isolati on unti l real-ti me detecti on (20,26). 
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ANTIͳGANGLIOSIDE ANTIBODIES AND ROUTINE 
DIAGNOSTIC TESTS
Serum and cerebrospinal fl uid (CSF) were obtained before start of treatment. From 156 
pati ents (95%) pre-treatment serum samples could be obtained. Sera were screened for 
the presence of IgG and IgM anti bodies against GM1, GM2, GD1a and GQ1b using ELISA 
using standard techniques (27,28). Standard serological diagnosti c tests, serum creati ne 
kinase (CK) and the CSF number of cells and protein were determined according to routi ne 
laboratory procedures. 
ELECTROMYOGRAPHIC STUDIES
Electrophysiological investi gati ons were obtained from 148 pati ents (90%). According to 
the protocol, electrophysiological investi gati ons were scheduled within three weeks aft er 
inclusion. The electrophysiological investi gati ons were executed according to local setti  ngs 
of the parti cipati ng hospitals. The nerves were sti mulated at the conventi onal sti mulati on 
points (29). 
 Motor nerve conducti on (orthodromic) from the ulnar, peroneal, and opti onally the 
median and ti bial nerve. In these nerves the distal and proximal compound muscle acti on 
potenti al (dCMAP and pCMAP) amplitude, distal motor latency (DML), motor nerve 
conducti on velocity (mNCV), and F-wave latencies were measured. 
 Sensory nerve conducti on studies (anti dromic) from the median, ulnar, and opti onally 
the sural nerves. The sensory nerve acti on potenti al (SNAP) amplitude and sensory nerve 
conducti on velocity (sNCV) were measured. 
 Needle EMG performed opti onally. Pati ents were classifi ed as demyelinati ng, axonal, 
equivocal or normal according to the published classifi cati on (30). Reference values were 
derived from Buschbacher and Pralow (29). 
SKIN BIOPSIES
Pati ents included in the GRAPH study and admitt ed to one of the hospitals in region 
of Rott erdam were considered for taking skin biopsies. Exclusion criteria for taking 
skin biopsies were age below 18 years, already known with signs or symptoms of a 
polyneuropathy or the presence of diabetes mellitus in medical history. Finally 35 pati ents 
were included in the skin biopsy analysis. 
binnenwerk l ruts.indd   47 31-3-2010   11:54:29
Ch
ap
te
r 
2 
48 
Skin biopsies were taken using a disposable 3-mm punch, aft er local anaesthesia with 2% 
lidocaine, from:
  the lateral side of the distal leg, 10 cm above the malleolus within the territory of the 
sural nerve 
  the back, 3 cm besides the third/fourth lumbar vertebrae
No suture was used. 
Pati ents underwent skin biopsies:
  in the acute phase 
  6 months aft er inclusion close to the scar of the former skin biopsy
For comparison, distal leg (n=24) and lumbar site (n=23; 1 lost) skin biopsies from aged 
and gender-matched control subjects were performed aft er obtaining a writt en informed 
consent. Exclusion criteria were age below 18 years, already known with signs or symptoms 
of a polyneuropathy or the presence of diabetes mellitus in medical history.
 All biopsies were fi xed for 24 hours, cryoprotected, coded at Erasmus MC, and shipped 
to the Skin Biopsy laboratory at the Neurological Insti tute ‘Carlo Besta’ of Milan to be 
processed. Skin biopsy examiners were blinded for the biopsy site and the clinical 
conditi on. Three secti ons randomly chosen from each biopsy were immunoassayed with 
polyclonal anti -PGP 9.5 anti bodies (Biogenesis Ltd, Poole, UK; 1:1000) using the free-
fl oati ng protocol for bright-fi eld immunohistochemistry previously described (31). The 
intraepidermal nerve fi bre density (IENFD) was derived from the linear quanti fi cati on 
of PGP 9.5 positi ve nerves. The IENFD was determined and reported according to the 
guidelines of the European Federati on of Neurological Societi es (32).
AUTONOMIC CARDIOVASCULAR MEASUREMENT
Pati ents included in this skin biopsy study and admitt ed to the Erasmus MC (main 
study centre in the GRAPH study) were also evaluated for an autonomic cardiovascular 
measurement. The autonomic cardiovascular measurement was done in 19 pati ents. 
Spectral analysis of heart rate (HR) and blood pressure (BP) variability was applied to 
investi gate details of cardiovascular control mechanisms (33-36). 
  HR variability in the high frequency band (HF: 0.15-0.50 Hz) is related to respiratory 
variati ons (respiratory sinusarrythmia) and refl ects vagal (parasympatheti c) modulati on. 
  HR variability in the low frequency band (LF: 0.07-0.14 Hz) represents changes in 
barorefl ex response and similarly refl ects sympatheti c acti vity, although an infl uence of 
vagal modulati on has been suggested. 
binnenwerk l ruts.indd   48 31-3-2010   11:54:29
GRAPH (GBS Research about Pain and Heterogeneity)  study 49
  BP variability in the low frequency band (LF: 0.07-0.14 Hz) refl ects alterati ons in 
peripheral vasomotor resistance due to barorefl ex-mediated sympatheti c control. 
  Barorefl ex sensiti vity (BRS) can be provided by the transfer functi ons between systolic 
BP (SBP) and R-R interval of the ECG, called interbeat interval (IBI) ti me series (37). 
ECG, BP (using a 2300 Finapres TM blood pressure monitor; Ohmeda, Englewood CO, USA) 
and respirati on were conti nuously recorded during a 10 minute period of supine rest. R-R 
intervals in the ECG were transposed to HR series and SBP and DBP were defi ned per R-R 
interval of the ECG. Periods of stati onary signals with a length of 5 minutes were selected 
from the 10 minute recording period and corrected for technical and physiological artefacts 
in the HR, SBP, DBP and respirati on ti me series. Isolated extra-systolic contracti ons within 
a ti me segment were corrected by a linear interpolati on procedure. If more than 5% of the 
total number of IBI’s and BP pulses in a ti me segment needed correcti on, the period was 
excluded from further analyses. 
 HR and BP ti me series of the 5 minute ti me segments were subjected to a Fourier 
transformati on (38), to yield power spectra of the rhythmic oscillati ons over a frequency 
range of 0.02 to 0.50 Hz. The following cardiovascular parameters were calculated: mean 
HR, mean SBP and mean DBP, power of the LF band of HR and SBP, and power of the HF 
band of HR. The spectral power data were transformed to natural logarithmic values to 
obtain a normal distributi on of data. Per ti me segment the gain in the LF band between 
SBP and IBI ti me series was computed as an index of BRS, based on frequency points 
within the frequency range with a coherence higher than or equal to 0.35 (37). Finally, 
samples of the respiratory signals were obtained per ti me segment at each incidence of 
the R-wave. Respiratory ti me series were subjected to spectral analysis in the same way 
as the HR and BP ti me series, to assess the dominant respiratory frequency within the 5 
minute ti me period, as a control for regularity of breathing. 
 For comparison spectral analyses of cardiovascular variability, autonomic measurements 
from 25 age and gender-matched healthy control subjects were used. The controls were 
recruited by means of adverti sements. Specifi c inclusion criteria for the control group 
were: medicati on-free for at least 3 months, absence of any medical illness, in parti cular 
cardiovascular and neurological illnesses, and the absence of any mental illness. 
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ABSTRACT
Background: It is unknown why symptoms of the Guillain-Barré syndrome (GBS) remain 
limited in some pati ents. Detailed informati on about preceding infecti ons, autonomic 
dysfuncti on, course of disease, and outcome within the whole spectrum of GBS including 
pati ents with the Miller Fisher syndrome (MFS) could be helpful to elucidate this important 
issue.
Objecti ves: The aim of this study was to obtain detailed informati on about infecti ons, 
autonomic dysfuncti on, course of disease and outcome in MFS pati ents and mildly aff ected 
GBS pati ents and to compare this with non-MFS pati ents and severely aff ected GBS 
pati ents. This informati on may improve knowledge about the relati on between infecti ons, 
symptoms, and severity of GBS and may help to guide the needs to be investi gated in new 
treatment trials.
Methods: A Dutch prospecti ve cohort study in pati ents with GBS. Eighteen of the 156 
pati ents included, presented with MFS. Of the 138 other pati ents, 114 were severely 
(not able to walk unaided) aff ected and 24 were mildly (able to walk unaided) aff ected. 
We compared the 138 GBS (non-MFS) pati ents with 18 cases with MFS; and 24 mildly 
versus 114 severely aff ected GBS (non-MFS) pati ents. Clinical signs and symptoms, signs 
of autonomic dysfuncti on, preceding infecti ons, electrophysiological, and immunological 
data were collected during one year follow-up. 
Results: Mildly aff ected GBS pati ents more oft en showed a preceding virological infecti on 
compared to severely aff ected GBS pati ents (65% versus 43%; p=0.05). Severely aff ected 
GBS pati ents more oft en showed tachycardia (p<0.05), hypertension (p<0.05), gastro-
intesti nal (p<0.001) and bladder dysfuncti on (p<0.05) compared to mildly aff ected 
pati ents. Aft er one year, 59% of MFS pati ents sti ll had disability (GBS disability score ≥1), 
31% had severe fati gue, and 25% reported pain. In the mildly aff ected GBS group, 46% sti ll 
had disability, 29% had severe fati gue, and 17% reported pain aft er one year.
Conclusions: Preceding infecti ons may at least parti ally determine symptoms and severity 
of disease. A substanti al proporti on of MFS and mildly aff ected GBS pati ents appeared to 
have residual defi cit aft er one year. 
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INTRODUCTION
The extent and distributi on of weakness, sensory involvement, presence of pain and 
autonomic dysfuncti on, but also the course of disease vary largely between individuals 
with Guillain-Barré syndrome (GBS). Most treatment trials and the majority of other 
larger studies have focussed on severely disabled GBS pati ents that are unable to walk. 
In the western world, these GBS pati ents most frequently have acute infl ammatory 
demyelinati ng polyneuropathy (AIDP). The aim of our prospecti ve study was to provide 
detailed informati on about symptoms and signs not only in the acute phase, but also during 
the course of disease within the whole GBS spectrum, including mildly aff ected and Miller 
Fisher syndrome (MFS) pati ents. We additi onally aimed to study preceding infecti ons into 
detail. This informati on potenti onally is not only of benefi t for determining the prognosis 
and helpful in clinical decision-making, but it may also add to the pathophysiological 
understanding of GBS. Additi onally this informati on may help to guide current medical 
treatment and helps to design new treatment trials. 
 The best known subgroups of GBS based on clinical and electrophysiological 
characteristi cs are AIDP, acute motor axonal neuropathy (AMAN) and MFS (1). Besides 
these well known subgroups, GBS pati ents can also be classifi ed according to the level of 
severity in the acute phase, to the course of disease or in relati on to outcome. Examples 
of GBS pati ents with a less usual course are pati ents with one or more deteriorati ons 
aft er initi al improvement or stabilisati on following treatment (plasma exchange (PE) or 
intravenous immunoglobulin (IVIg)), classifi ed as GBS with ‘treatment related fl uctuati ons’ 
(GBS-TRF) (2-6) and pati ents initi ally diagnosed as GBS who fi nally develop CIDP, known as 
acute onset CIDP (A-CIDP) (7). 
 In Europe, about 20% of pati ents with GBS remain mildly aff ected (being able to walk 
unaided at nadir) (8-10). There is one prospecti ve study assessing diff erences in the acute 
phase between mildly (n=19) and severely aff ected pati ents (n=120) (11). It was shown 
that in the acute phase more females, pati ents under 50 years of age, and pure motor 
pati ents were within the mildly aff ected group. In severely aff ected pati ents, it has been 
shown that, despite treatment, about 20% remain unable to walk aft er 6 months (12). 
It has also been observed that many pati ents remain otherwise disabled, having pain 
or are severely fati gued even aft er many years (13-15). Cross-secti onal studies showed 
that even 3-6 years aft er onset, GBS has a large impact on social life and the ability to 
perform acti viti es (16-18). There is one longitudinal two years follow-up study in 42 GBS 
pati ents concluding that motor and sensory impairment were each sti ll detectable in a 
majority of GBS pati ents aft er 2 years (19). From one retrospecti ve study, there is some 
indicati on that a considerable proporti on of mildly pati ents had residual disabiliti es aft er 6 
months (11). In a randomised PE trial from France, about one third of the mildly aff ected 
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GBS group showed residual signs aft er one year (8). As far as we know, there is no study 
that prospecti vely investi gated various symptoms (other than onset of motor recovery) 
and residual signs at regular ti me-points in the fi rst year aft er onset of disease in mildly 
aff ected pati ents.
 In severely aff ected pati ents, standard treatment with PE or IVIg shortens the acute 
phase, however it does not, or not substanti onally, infl uence the long-term outcome of 
the disease (20). Randomised placebo-controlled trials (RCTs) that have assessed the 
eff ect of IVIg have not studied the eff ect in mildly aff ected pati ents (12). One trial studied 
the eff ect of PE in pati ents in mildly aff ected pati ents (8). Onset of motor recovery was 
faster in mildly aff ected pati ents who received two PE sessions compared to those who 
received no PE.
 RCTs on the eff ect of PE or IVIg in pati ents with MFS have not been performed so far (21). 
From a Japanese uncontrolled retrospecti ve observati onal study of 92 MFS pati ents, it was 
concluded that it is likely that IVIg and PE do not infl uence the outcome of pati ents with 
MFS (22). Oculomotor disturbances and ataxia however tended to improve faster in the 
IVIg treated group. The same group published an observati onal retrospecti ve study about 
28 untreated MFS pati ents and concluded that all pati ents are almost free from ataxia and 
ophthalmoplegia and are returned to their normal acti viti es aft er 6 months (23). There is 
one other retrospecti ve study in 19 pati ents concluding that MFS is characterized by an 
excellent recovery (24).
 Mildly aff ected pati ents and MFS pati ents potenti ally could benefi t from IVIg treatment, 
but treatment trials are lacking. However, before indicati ng the need for a new treatment 
trial, further studies about the course of disease and the presence of residual signs 
especially in mildly aff ected GBS and MFS pati ents would be very helpful. Here we 
report the results of a nati onwide prospecti ve follow-up study examining the whole 
spectrum of GBS, including mildly aff ected and MFS pati ents. We studied the course of 
disease and outcome over a follow-up period of one year. In additi on, detailed clinical, 
electrophysiological and serological data were obtained to be able to study diff erences 
between subgroups of GBS. Knowledge of factors limiti ng the severity of disease could 
also be of importance in unravelling the pathogenesis of GBS and may help to identi fy and 
to design new treatment trials in these immune-mediated neuropathies. 
MATERIALS AND METHODS
Pati ents
Pati ents diagnosed with GBS were eligible to be included in the GRAPH (GBS Research about 
Pain and Heterogeneity) study. Exclusion criteria were: age below twelve and signifi cant 
binnenwerk l ruts.indd   58 31-3-2010   11:54:41
Course of disease and treatment of GBS and CIDP 59
co-morbidity with an expected worse prognosis (less than 1 year survival) (25;26). In total, 
170 pati ents were included. Pati ents with Bickerstaff  brainstem encephaliti s and pati ents 
who developed A-CIDP were excluded. 
Study design
Pati ents admitt ed in the 55 parti cipati ng Dutch centres could be included in the GRAPH 
study in the period from February 2005 unti l October 2008. The protocol was approved 
by the ethics committ ee of the parti cipati ng centres. Clinical data, biological material, 
and electrophysiological data were collected systemati cally during 1 year follow-up, aft er 
obtaining writt en informed consent. 
 Questi onnaires were fi lled in by the parti cipati ng neurologist twice a week in the fi rst 
three weeks aft er inclusion, weekly during the further hospital stay, and once aft er 26 
weeks. The fi rst three weeks aft er inclusion were determined as the acute phase, because 
all included pati ents had their nadir within 3 weeks aft er inclusion. When the pati ent was 
discharged from hospital, additi onally questi onnaires were fi lled in by the pati ent at 13, 
26, 39, and 52 weeks aft er inclusion. If the pati ent was not able to fi ll in the questi onnaire, 
relati ves were asked for help. 
Questi onnaires
Baseline characteristi cs and data about medical history were obtained. Neurological 
symptoms and signs, disability scales (GBS disability score -ranging from 0 ‘no symptoms 
or signs’ to 6 ‘dead’- (27), overall disability sumscore (ODSS) -ranging from 0 ‘no signs 
of disability’ to 12 ‘most severe disability score’- (28,29), MRC sumscore -ranging from 
0 ‘paralysis’ to 60 ‘normal strength’-(28,31)), treatment, and course of disease were 
obtained. 
 Additi onally we asked for the presence and intensity of pain in the past week. To 
determine the intensity of pain we used the 11-point numerical rati ng scale (NRS), in 
which 0 represents no pain and 10 represents extreme pain (32). Aft er hospital discharge 
we asked the pati ent for the presence of fati gue. To determine the severity of fati gue 
we used the Fati gue Severity Scale (FSS, ranging from 1 ‘no signs of fati gue’ to 7 ‘most 
disabling fati gue’) (32,33).
 Clinical autonomic functi ons were assessed and refl ected the last 7 days. Clinical 
autonomic dysfuncti on parameters were defi ned prior to study onset: hypertension 
(systolic >140 and/or diastolic >90 mmHg), hypotension (systolic <90 mmHg), tachycardia 
(heart rate >100 bpm), bradycardia (heart rate <60 bpm), gastrointesti nal dysfuncti on 
(diarrhoea, consti pati on, or inconti nence) bladder dysfuncti on (urine retenti on or 
inconti nence) or other symptoms of autonomic dysfuncti on (for example excessive 
sweati ng, Horner’s syndrome, and pupil dilatati on). 
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 We used the GBS disability score to indicate the severity of disease during diff erent 
phases of disease. Mildly aff ected = able to walk unaided = GBS disability score ≤ 2; severely 
aff ected = unable to walk unaided = GBS disability score ≥ 3. Disability = GBS disability 
score ≥ 1. We defi ned pati ents as clinically ‘pure motor’ when pinprick and vibrati on sense 
were normal in the fi rst three weeks aft er inclusion (acute phase). We defi ned ‘severe 
fati gue’ when mean FSS was ≥ 5 (33).
Recent infecti ons 
Clinically
The following recently preceding infecti ons were judged clinically: respiratory tract 
infecti on or infl uenza(-like) symptoms, and gastro-enteriti s or diarrhoea. These were 
considered positi ve when pati ents reported symptoms meeti ng the criteria for these 
infecti ons according to the Centre of Disease Control (CDC) defi niti ons for nosocomial 
infecti ons (34) and when they occurred within four weeks before onset of weakness.
Serology
Serum samples obtained in the acute phase of disease and before start of treatment. 
Serum samples were stored at -80°C. The sera were tested in the co-ordinati ng centre 
and the Delft  Diagnosti c Laboratory to determine recent infecti on with Campylobacter 
jejuni, human adenoviruses, respiratory syncyti al virus (RSV), infl uenza A virus, infl uenza 
B virus, parainfl uenza virus 1, 2, and 3, cytomegalovirus (CMV), Epstein-Barr virus (EBV) 
and Mycoplasma pneumoniae using standard assays detecti ng specifi c IgG, IgM of IgA 
anti bodies (35-37). Serum examiners were blinded for clinical data.
Culture 
In the co-ordinati ng centre we cultured stools for Campylobacter jejuni and throat 
specimen for Haemophilus infl uenzae using a standard assay (38-40). Additi onally stool 
samples were analysed for the presence of human adenoviruses and enteroviruses by 
cell culture. Throat specimens were analysed for the presence of respiratory viruses using 
rapid cell culture with centrifugati on and immunofl uorescence (IF). All throat specimens 
were tested for RSV, infl uenza viruses type A and B, parainfl uenza viruses 1, 2, 3, and 4, 
herpes simplex virus (HSV) types 1 and 2, human adenoviruses, rhinovirus, and human 
metapneumovirus (hMPV)). 
Nucleic acid extracti on and real ti me amplifi cati on (PCR)
The stool swabs were tested by means of real-ti me PCR for human adenoviruses, 
norovirus, enterovirus, parechovirus using a standard assay (41,42). The throat specimens 
were tested by real-ti me PCR for the presence of RSV types A and B, infl uenza virus types 
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A and B, human adenoviruses, parainfl uenza virus types 1, 2, and 3, rhinovirus, herpes 
simplex virus (HSV) types 1 and 2, hMPV, and human coronavirus (hCoV) types 229E, OC43 
and NL63. Total nucleic acids were routi nely isolated at the MagnaPureLC Isolati on Stati on 
(Roche Applied Science, Penzberg, Germany). A universal internal control virus was used 
to monitor the whole process from nucleic acid isolati on unti l real-ti me detecti on (36,43). 
Anti -gangliosides
Pre-treatment sera obtained aft er inclusion were tested for the presence of IgG and IgM 
anti body reacti vity against GM1, GM2, GD1a, and GQ1b using ELISA (44-45). 
Cerebrospinal fl uid
In the acute phase of disease, number of cells and protein level in the pre-treatment 
cerebrospinal fl uid (CSF) was determined according to routi ne laboratory procedures.
Electromyographic studies
Electrophysiological investi gati ons were scheduled within three weeks aft er inclusion. 
These investi gati ons were performed according to the standard protocol for the GRAPH 
study, when necessary adapted to the local setti  ngs of the parti cipati ng hospitals. Age and 
sex matched reference values were used (46). The electrophysiological investi gati ons were 
re-examined in the co-ordinati ng centre (JD and GHV) classifi ed as demyelinati ng, axonal, 
inexcitable, equivocal or normal (47).
Stati sti cs
The populati on of pati ents was divided into diff erent GBS subgroups. We disti nguished 
GBS (non-MFS) versus MFS and mildly versus severely aff ected GBS pati ents. To compare 
characteristi cs between GBS subgroups an unpaired t-test or χ2 tests were performed. 
If appropriate, the Fisher exact test or the Mann-Whitney U test was used. Data are 
presented with mean +/- Standard Deviati on (SD) or median + IQR.
 Longitudinal analysis of disability, impairment, pain intensity, and fati gue scores 
allowing for occasional missing data at some ti me points, was performed using repeated-
measurement-analysis of variance in the total group and in subgroups using data from 
the acute phase and from the chronic phase (week 13, 26, 39, and 52 aft er inclusion). 
When there was no signifi cant diff erence in the profi le of mean values of the diff erent 
scores between the subgroups, we calculated the mean diff erence + 95% CI between 
the subgroups. For the acute phase we used the data from the questi onnaires up to and 
including week 3, because all pati ents had their nadir within 3 weeks aft er inclusion. For 
reason of comparability between mildly and severely aff ected GBS pati ents, pati ents 
with MFS were excluded. All calculati ons were performed using SPSS for Windows 2000 
(version 15.0 SPSS, Chicago). A p-value <0.05 was considered to be signifi cant.
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RESULTS
Pati ents
Between February 2005 and October 2008, 170 pati ents with GBS were enrolled in the 
GRAPH study (fi gure 1). During follow-up some initi ally diagnosed and included ‘GBS’ 
pati ents fi nally revealed to have another diagnosis (n=3: herniated nucleus pulposus, 
Sjögren syndrome, diff use white matt er disease), Bickerstaff  encephaliti s (n=2), an 
accompanying myeliti s (n=1) or A-CIDP (n=8). These 14 pati ents were excluded from 
analysis. Of the remaining 156 pati ents, 138 (88%) fulfi lled the diagnosti c criteria for GBS 
(non-MFS) and 18 (12%) had MFS (25;48). These pati ents were followed for one year. All 
156 pati ents reached nadir of weakness within 29 days aft er onset of disease (fi gure 2). 
Aft er inclusion in the GRAPH study all pati ents reached nadir of weakness within 3 weeks. 
During follow-up 3 pati ents were lost to follow-up and 4 pati ents died. Of the 138 GBS 
(non-MFS) pati ents, 17% (24/138) was mildly aff ected at nadir.
Figure 1 | Study profi le GRAPH study
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Figure 2 | Frequency histogram displaying the period (in number of days) from onset of 
weakness to the maximal weakness (nadir) related to the GBS disability score (table 6) at nadir 
in 156 GBS pati ents (eight A-CIDP pati ents were excluded from the total group of 164 pati ents 
initi ally diagnosed with GBS)
Baseline and clinical characteristi cs in the acute phase
Baseline and clinical characteristi cs in the acute phase are presented in table 1. 
GBS (non-MFS) versus MFS
Besides the fi nding that pati ents with MFS more oft en had cranial nerve involvement which 
is explained by the defi niti on of MFS, we found that symptoms of pain were signifi cantly 
diff erent in the acute phase (69%, GBS versus 44 %, MFS (p<0.05)).
Mildly versus severely aff ected GBS (non-MFS) pati ents
The median age was signifi cantly lower in the mildly aff ected pati ents compared to 
the severely aff ected pati ents (36 y versus 53 y; p<0.01). Furthermore, the pure motor 
form was more frequently found in the mildly aff ected group (54% versus 28 %; p<0.05). 
Abnormal autonomic functi ons (tachycardia, hypertension, gastro-intesti nal and bladder 
dysfuncti on) occurred in a signifi cantly lower percentage in the mildly aff ected pati ents 
compared to the severely aff ected pati ents. 
Electrophysiological data 
Table 2 shows the electrophysiological data. 
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Mildly versus severely aff ected GBS (non-MFS) pati ents
A demyelinati ng electrophysiological investi gati on was more frequently found in the 
severely aff ected group compared to the mildly aff ected group (56% versus 32 %, p<0.05). 
Number of pati ents that had needed arti fi cial respirati on was not signifi cantly diff erent 
between GBS pati ents with a demyelinati ng or non-demyelinati ng electrophysiological 
investi gati on (25% versus 13%; p=0.1). 
Recent infecti ons 
From 147 pati ents (94%) pre-treatment serum samples and from 105 pati ents (67%) stool 
and throat specimen samples could be obtained to determine a recent infecti on. The 
clinical infecti ons and serological results are indicated in table 2. 
GBS (non-MFS) versus MFS 
There were no signifi cant diff erences in preceding clinical infecti ons and serological 
screening of a recent infecti on between these two groups (table 2).
 In two GBS and none of the MFS pati ents Haemophilus infl uenzae was cultured. In two 
other GBS pati ents and none of the MFS pati ents Campylobacter jejuni was cultured. 
 In GBS rapid cell culture with immunofl uorescence of throat samples yielded in the 
following positi ve results: one CMV, three HSV1, one HSV2, one hMPV, one human 
adenovirus. In MFS rapid cell culture with immunofl uorescence of throat samples revealed 
no positi ve results. PCR of throat swabs from GBS pati ents as well as MFS pati ents resulted 
in one hCoV and one rhinovirus positi ve sample. In GBS rapid cell culture of faeces samples 
resulted in the following positi ve numbers: one picornavirus, one human adenovirus. 
PCR of faeces swabs from GBS pati ents resulted in the following positi ve results: fi ve 
noroviruses, two enteroviruses and one parechovirus. In MFS rapid cell culture with 
immunofl uorescence of faeces samples did not reveal positi ve samples.
Mildly versus severely aff ected GBS (non-MFS) pati ents
The results of the serological screening showed a diff erence in the percentage of preceding 
recent infecti ons of human adenoviruses (35% in the mild group and 14% in the severe 
group, p<0.05) (table 2). There were no other diff erences in preceding clinical infecti ons
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and serological screening of a recent infecti on between the two groups (table 2). Fourteen 
GBS pati ents with a positi ve campylobacter serology (n=30) also had a positi ve virus 
serology (n=3 had a positi ve human adenovirus serology).
 In two severely aff ected pati ents Haemophilus infl uenzae was cultured and in one mildy 
as well as one severely aff ected pati ent Campylobacter jejuni was cultured. 
 Regarding the rapid cell culture with immunofl uorescence and PCR results described 
above in the GBS (non-MFS) versus MFS part, there was only one mildy aff ected GBS 
pati ent with a positi ve PCR for enterovirus; the other positi ve results were obtained in 
severely aff ected pati ents. 
Anti ganglioside anti bodies
GBS (non-MFS) versus MFS
MFS pati ents had signifi cantly more frequent GQ1b anti bodies, compared to GBS 
(p<0.001). The other anti -ganglioside anti bodies did not show any diff erences (table 2).
Mildly versus severely aff ected GBS (non-MFS) pati ents
No diff erences were found in the presence of anti -ganglioside anti bodies (table 2). 
Residual symptoms and signs
Table 3 shows the residual signs and symptoms from the GBS (non-MFS) versus MFS, and 
mildly versus severely aff ected GBS (non-MFS) pati ents. 
GBS (non-MFS) versus MFS
When we compared GBS (non-MFS) with MFS, there were no signifi cant diff erences in the 
presence of disability, fati gue, and pain aft er one year. Even 59% of the MFS pati ents sti ll 
had disability (GBS disability score ≥1) aft er one year. Aft er 6 months, three MFS pati ents 
sti ll had ophthalmoplegia and one MFS pati ent sti ll had facial weakness. 
Mildly versus severely aff ected GBS (non-MFS) pati ents
Aft er one year, 46% in the mildly aff ected GBS (non-MFS) group sti ll had disability (33% GBS 
disability score 1, 13% GBS disability score 2), 29% had severe fati gue and 17% had pain. 
Aft er 1 year, all GBS pati ents classifi ed as axonal had functi onal disability (GBS disability 
score>1) compared to 70% of GBS pati ents classifi ed as demyelinati ng (p=0.07). 
 In the enti re GBS (non-MFS and MFS) group, no signifi cant correlati ons were found 
between the level of fati gue (FSS) during follow-up and severity of disease as measured 
with the MRC sumscore and disability scores at nadir. However, there was a signifi cant 
(p<0.001) correlati on between the level of fati gue (FSS) versus disability at all other ti me-
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points from week 13 to 52 (GBS disability score: week 13: rs=0.40; week 26: rs =0.39; week 
39: rs =0.47; week 52: rs =0.45; ODSS: week 13: rs=0.48; week 26: rs =0.45; week 39: rs 
=0.50; week 52: rs =0.42). 
Table 3 | Residual signs and symptoms
n/N (%) GBS
(non-MFS)
(n=138)
MFS
 (n=18)
p Value
GBS 
versus 
MFS
Severe GBS 
(non-MFS)
(n=114)
Mild GBS 
(non-MFS)
(n=24)
p Value
Severe 
versus 
mild
Aft er 3 months 
Residual disability
  GBS disability score ≥1
  Unable to walk without aid
Severe fati gue 
Pain
117/133 (88) 
26/133 (20) 
70/126 (56) 
74/130 (57) 
12/18 (67)
2/18 (11)
12/18 (67)
10/18 (56)
<0.05
0.53
0.37
0.91
101/109 (93) 
26/109 (24) 
59/102 (58) 
63/107 (59)
16/24 (67)
  0/24 (0)
11/24 (46)
11/23 (48) 
<0.01
<0.01
0.29
0.33
Aft er 6 months 
Residual disability
  GBS disability score ≥1
  Unable to walk without aid
Residual impairment
  Weakness
  Sensory disturbances
Severe fati gue 
Pain
110/136 (81) 
16/136 (12) 
39/125 (31) 
51/115 (44) 
61/129 (47) 
68/132 (52) 
11/18 (61) 
   1/18 (6)
   0/18 (0)
    4/13 (31)
    8/17 (47) 
    6/18 (33)
0.07
0.70
<0.05
0.35
0.99
0.15
97/112 (87)
16/112 (14)
36/101 (36)
48/92 (52)
54/105 (51)
61/109 (56)
13/24 (54)
  0/24 (0)
  3/24 (13)
  3/23 (13)
  7/24 (29)
  7/23 (30) 
<0.01
0.07
<0.05
<0.01
<0.05
<0.05
Aft er 9 months 
Residual disability
  GBS disability score ≥1
Unable to walk without aid 
Severe fati gue 
Pain
97/135 (72)
13/135 (10)
55/130 (42)
55/131 (42)
11/18 (61)
   1/18 (6)
    7/17 (41)
    3/17 (18)
0.35
1.0
0.93
0.05
85/110 (77)
12/110 (11)
51/106 (48) 
51/108 (47)
11/24 (46)
  0/24 (0)
  4/24 (17)
  4/23 (17) 
<0.01
0.12
<0.01
<0.01
Aft er 12 months 
Residual disability
  GBS disability score ≥1
  Unable to walk without aid
Severe fati gue 
Pain
96/136 (71)
11/136 (8)
59/132 (45) 
51/130 (39)
 10/17 (59)
   1/18 (6) 
   5/16 (31)
   4/16 (25)
0.32
1.0
0.31
0.27
85/114 (76)
10/111 (9) 
52/108 (48) 
47/107 (44) 
11/24 (46)
  0/24 (0)
  7/24 (29) 
  4/23 (17) 
<0.01
0.21
0.09
<0.05
Any disability = GBS disability score > 0
Unable to walk without aid = GBS disability score ≥ 3
Severe fati gue = mean FSS≥5
Course of disease
GBS (non-MFS) versus MFS
Figure 3 shows the 1 year follow-up for GBS (non-MFS) and MFS pati ents expressed by 
the course of GBS disability score, ODSS, NRS score and FSS score. During the enti re 1 
year follow-up, MFS pati ents had a signifi cant lower mean diff erence in the GBS disability 
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score, ODSS score and pain as measured with the NRS score. The mean FSS score was not 
signifi cantly diff erent between the two groups.
Figure 3 | Mean GBS disability score (a.), overall disability sum (ODSS) score (b.), pain intensity 
(NRS) score (c.) and fati gue severity scale (FSS) score (d.) over ti me in GBS (non-MFS) (n=138) 
and MFS (n=18)
Legend: Data shown are means (+/-SE) from ANOVA. Mean diff erences (solid minus dott ed line) from inclusion 
day to 52 weeks aft er onset of weakness between the diff erent groups with 95% CI and p-value are indicated 
when there was no signifi cant diff erence in the profi le of mean values of the pain intensity score during the whole 
follow-up between the subgroups.
Mildly versus severely aff ected GBS (non-MFS) pati ents
Figure 4 shows the follow-up during one year for mildly and severely aff ected GBS (non-
MFS) pati ents expressed by the course of the GBS disability score, ODSS, NRS score and 
FSS score. For disability a diff erence between mildly and severely aff ected already can 
be observed at the day of inclusion. Time to reach nadir was not signifi cantly diff erent 
between the two groups. The rate of improvement of disability in the acute phase is faster 
in the severely aff ected group; where aft er the mean diff erence between both groups 
remained identi cal during follow-up. The mean NRS and FSS score during the enti re course 
was signifi cantly lower in the mildly aff ected pati ents, compared to the severely aff ected 
pati ents.
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Figure 4 | Mean GBS disability score (a.), overall disability sum (ODSS) score (b.), pain intensity 
(NRS) score (c.) and fati gue severity scale (FSS) score (d.) over ti me in mildly (GBS disability score 
at nadir ≤2) and severely (GBS disability score at nadir ≥3) aff ected GBS (non-MFS) pati ents
Legend: Data shown are means (+/-SE) from ANOVA. Mean diff erences (solid minus dott ed line) from inclu sion 
day to 52 weeks aft er onset of weakness between the diff erent groups with 95% CI and p-value are indicated 
when there was no signifi cant diff erence in the profi le of mean values of the pain intensity score during the whole 
follow-up between the subgroups.
DISCUSSION
This is the fi rst large prospecti ve follow-up study on diff erent infecti ons, course of disease 
and outcome in mildly aff ected GBS pati ents and MFS pati ents when compared with 
severely aff ected GBS pati ents and GBS (non-MFS) pati ents. As shown in this study, mildly 
aff ected GBS pati ents more oft en had serological evidence of a preceding virological 
infecti on compared to severely aff ected GBS pati ents. Severely aff ected GBS pati ents more 
oft en had abnormal autonomic functi ons. Residual symptoms aft er 6-12 months appeared 
to be very common, also in mildly aff ected GBS and in MFS pati ents.
 It is important to discuss whether the study populati on is representati ve. Based on 
the incidence rate of GBS in the Netherlands (1.18/100.000) (49), the 170 pati ents that 
entered the study cover about 25% of the total number of expected pati ents. 12% of 
the included GBS pati ents had the MFS subtype, which is higher than the 5% published 
in the literature, but lower when compared to studies from Asian countries (10,50). A 
plausible explanati on could be that parti cipati ng centres more oft en contacted our centre, 
for testi ng of anti -ganglioside anti bodies (anti -GQ1b) or for asking advice how to handle 
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in case of a MFS suspected pati ent. When excluding the MFS pati ents, we found 17% 
(24/138) of the GBS pati ents to be mildly aff ected being comparable with the 14% in 
our former study (11). Other percentages of baseline characteristi cs in the acute phase 
in our study are similar to percentages reported in earlier studies (20). Taken together, 
we consider this study populati on to be representati ve for a study executed in Western-
Europe. We did not include a non-GBS group or healthy controls in our study because we 
want to compare diff erences between GBS subgroups.
 Based on serology, we found a preceding virological infecti on more frequently in the 
mildly aff ected GBS pati ents compared to the severely aff ected GBS group. This diff erence 
was especially found for the human adenoviruses. Additi onally, although not stati sti cally 
signifi cant, EBV infecti ons were more frequently found in the mildly aff ected group. In our 
former study (that has not studied the occurrence of such a large number of virological 
infecti ons into depth) this diff erence in preceding EBV infecti on was signifi cantly diff erent 
(11). Base on these fi ndings, our study suggests that an infecti on with human adenovirus 
and possibly also EBV more frequently is related with the mild form of GBS. A previous 
study has reported a low percentage of pati ents with a positi ve infecti on with human 
adenovirus, probably mainly because only severely aff ected pati ents were included (51). 
Clinically, no diff erence was found in symptoms of preceding infecti ons between mildy and 
severely aff ected pati ents. This suggests that subclinical virological infecti ons may play a 
role in the inducti on of mild forms of GBS. Because virological infecti ons predominantly 
occur in cases not related to GBS, we tried to substanti ate this further by culturing stools 
and throat specimens. Possibly due to a prolonged period of ti me between taking the 
specimen unti l culturing, the numbers of culture positi ve infecti ons were very limited, 
making it impossible to draw meaningful conclusions. 
 In about one third of our pati ents we found serum anti bodies to various anti -
gangliosides, a bit lower than described in the literature (20). As expected, IgG and IgM 
acti vity against GQ1b was predominantly present in MFS and acti vity against GM1 was 
mostly found in pure motor pati ents. We found no signifi cant diff erences in the presence 
of anti -ganglioside anti bodies between mildly and severely aff ected pati ents. In our 
previous studies, a signifi cantly higher percentage of anti -ganglioside anti bodies was 
found in severely aff ected pati ents (11,52). We do not have a good explanati on for this 
as there were no diff erences in the methods or assays used. Diff erences can possibly be 
explained by subclass distributi on of anti -ganglioside anti bodies and the relati ve limited 
number of mildly aff ected pati ents included in the GRAPH study. This study suggests 
that the presence of anti -ganglioside anti bodies is not directly related to the severity of 
disease.
 Clinically autonomic dysfuncti on described in GBS is highly variable (53). This already 
suggests the diffi  culty in assessing autonomic neuropathy in clinical setti  ng. It has 
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already been described that autonomic dysfuncti on can occur both in MFS and in mildy 
aff ected GBS pati ents (54-56). However, this is likely to be the fi rst ti me that autonomic 
functi ons like blood-pressure, heart rate, gastro-intesti nal, and bladder functi on were 
systemati cally obtained and were compared between GBS subgroups. We found no 
diff erences in abnormal autonomic functi ons between GBS (non-MFS) and MFS pati ents. 
However, severely aff ected GBS pati ents more oft en had tachycardia, hypertension, 
gastro-intesti nal and bladder dysfuncti on in the acute phase compared to mildly aff ected 
pati ents. Some remarks about our assessment of abnormal autonomic functi ons must 
be made. Informati on about possible abnormal autonomic functi ons already present 
in medical history was not obtained and factors resulti ng in cardiovascular dysfuncti on 
like abnormal stress, infecti on and sepsis were not noted. We did not include a non-GBS 
control group. Therefore, it cannot be concluded from this study whether the pati ents had 
abnormal autonomic functi ons due to autonomic neuropathy caused by GBS. However, 
assuming the same hospital conditi ons for both groups, the results of our study suggest 
that autonomic dysfuncti on in the acute phase occurs more oft en in the severely aff ected 
compared to the mildly aff ected pati ents. Fortunately none of the pati ents in this study 
died due to autonomic dysfuncti on. 
 We showed that aft er one year most of the pati ents sti ll had residual symptoms. Even 
half of the MFS and mildly aff ected GBS pati ents sti ll experienced disability aft er one 
year. Also pain and severe fati gue were frequently present in MFS and GBS pati ents. In 
two retrospecti ve studies, it has been described that MFS pati ents have a fast excellent 
recovery (24,49). The GBS disability score, although not validated for pati ents with MFS, 
but also the presence of pain and fati gue were not studied in these studies. This might 
parti ally explain the diff erence in conclusion about residual signs that can be found in 
pati ents with MFS. In our study 4 of the 18 MFS pati ents sti ll had cranial nerve defi cit 
aft er 6 months. This diff erence possibly implicates some slower recovery in Dutch MFS 
pati ents compared to MFS pati ents from Japan. While considering residual symptoms and 
course of disease it is important to realise that a substanti onal proporti on of MFS pati ents 
included in our study received treatment while most mildly GBS pati ents were not treated 
and most other GBS pati ents did receive treatment which may have infl uenced the results 
that we have found over ti me. On the other hand, this refl ects daily practi ce in many 
neurological insti tutes. 
 Our study confi rmed our previous cross-secti onal published data about the high 
percentage of severe fati gue aft er GBS (57). We also confi rmed that impaired muscle 
strength and disability in the initi al phase of GBS were not signifi cantly related to fati gue 
in the later stage of disease (57). However, as shown in this study, residual disability was 
associated with the level of fati gue during follow-up. This is in line with the results of a 
study showing a relati on between fati gue, pain, and muscle weakness years aft er GBS 
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(58). Whether fati gue causes part of disability or disability contributes to fati gue cannot 
be concluded from our study. 
 There are no prospecti ve controlled trials of immunotherapy in MFS and IVIg treatment 
has never been evaluated in a RCT in mildly aff ected pati ents (21). One RCT showed the 
eff ecti veness of PE in mildly aff ected pati ents (8,49). In our study, the vast majority of 
mildly aff ected GBS pati ents were not treated with IVIg. Because a large proporti on of 
mildly aff ected GBS pati ents do have functi onal defi cit and disability at least for a period of 
one year aft er onset of disease, new treatment trials should at least consider to include also 
mildly aff ected GBS pati ents. Although most MFS pati ents are in a relati ve good conditi on 
one year aft er onset, a proporti on of pati ents do have functi onal defi cit, and fati gue but 
also pain may be present for a long period of ti me. When considering studying the eff ect 
of immunotherapy, it is important to study not only the eff ect of immunotherapy aft er 4 
weeks from inclusion in a trial, but also to look for residual signs aft er a longer period of 
follow-up since not only functi onal disability, but also residual fati gue and pain may persist 
for years. 
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CHAPTER 3.2
DISTINGUISHING ACUTE ONSET CIDP 
FROM GUILLAINͳBARRÉ SYNDROME 
WITH TREATMENT RELATED FLUCTUATIONS
L. Ruts, R. van Koningsveld, P.A. van Doorn
Neurology 2005;65(1):138-40
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ABSTRACT 
Guillain-Barré syndrome (GBS) pati ents may worsen following initi al treatment (treatment 
related fl uctuati on (TRF)). It is diffi  cult to disti nguish GBS-TRF from chronic infl ammatory 
demyelinati ng polyneuropathy with acute onset (A-CIDP). The authors compared 13 
pati ents with A-CIDP with 11 pati ents with GBS-TRF and concluded that A-CIDP should 
be suspected when a pati ent with GBS deteriorates aft er 9 weeks from onset or when 
deteriorati on occurs three ti mes or more. Maintenance treatment should then be 
considered. 
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INTRODUCTION
The spectrum of infl ammatory demyelinati ng polyneuropathy ranges from the acute 
variant, Guillain-Barré syndrome (GBS), to a slowly progressive form, chronic infl ammatory 
demyelinati ng polyneuropathy (CIDP). Diff erences between these variants are, among 
others, the ti me to reach maximum severity (nadir) and the following course of the 
disease. By defi niti on, the ti me to reach nadir in GBS is within 4 weeks; thereaft er the 
course is monophasic (1). According to the research criteria for CIDP, progression develops 
during a period of at least 2 months. Thereaft er the course may be relapsing-remitti  ng, 
steadily progressive, or monophasic (2).
 Despite these, somewhat arti fi cially, defi ned ti me points, it may be diffi  cult to disti nguish 
CIDP from GBS, especially during the early phase of disease. Pati ents, who initi ally have 
a course of disease compati ble with that of GBS later on may develop exacerbati ons and 
remissions and ulti mately are diagnosed as CIDP (3,4). 
 Additi onally, it has been reported that 16 to 20% of pati ents with CIDP have rapid, 
progressive weakness with a nadir of the fi rst episode of weakness within 8 weeks from 
onset of disease and a consecuti ve chronic course suff er from acute-onset CIDP (A-CIDP) 
(5,6). Conversely, 8 to 16% of pati ents with GBS have one or more deteriorati ons aft er initi al 
improvement or stabilisati on aft er treatment (plasma exchange or immunoglobulins), 
described as treatment related fl uctuati ons (TRFs) (7-9). 
 In clinical practi ce, it may be diffi  cult to disti nguish a pati ent with GBS having a secondary 
deteriorati on aft er initi al improvement or stabilisati on within the fi rst weeks or months 
aft er onset of disease (GBS-TRF) from a pati ent having a second episode of weakness due 
to A-CIDP. It is relevant to disti nguish between these two variants as soon as possible 
because treatment strategy and prognosis diff er considerably. 
 In this study we investi gated characteristi cs and course of the disease in pati ents with 
GBS-TRF and A-CIDP and aimed to provide clinical factors that can help to disti nguish 
between these two variants of infl ammatory polyneuropathy in the early phase of disease. 
METHODS
Clinical data were obtained from medical records of consecuti ve pati ents with GBS and 
CIDP hospitalized or assessed in the Erasmus MC during the period 1987 to 2003. All 
pati ents fulfi lled the criteria for GBS or CIDP (1). Pati ents with Miller-Fisher syndrome 
were excluded. A GBS-TRF case was defi ned as a pati ent with GBS with one or more TRFs 
aft er the fi rst episode of weakness, eventually followed by a monophasic course. 
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 To determine the severity of weakness, nadir, and improvement or deteriorati on, the 
Medical Research Council (MRC) sum score and the GBS disability scale were used (7,10). 
A TRF was defi ned as 1) improvement in GBS disability score of at least one grade or 
improvement in the MRC sum score of more than 5 points aft er completi on of therapy, 
followed by a worsening in GBS disability score of at least one grade or a decrease in the 
MRC sum score of more than 5 points within the fi rst months aft er onset of disease or 
2) stabilisati on of the clinical course for more than 1 week aft er completi on of therapy, 
followed by a worsening of at least one grade of the GBS disability score or more than 5 
points on the MRC sum score (7). 
 An A-CIDP case was defi ned as a pati ent with CIDP in whom the nadir of the fi rst episode 
of weakness was within 8 weeks from onset of disease and the consecuti ve course was 
chronic, like CIDP (2). Exacerbati on in A-CIDP was defi ned as deteriorati on aft er the 
fi rst episode of weakness, using the same criteria as for TRFs, with the excepti on that 
completi on of therapy and occurrence within the fi rst months aft er onset of disease are 
not requirements.
 Because only part of the exacerbati ons in CIDP is treatment related, we use the term 
exacerbati ons in stead of treatment-related deteriorati ons. For both groups, follow-
up data were obtained for a 2-year period aft er onset of disease. Onset of disease was 
defi ned as onset of initi al weakness. 
 For diff erences in characteristi cs, symptoms, GBS disability score, and number of days 
to TRF or exacerbati on, the c2 test was used or the exact two-sample test of Wilcoxon-
Mann-Whitney when appropriate. All calculati ons were performed using Stata/SE 8.2 
for Windows 2000 (Stata Stati sti cal Soft ware, College Stati on, TX). A p value < 0.05 was 
considered to be signifi cant.
RESULTS 
Eleven of 190 pati ents with GBS (6%) had at least one TRF. Thirteen of 100 CIDP pati ents 
had A-CIDP. 
 Baseline characteristi cs, clinical features, and initi al treatment are listed in table 1. In 
the pati ents with A-CIDP, a fi xed intermitt ent treatment regimen was started aft er three 
exacerbati ons. There was a diff erence in the median ti me to reach nadir between the 
GBS-TRF and A-CIDP group (table 2). At nadir, there was a signifi cant diff erence in GBS 
disability score. All pati ents with GBS-TRF had their fi rst TRF within 11 weeks (median 
17 days; range 7 to 74 days). The median ti me to reach the fi rst exacerbati on in pati ents 
with A-CIDP was higher (74 days, range 17 to 125). Of the pati ents with GBS-TRF, 27% 
had a second TRF. Only one pati ent with GBS (9%) had also a third TRF. Of the pati ents 
with A-CIDP, 54% had at least three exacerbati ons in the fi rst 2 years. Of the pati ents with 
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GBS-TRF, 82% had their TRF(s) within 9 weeks from onset of disease, whereas 92% of the 
pati ents with A-CIDP had their exacerbati on(s) aft er 9 weeks from onset of disease. The 
relati onship between the course of the disease, TRFs in GBS-TRF, and exacerbati ons in 
A-CIDP is expressed in the fi gure.
Table 1 | Baseline characteristi cs
GBS-TRF 
(n=11)
A-CIDP 
(n=13)
Sex distributi on, n (%)
  Male 
  Female
4 (36)
7 (64)
7 (54)
6 (46)
Median age at onset, y 
(90% intercenti le range)
       44.8 
   (14.1-71.6)
      32.1 
   (7.1-58.6)
Cranial nerve involvement, n (%) 5 (45) 3 (23)
Pure motor variant, n (%) 1 (9) 2 (15)
Initi al treatment, n (%)
  PE
  IVIg
  IVIg + corti costeroids
  None
0 (0)
7 (64)
4 (36)
0 (0)
1 (8)
8 (62)
1 (8)
3 (23)
GBS-TRF = Guillan-Barré syndrome with treatment-related fl uctuati on(s), A-CDIP = chronic infl ammatory 
demyelinati ng polyneuropathy with acute onset, PE = plasma exchange, IVIg = intravenous immuno-globulins 
Table 2 | Clinical informati on on course of disease 
GBS-TRF 
(n=11)
A-CIDP 
(n=13)
p Value
Time to reach nadir, median (90% intercenti le range), d  8 (2-28) 26 (3-52) 0.02
Nadir, n (%)
  ≤ 4 weeks 
  4 - 8 weeks
11 (100) 
 0 (0)
 8 (62)
 5 (38)
0.03 
GBS disability score at nadir, n (%)
  ≤ 2
  ≥ 3
 0 (0)
11 (100)
 6 (46) 
 7 (54)
0.02
Time to reach 1st TRF/exacerbati on from onset of 
disease, median (90% intercenti le range), d
17 (7-74) 74 (17-125) 0.01
Number of TRFs (GBS-TRF) or exacerbati ons (A-CIDP) 
within two years from onset of disease, n (%)
  ≤ 2
  ≥ 3
10 (91)
 1 (9)
 6 (46)
 7 (54)
0.03
Number of weeks from onset of disease TRFs 
(GBS-TRF) or exacerbati ons (A-CIDP) occur, n (%)
  ≤ 9 
  > 9 
9 (82)
2 (18)
 1 (8) 
12 (92) 
0.03
TRF = Treatment related fl uctuation, GBS disability score ≤ 2 = able to walk unaided, GBS disability score ≥ 3 = 
not able to walk unaided or bed bound
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Figure 1 | Comparison between TRFs in GBS and exacerbati ons in A-CIDP pati ents
Legend: TRF = Treatment related fl uctuati on, GBS-TRF = GBS pati ent with one or more TRFs aft er the fi rst episode 
of weakness, A-CIDP = CIDP pati ent in which the nadir of the fi rst episode of weakness is within eight weeks from 
onset of disease and the consecuti ve course is chronic like CIDP
Nadir, TRFs and exacerbati ons (median) in GBS-TRF (upper part) and A-CIDP (lower part). Only the fi rst three 
exacerbati ons are indicated and the ti me-axis ands at 36 weeks. When a 'GBS-pati ent' deteriorates, the suspicion 
of A-CIDP should rise when this occurs three ti mes or more, or deteriorati on takes place aft er nine weeks from 
onset of disease (indicated with arrow in the upper part)
DISCUSSION
Because prognosis and treatment strategy in pati ents with GBS-TRF and those with A-CIDP 
diff er, it is important to disti nguish these two enti ti es in an early phase of disease. TRFs 
have been reported in 8 to 16% of pati ents with GBS (7-9). In our study, 6% had TRFs; 
diff erences may be explained by the defi niti on and numbers of pati ents studied . Of the 
pati ents with CIDP, 13% had an acute onset, which is comparable with another study (5). 
 The median ti me to reach nadir was signifi cantly shorter in the GBS-TRF group compared 
with the A-CIDP group. Becuase 62% of the pati ents with A-CIDP reached their nadir 
already within 4 weeks, this underscores the diffi  culty in disti nguishing a pati ent withA-
CIDP one with GBS-TRF early in the course of disease. All pati ents with GBS-TRF at nadir 
were unable to walk unaided compared with 54% in the A-CIDP group (p = 0.02). Here, 
selecti on bias has to be taken into account, because we only treated GBS pati ents unable 
to walk unaided.
 In counti ng the number of and ti me to TRFs and exacerbati ons, it should be considered 
that therapy is a confounder. A TRF is by defi niti on related to therapy. The number and 
severity of exacerbati ons in CIDP may also largely be infl uenced by therapy. However, the 
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fl uctuati ons in severity of disease in CIDP, irrespecti ve the use of therapy, closely resembles 
clinical practi ce. 
 Our experience suggests that the diagnosis of A-CIDP should be considered when a 
pati ent with GBS deteriorates aft er 9 weeks from onset or when deteriorati on occurs three 
ti mes or more. Maintenance treatment should then be considered. A prospecti ve study 
is needed to help to disti nguish pati ents with GBS-TRF from those with A-CIDP even more 
accurately early in the course of disease.
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ABSTRACT
Background: The disti ncti on between GBS with fl uctuati ons shortly aft er start of treatment 
(treatment related fl uctuati ons or GBS-TRF) and chronic infl ammatory demyelinati ng 
polyneuropathy with acute onset (A-CIDP) is diffi  cult but important because prognosis 
and treatment strategy largely diff er. 
Objecti ves: The aim of the study was to provide criteria that can help to disti nguish 
between GBS-TRF and A-CIDP already in the early phase of disease. 
Methods: GBS pati ents (n=170) were included in a prospecti ve longitudinal study. GBS-TRF 
(n=16) and A-CIDP pati ents (n=8) were analysed and compared. Extended clinical data, 
biological material and electrophysiological data were collected during 1 year follow-up. 
Results: The fi rst TRF in the GBS-TRF group always occurred within 8 weeks (median 18 
days; range 10-54 days) from onset of weakness. In the GBS-TRF group fi ve (31%) pati ents 
had a 2nd TRF, none had more TRFs. At all ti me-points, pati ents in the A-CIDP group were less 
severely aff ected than the pati ents with GBS-TRF, did not need arti fi cial venti lati on, rarely 
have cranial nerve dysfuncti on and tended to have more ‘CIDP-like’ electrophysiological 
abnormaliti es. More GBS-TRF pati ents were severely aff ected and more pati ents had 
sensory disturbances when compared to the GBS group without fl uctuati ons.
Conclusions: The diagnosis of A-CIDP should be considered when ‘a pati ent with GBS’ 
deteriorates again aft er eight weeks from onset or when deteriorati on occurs three ti mes 
or more. Especially when the pati ent remains able to walk independently, has no cranial 
nerve dysfuncti on and electrophysiological features likely to be compati ble with CIDP, 
maintenance treatment for CIDP should be considered. 
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INTRODUCTION
Guillain-Barré syndrome (GBS) and chronic infl ammatory demyelinati ng polyneuropathy 
(CIDP) are immune-mediated neuropathies, sharing many symptoms and signs in the 
acute phase of disease (1-3). To diff erenti ate between GBS and CIDP in the early phase 
of disease, clinicians primarily use the ti me to reach maximum severity (nadir) and the 
subsequent course of the disease. GBS is a monophasic disease in which the ti me to 
reach nadir by defi niti on is within four weeks (4,5). In CIDP, the initi al progressive phase 
lasts more than two months, whereaft er the course may be relapsing-remitti  ng, steadily 
progressive or monophasic (6). 
 However, not all pati ents fulfi l all diagnosti c criteria for either GBS or CIDP. It has 
been reported that 16% of pati ents with CIDP have rapidly progressive weakness, with 
a nadir within eight weeks from onset of disease which is followed by a chronic course. 
These pati ents are considered to suff er from acute onset CIDP (A-CIDP) (7). On the other 
hand, 8-16% of pati ents with GBS have one or more deteriorati ons shortly aft er initi al 
improvement or stabilisati on following plasma exchange or intravenous immunoglobulin 
(IVIg), described as “treatment related fl uctuati ons” (TRF) (8-11). Additi onally a group 
of pati ents with a progressive phase of 4-8 weeks and a monophasic course has been 
described as subacute infl ammatory demyelinati ng polyneuropathy (SIDP) (13,14). In 
clinical practi ce, it may be very diffi  cult to disti nguish a GBS pati ent having a secondary 
deteriorati on aft er initi al improvement or stabilisati on within the fi rst weeks or months 
aft er onset of disease (GBS-TRF) from a pati ent having a second episode of weakness due 
to A-CIDP (15,16). 
 Because treatment strategy and prognosis for GBS-TRF and A-CIDP diff er considerably, 
it is relevant to disti nguish between these two variants early in the course of disease. 
A pati ent with GBS-TRF generally requires a repeated IVIg course or plasma exchanges, 
whereas A-CIDP pati ents require long-term maintenance treatment with steroids, IVIg or 
plasma exchange with or without immunosuppressive agents. In a retrospecti ve study, 
we suggested that the diagnosis A-CIDP should be considered when ‘a pati ent with GBS’ 
deteriorates aft er nine weeks from onset, or when deteriorati on occurs three ti mes or 
more (11). There currently is no prospecti ve study that provides robust criteria that can 
help to disti nguish between GBS-TRF and A-CIDP already in the early phase of  disease. 
 Regarding electrophysiological patt erns, a direct comparison between GBS-TRF and 
A-CIDP in the literature is also lacking. However, A-CIDP pati ents seem to have some 
disti nct electrophysiological features when compared to CIDP pati ents with a more chronic 
onset of disease (17). GBS-TRF pati ents more frequently have sensory disturbances, but 
otherwise no disti nct electrophysiological characteristi cs when compared to GBS pati ents 
(12). 
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 In this study we prospecti vely investi gated a large number of pati ents initi ally diagnosed 
as GBS. Detailed clinical, biological and electrophysiological characteristi cs were analysed 
into more detail. We aimed to provide more criteria that can help to disti nguish between 
GBS-TRF and A-CIDP pati ents already in the early phase of disease. 
METHODS
Pati ents
170 pati ents diagnosed with GBS or MFS were prospecti vely included in the GRAPH 
study (GBS Research about Pain and Heterogeneity) (4,18). During follow-up, part of the 
pati ents showed one or more TRFs. Some pati ents initi ally diagnosed and included in the 
GRAPH study as having “GBS”, fi nally revealed to have a chronic relapsing and remitti  ng 
course. These pati ents were re-classifi ed as A-CIDP (11). Because we aimed to diff erenti ate 
between GBS-TRF and A-CIDP, we only analysed these two groups of pati ents. 
Study design
Between February 2005 and October 2008 pati ents admitt ed in one of the 55 parti cipati ng 
Dutch centres were included in the GRAPH study. Exclusion criteria were: age below 
twelve and signifi cant co-morbidity with a worse prognosis (less than 1 year survival). The 
protocol was approved by the ethics committ ee of the Erasmus MC and subsequently by 
the other parti cipati ng centers. Clinical data, biological material and electrophysiological 
data were collected systemati cally during 1 year follow-up aft er obtaining writt en informed 
consent for parti cipati ng the study. 
 Questi onnaires were fi lled in by the neurologist twice a week during hospital stay and 
once aft er 6 months. If the pati ent, due to deteriorati on aft er hospital discharge, visited 
the hospital again during one year follow-up, an additi onal questi onnaire was fi lled in by 
the neurologist.
 When the pati ent was discharged from hospital, additi onally questi onnaires were fi lled 
in by the pati ent or relati ves at 3, 6, 9 and 12 months aft er inclusion. Aft er receiving the 
questi onnaires back, the research coordinator phoned the pati ent when questi ons were 
not fi lled in. 
Questi onaires
Baseline characteristi cs and data about medical history were obtained. Neurological 
symptoms and signs, disability scale (GBS disability scale -ranging from 0 “no symptoms or 
signs” to 6 “dead” (19)), impairment scale (MRC sumscore -ranging from 0 “paralysis” to 
60 “normal strength” (20,21)), treatment and course of disease were obtained from the 
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questi onnaire fi lled in by neurologist. Aft er hospital discharge, the GBS disability score and 
course of disease were obtained from the questi onnaire fi lled in by pati ent. 
 To determine nadir, improvement, deteriorati on or stabilisati on during 1 year follow-up, 
the GBS disability score (19) and MRC sumscore (20,21) were used. The fi rst progressive 
phase needs to have its nadir within four weeks, in accordance with the criteria for GBS. 
Thereaft er, TRFs (in case of GBS-TRF) and exacerbati ons (in case of A-CIDP) occurred with 
their own nadir. Because only part of the exacerbati ons in A-CIDP is treatment related 
(especially during the later phase of disease), here we used the term exacerbati ons in 
stead of TRFs. In every questi onnaire, informati on on improvement, stabilisati on or 
deteriorati on was obtained and we questi oned if there was a new hospital visit or any 
re-treatment. A TRF or exacerbati on was defi ned as: 1) Improvement in GBS disability 
score of at least one grade or improvement in MRC sumscore of more than fi ve points 
aft er completi on of therapy, followed by a worsening in GBS disability score of at least one 
grade or a decrease in MRC sumscore of more than fi ve points within the fi rst months aft er 
onset of disease or: 2) Stabilisati on of the clinical course for more than one week aft er 
completi on of therapy, followed by a worsening of at least one grade of the GBS disability 
score or more than fi ve points on the MRC sumscore (8,11). For both groups, follow-up 
was 1 year aft er inclusion. However for counti ng the number of exacerbati ons in case of 
A-CDIP we only used the period before maintenance treatment with IVIg or steroids was 
started. Time to TRF or exacerbati on is defi ned as the number of days from onset of fi rst 
weakness unti l nadir of the TRF or exacerbati on.
 We defi ned pati ents as ‘pure motor’ when pinprick and vibrati on sense, were normal. 
We used the MRC sumscore and the GBS disability scale to indicate the severity of disease 
(mildly aff ected = able to walk unaided = GBS disability scale ≤ 2; severely aff ected = unable 
to walk unaided = GBS disability scale > 2).
Preceding infecti ons
The following preceding infecti ons were scored within four weeks of onset of GBS: 
respiratory tract infecti on or infl uenza(-like) illness and gastro-enteriti s or diarrhoea. These 
pati ents were considered to have a clinically defi ned infecti on when these symptoms met 
the criteria for these infecti ons according to the Center of Disease Control (CDC) defi niti ons 
for nosocomial infecti ons (22). Acute phase serum samples were tested to determine 
recent infecti on with Campylobacter jejuni using the assay described before (23). 
Anti -ganglioside anti bodies
We screened for the presence of IgG and IgM anti bodies against GM1, GM2, GD1a, GD1b 
and GQ1b in ELISA, according to methods described earlier (24,25).
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Cerebrospinal fl uid examinati on
In the acute phase of disease, number of cells and protein level in the cerebrospinal fl uid 
(CSF) was determined. 
Electrophysiology
According to the protocol, electrophysiological investi gati ons were scheduled within three 
weeks aft er inclusion in the GRAPH study. Pati ents were analysed whether they fulfi lled 
the electrophysiological criteria for CIDP (26). The electrophysiological investi gati ons 
were executed according to local setti  ngs of the parti cipati ng hospitals. Motor nerve 
conducti on studies were performed orthodromically in the ulnar, peroneal, and opti onally 
in the median and ti bial nerve. In these nerves the distal and proximal compound muscle 
acti on potenti al (dCMAP and pCMAP) amplitude, distal motor latency (DML), motor 
nerve conducti on velocity (mNCV), and F-wave latencies were measured. Anti dromic 
sensory nerve conducti on studies were performed in the median, ulnar, and opti onally 
in the sural nerves. The sensory nerve acti on potenti al (SNAP) amplitude and sensory 
nerve conducti on velocity (sNCV) were measured. The nerves were sti mulated at the 
conventi onal sti mulati on points (27). Needle EMG was performed opti onally. Pati ents 
were classifi ed as demyelinati ng, axonal, equivocal or normal according to the published 
classifi cati on (28). Reference values were derived from Buschbacher and Pralow (27). In 6 
A-CIDP pati ents, also a second electrophysiological investi gati on was performed.
Stati sti cs
To compare characteristi cs of GBS pati ents and controls an unpaired t-test or c2 test 
was performed tested two sided. If appropriate, the Mann-Whitney U test or the Fisher 
exact test was used. Data are cited with mean +/- Standard Deviati on (SD), median + 95% 
confi dence interval (95% CI) for the median. For categorical variables, frequencies and 
percentages are given. All calculati ons were performed using SPSS for Windows 2000 
(version 15.0 SPSS, Chicago). A p-value < 0.05 was considered to be signifi cant.
RESULTS 
Pati ents
Between February 2005 and October 2008, 170 pati ents with GBS or MFS were enrolled 
in the GRAPH study. Three misdiagnosed pati ents were excluded. Three other pati ents 
were excluded because they had Bickerstaff  encephaliti s (n=2) or myeliti s (n=1). Of the 
remaining 164 pati ents (146 GBS and 18 MFS), there were 16 pati ents (10%) with at least 
one TRF, and 8 pati ents (5%) that turned out to have A-CIDP. None of these 24 pati ents 
were included in our previous retrospecti ve study (11). There were no SIDP pati ents.
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 Clinical characteristi cs, preceding infecti ons and laboratory fi ndings in GBS-TRF (n=16) 
and A-CIDP pati ents (n=8) in the acute phase are listed in table 1. Pati ents with A-CIDP had 
signifi cant less cranial nerve dysfuncti on compared to GBS-TRF (13% versus 69%, p=0.03). 
One A-CIDP and no GBS-TRF pati ents had a preceding vaccinati on. The same items listed 
in table 1 were also compared between GBS (n=140) and GBS-TRF (n=16) pati ents. The 
only signifi cant diff erence we found was a lower percentage of pure motor pati ents in the 
GBS-TRF group compared to the GBS group without fl uctuati ons (6% versus 39%; p<0.05). 
Table 1 | Clinical characteristi cs, preceding infecti ons and laboratory fi ndings in the acute 
phase in GBS-TRF and A-CIDP pati ents
GBS-TRF
(n=16)
A-CIDP 
  (n=8)
p Value
Male, n (%) 12 (75)    6 (75) 1.0
Age at onset, mean ± SD 54 ± 17    47  ± 18 0.37
Previous GBS-like episode in medical history, n (%) 1 (6)    1 (13) 1.0
Parestheti c / hypestheti c sensati ons, n (%)
  Pure motor
  Pain before onset of weakness 
  Pain in acute phase 
14 (88)
1 (6)
  6 (38)
13 (81)
   8 (100)
   2 (25)
   4 (50)
   5 (71)*
0.54
0.25
0.67
0.62
Cranial nerve dysfuncti on, n (%)
  III, IV or VI
  VII
  IX, X or XII
11 (69) 
  6 (38)
10 (63)
  4 (25)
   1 (13) 
   0
   1 (13)
   0
0.03
Clinical preceding infecti ons, n (%) 
  Respiratory tract / Infl uenza(-like)
  Gastro-enteriti s / Diarrhea
  5 (31)
  4 (25)
   2 (25)
   2 (25)
1.0
1.0
CSF
  Cells, 106/l, median (95%CI)
  Protein, g/L, median (95%CI)
  Increased protein, >0,55 g/L, n (%)
     2 (2-4)+
  0.9 (0.4-1.8)
10 (63)
   2 (0-5)‡ 
0.7 (0.5-1.6)*
   4 (57)*
0.30
0.68
1.0
Anti -ganglioside anti bodies, n (%)
  IgM reacti vity against GM1, GM2, GD1a, GD1b or 
GQ1b
  IgG reacti vity against GM1, GM2, GD1a, GD1b or 
GQ1b
  2 (13)
  3 (19)
   1 (13)
   0
1.0
0.53
‡ n=6, *n=7, + n=15, GBS-TRF= GBS with treatment related fl uctuati ons, A-CIDP= acute onset chronic infl ammatory 
demyelinati ng polyneuropathy
TRFs and exacerbati ons
The course of disease during follow-up is indicated in table 2. There was a signifi cant 
diff erence in the median ti me to reach nadir, 1st TRF / exacerbati on and 2nd TRF / 
exacerbati on between GBS-TRF and A-CIDP. All GBS -TRF pati ents had their nadir within 16 
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days and the A-CIDP pati ents within 22 days. The median ti me to reach nadir in the GBS 
group without fl uctuati ons was 8 days which was very much comparable with GBS-TRF 
group. 
 The fi rst TRF in the GBS-TRF group was always within 8 weeks (median 18 days; range 
10-54 days), and 14 of the 16 GBS-TRF pati ents had their fi rst TRF within 4 weeks. Five 
(31%) GBS-TRF pati ents had also a 2nd TRF and none of these pati ents had more than 
2 TRFs. All A-CIDP pati ents had their exacerbati ons aft er 4.5 weeks (median 51 days; 
range fi rst exacerbati on: 31-63 days). The A-CIDP pati ents had 2 to 5 exacerbati ons unti l 
intermitt ent treatment was started. At all ti me-points there was a signifi cant diff erence in 
level of weakness and severity between GBS-TRF and A-CIDP (table 2). The GBS-TRF group, 
in comparison with the GBS group without fl uctuati ons, was more severely aff ected (100% 
versus 79%; p<0.05) and contained more venti lated pati ents (44% versus 15%; p<0.05) at 
nadir. 
Table 2 | Course, number and severity of TRFs in GBS-TRF and exacerbati ons in A-CIDP
GBS-TRF 
(n=16)
A-CIDP
 (n=8)
p Value
Course
  Days to reach nadir+, median (95%CI)
  Days to reach 1st TRF/exacerbati on+, median (95%CI)
  Days to reach 2nd TRF/exacerbati on+, median (95%CI)
  Days from onset of weakness ti ll inclusion
  Days from onset of paresthesia ti ll inclusion 
  Days from onset of hypesthesia ti ll inclusion
8,5 (6-11)
 18 (15-27)
 38 (31-46)*
   5 (2-10)
   8 (5-17)∞
6.5 (3-12)≈
16,5 (5-22)
    51 (31-63)
 105 (52-116)*
14.5 (5-26)
12.5 (7-24)
   10 (7-21)∆
0.03
0.00
0.01
0.01
0.04
0.12
Number, n (%) 
  >2 TRFs /exacerbati ons ‡    0      4 (50) 0.01
Severity 
  GBS disability score ≤2 at nadir, n (%)
  MRC sumscore at nadir, median (95%CI)
  GBS disability score ≤2 at 1st TRF / exacerbati on
  MRC sumscore at 1st TRF / exacerbati on, median 
(95%CI)
  Venti latory support aft er onset of disease
   0
 42 (26-48)
   0
 31 (10-40)∞
   7 (44)
     5 (63) 
    49 (46-54)
     4 (50)
   50 (45-52)**
     0
0.00
0.01
0.01
0.00
0.05
* n=5, ∆ n=6, ** n=7, ≈ n=10, ∞ n=14, + from onset of disease, ‡ unti l intermitt ent treatment was started, TRF = 
treatment related fl uctuati on, GBS-TRF = GBS with treatment related fl uctuati ons, A-CIDP = acute onset chronic 
infl ammatory demyelinati ng polyneuropathy, GBS disability score ≤2 = able to walk independently = mildly aff ected
Laboratory fi ndings
Table 1 shows the results from the laboratory fi ndings. There were no diff erences in CSF 
protein level and number of cells in CSF between GBS-TRF and A-CIDP. In one GBS-TRF 
pati ent (6%) and none of the A-CIDP pati ents, serological evidence was found for a recent 
infecti on with Campylobacter jejuni. One GBS-TRF pati ent had IgG and IgM reacti vity 
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against GM1 and GD1b. In one GBS-TRF pati ent IgG reacti vity against GD1b and GQ1b was 
found, in another GBS-TRF pati ent IgG reacti vity against GD1b was found. In one GBS-TRF 
and one A-CIDP pati ent IgM reacti vity against GM1 was found.
Electrophysiologic fi ndings
Electrophysiological investi gati ons of 14 GBS-TRF pati ents and 8 A-CIDP pati ents were 
performed aft er 13 days (median; 95% CI: 0-16 days). Of 18 pati ents the electrophysiological 
investi gati ons were performed within 3 weeks aft er inclusion (as was formulated in the 
protocol). Due to clinical conditi ons, 4 pati ents had their electrophysiological investi gati on 
1 or 2 weeks later. In 6 A-CIDP pati ents, also a second electrophysiological investi gati on 
was performed (median 67 days, 95% CI: 15-187 days). Of 2 GBS-TRF pati ents, the 
electrophysiological investi gati ons could not be retrieved. The A-CIDP group tended to 
have more “CIDP-like” abnormaliti es (table 3). A higher percentage of A-CIDP pati ents 
showed decreased mNCVs compared to the GBS-TRF group (p=0.04). The A-CIDP group 
showed a higher percentage of other demyelinati ng features, more sensory abnormaliti es 
and a lower percentage of pati ents showed acti ve denervati on. However, these diff erences 
did not reach stati sti cal signifi cance. Only 2 pati ents in the A-CIDP group fulfi lled the 
electrophysiological criteria for CIDP (26). Yet, also in the GBS-TRF group 2 pati ents 
fulfi lled these criteria. In the second EMG the demyelinati ng features of the A-CIDP group 
were more pronounced, though sti ll only 2 pati ents fulfi lled the strict electrophysiological 
criteria for CIDP (26). 
DISCUSSION
Because prognosis and treatment strategy in GBS-TRF and A-CIDP pati ents diff er, it 
is important to disti nguish these two enti ti es already in an early phase of disease. We 
prospecti vely investi gated the diff erences between GBS-TRF and A-CIDP pati ents
 In the current study, 5% of the pati ents initi ally diagnosed as GBS revealed to have 
A-CIDP. This is the fi rst study that prospecti vely investi gated the development of A-CIDP in 
a large group of pati ents initi ally diagnosed as GBS. By defi niti on CIDP pati ents should have 
their nadir beyond eight weeks. In this study all A-CIDP pati ents had their nadir already 
within four weeks, being the reason that they initi ally were diagnosed as GBS, however 
acti ve disease exceeded 8 weeks in all A-CIDP pati ents (4,5). In our retrospecti ve study on 
this issue for which we used our CIDP database, it appeared that over half of the A-CIDP 
pati ents already reached their nadir within four weeks (11). The fact that nadir for A-CIDP 
oft en already is reached within four weeks underscores the diagnosti c diffi  culti es between 
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GBS-TRF and A-CIDP. In this study, 10% of the GBS pati ents had at least one TRF. This 
percentage is comparable with the percentages described before (9,11,12).
Table 3 | Elelectrophysiological fi ndings in GBS-TRF and A-CIDP pati ents
GBS-TRF 
(n=14)
A-CIDP
 (n=8)
p Value$ A-CIDP
2nd EMG
 (n=6)
Demyelinati ng features, n (%)
  Prolonged DML 9 (64) 6 (75) 0.86 6 (100)
  Decreased mNCV 4 (29) 6 (75) 0.04 4 (67)
  Conducti on block and/or temporal dispersion 4 (29) 3 (38) 0.67 2 (33)
  Increased latency F-wave 5 (50)+ 5 (83)‡ 0.18 5 (100)§
Axonal features, n (%)
  Denervati on potenti als 7 (54)# 6 (75) 0.06 1 (20)§
  Sensory abnormality arms 7 (50) 0 (0) 0.08 5 (83)
Classifi cati on, n (%) 0.53
  Demyelinati ng 9 (64) 6 (75) 5 (83)
  Axonal 2 (14) 0 0
  Equivocal 3 (21) 2 (25) 1 (17)
  Normal 0 0 0
CIDP criteria fulfi lled, n (%) 2 (14) 2 (25) 0.90 2 (33)
§ n=5, ‡ n=6, + n=10, # n=13, GBS-TRF= GBS with treatment related fl uctuati ons, A-CIDP= acute onset chronic 
infl ammatory demyelinati ng polyneuropathy, Prolonged DML: DML >110% of upper limit of normal (ULN) (120% 
if dCMAP < 100% of lower limit of normal (LLN)), Decreased mNCV: mNCV <90% LLN (85% if dCMAP <50%LLN), 
F-wave abnormality: F-wave latency >120% ULN or absent F-wave, Conducti on block or temporal dispersion: with 
pCMAP/dCMAP rati o of ≤50% (dCMAP≥ 20% LLN), Sensory abnormality: SNAP < 50% LLN or absent, $ p-value of 
diff erences between fi rst EMGs of GBS-TRF group and A-CIDP group 
This prospecti ve study showed diff erent clinical, biological and electrophysiological 
characteristi cs of A-CIDP pati ents compared to GBS-TRF pati ents. The median ti me to 
reach nadir, 1st exacerbati on and 2nd exacerbati on was signifi cantly longer in the A-CIDP 
group compared to the GBS-TRF group. In contrast to A-CIDP pati ents, none of the GBS-
TRF pati ents deteriorated aft er 8 weeks. Most GBS-TRF pati ents had their 1st deteriorati on 
within 4 weeks and none of the GBS-TRF pati ents had more than 2 TRFs. At least half of the 
A-CIDP pati ents were able to walk independently at nadir of the diff erent deteriorati ons 
and none of the A-CIDP pati ents needed arti fi cial venti lati on. This is signifi cantly diff erent 
from the GBS-TRF pati ents were none of the pati ents were able to walk independently 
and 44% needed arti fi cial venti lati on at nadir of the diff erent deteriorati ons. In line with 
the diff erences in severity based on the GBS disability score, the MRC sumscore was 
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signifi cantly lower in the GBS-TRF group compared to A-CIDP group. In counti ng the 
number of, ti me to and severity during the deteriorati ons it should be considered that 
therapy is a confounder in both groups. Therefore, we only counted the exacerbati ons in 
the A-CIDP group before the start of intermitt ent treatment. 
 A-CIDP pati ents had signifi cantly less cranial nerve dysfuncti on compared with the 
group of pati ents having GBS-TRF, which is in line with our previous retrospecti ve study 
(11). The percentage of pati ents with cranial nerve involvement and the level of disability 
and weakness in the A-CIDP group are in line with the clinical characteristi cs usually 
found in CIDP (7). There were no diff erences in preceding infecti ons between the GBS-
TRF and A-CIDP group. In GBS-TRF, preceding infecti ons have been described before in a 
similar percentage (12). There are no studies known about preceding infecti ons in A-CIDP, 
however the percentage of preceding infecti ons found in the group of A-CIDP pati ents are 
comparable with the preceding infecti ons found in CIDP (7). None of the A-CIDP pati ents 
had a positi ve Campylobacter Jejuni serology. In the GBS-TRF group there was only one 
pati ent with a positi ve Campylobacter Jejuni serology and the pure motor form. In a 
previous study none of the GBS-TRF pati ents had the pure motor form (12). 
 While not signifi cant, GBS-TRF pati ents more frequently had IgM and IgG reacti vity 
against anti -gangliosides as compared to the A-CIDP pati ents. IgM anti -GM1 reacti vity has 
been described before in CIDP and other chronic neuropathies, but in lower percentages 
than in GBS, comparable with our previous fi ndings (25).
 Although for most individual electrophysiological variables there was no stati sti cal 
signifi cance, the A-CIDP group displayed a trend towards a more “CIDP-like” electro-
physiological investi gati on (26). Signs of axonal damage (denervati on potenti als) are rare 
in the A-CIDP group, while more than half of the GBS-TRF pati ents showed signs of axonal 
damage in the acute phase. Probably the numbers of pati ents per group were too small to 
reach stati sti cal signifi cance. 
 None of the 18 Miller Fisher syndrome (MFS) pati ents enrolled in this study developed 
TRFs. This is a remarkable observati on because recurrences of MFS, are more frequent 
compared to GBS (29). 
 Compared to the group of GBS pati ents without TRFs, this study additi onally showed 
that the more severely aff ected GBS pati ents with sensory disturbances are at risk for 
developing TRFs. 
 This prospecti ve study confi rmed the results of our retrospecti ve study and added 
more robust factors and refi ned the results that can help to disti nguish more accurate 
between these variants of infl ammatory polyneuropathy already in the early phase of 
disease (11). These results and our experience indicate that the diagnosis of A-CIDP 
should be considered when ‘a pati ent with GBS’ deteriorates again beyond eight weeks 
from onset or when deteriorati on occurs three ti mes or more. A-CIDP pati ents generally 
binnenwerk l ruts.indd   97 31-3-2010   11:54:45
Ch
ap
te
r 
3.
3 
98 
are less severely disabled compared to GBS-TRF pati ents. Pati ents remaining able to walk 
independently at nadir of diff erent deteriorati ons, having no cranial dysfuncti on and 
showing electrophysiological features likely to be compati ble with CIDP, are more likely to 
have A-CIDP. In these pati ents maintenance treatment should be considered. 
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TREATMENT OF CHRONIC 
INFLAMMATORY DEMYELINATING 
POLYNEUROPATHY
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ABSTRACT
Purpose of the review: Chronic infl ammatory demyelinati ng poly(radiculo)neuropathy 
(CIDP) is a treatable disorder. There are three proven eff ecti ve treatments available. 
Randomised controlled trials have only focussed on short-term eff ects, but most pati ents 
need long-term therapy. The most up-to-date treatment opti ons are discussed. Att enti on 
is also paid to the use of appropriate assessment scales and treatment of residual fi ndings.
Recent fi ndings: A Cochrane review is available indicati ng that intravenous immunoglobulin 
is an eff ecti ve treatment. Equal effi  cacy of intravenous immunoglobulin and steroids was 
shown during a 6-week treatment period. New open studies indicated possible effi  cacy 
for mycophenolate, interferon-β and etanercept. Combinati ons of treatment are scarcely 
studied yet. Some Pati ents with CIDP may have a more acute onset of disease since 
maximum severity is reached within 4–8 weeks, resulti ng in confusion about the diagnosis. 
It was shown that severe fati gue can be a major complaint in Pati ents with CIDP, a training 
regimen might parti ally resolve these problems. 
Summary: CIDP is a treatable disorder, but most pati ents need long-term treatment. 
Intravenous immunoglobulin, steroids and plasma exchange are shown to be eff ecti ve. It 
is suggested that other immunomodulatory agents can also be eff ecti ve, but randomised 
trials are needed to confi rm these benefi ts. General measures to rehabilitate pati ents and 
to manage symptoms like fati gue and other residual fi ndings are important. 
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INTRODUCTION
Chronic infl ammatory demyelinati ng poly(radiculo)neuropathy (CIDP) is generally 
considered being the chronic variety of the Guillain-Barré syndrome (GBS), although there 
are obvious clinical and immunological diff erences (1). Criteria for GBS and CIDP are mainly 
based upon research purposes (2,3). From a clinical prospecti ve, the main diff erence is the 
durati on of clinical deteriorati on, which should be less then 4 weeks in GBS and more 
then 8 weeks in CIDP. The course of CIDP may be one with gradual progression, with steps 
of progression or with spontaneous relapses and remissions. Most pati ents with GBS 
reach their maximum severity of weakness within 2 or 3 weeks from onset. In general 
there will be no confusion with the course of CIDP; however some pati ents with CIDP may 
have a rather acute onset resulti ng in confusion with GBS. This is important because the 
prognosis and treatment diff er considerably. In CIDP it has been shown that intravenous 
immunoglobulin and plasma exchange are eff ecti ve (4,5). Although only one trial with a 
reasonable number of pati ents showed effi  cacy of steroids, it is generally accepted that 
steroids are eff ecti ve in CIDP (6). As the name already indicates, CIDP is a chronic disorder 
and many pati ents need treatment for years. The fear for side eff ects of long-term steroid 
treatment, the high costs of intravenous immunoglobulin and plasma exchange, but also 
the necessity for specialized equipment and the invasive nature of plasma exchange, are 
important factors determining the choice for one of these treatments. Another disabling 
problem for pati ents is the high incidence of fati gue, which may persist for years. These 
issues, and the fact that not all pati ents improve dramati cally and others need treatment 
for a very long period of ti me, led to roundtable meeti ngs on ’Current Opinions on the 
Management of CIDP’ and discussions about new fronti ers in therapy (7). Additi onally, 
the Medical Advisory Committ ee of the Neuropathy Associati on proposed new guidelines 
for the diagnosis and treatment of CIDP (8). Treatment of CIDP is an actual issue which 
is refl ected by the publicati on of several very useful reviews on treatment for CIDP (5,9-
13,14-16). 
What is considered to be chronic infl ammatory demyelinati ng poly(radiculo)
neuropathy?
The diagnosis of CIDP may be diffi  cult to make; an approach to the evaluati on of 
peripheral neuropathies was recently proposed (17). Classical clinical features of CIDP 
consist of a progressive (at least for 8 weeks), symmetrical sensory-motor neuropathy 
with demyelinati ng features on electromyography and an increased cerebrospinal fl uid 
protein, in the absence of another explanati on for the neuropathy. CIDP, however, is not 
a homogeneous disorder. Not only does the extent of neurological involvement vary; the 
minimal requirements to meet the electrophysiological diagnosis are also a matt er of 
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debate (18,19). A helpful new set of electrodiagnosti c criteria for CIDP has been proposed, 
giving 75% sensiti vity and a 100% specifi city with regard to diabeti c neuropathy (20). The 
minimal durati on of initi al progression in CIDP is another issue. Some pati ents with rapid 
progressive weakness like GBS may subsequently follow the otherwise typical clinical 
course of CIDP (21,22,23-25). Within the group of chronic demyelinati ng neuropathies 
that comprise CIDP, several subgroups can be disti nguished like the sensory ataxic 
group, a (sub)-acute motor-sensory demyelinati ng neuropathy, a chronic motor-sensory 
demyelinati ng neuropathy, multi focal motor-sensory neuropathy and a symmetric motor 
demyelinati ng neuropathy (26). Based on clinical and neurophysiological characteristi cs 
the terms multi focal acquired demyelinati ng sensory and motor neuropathy (MADSAM) 
and distal acquired demyelinati ng symmetric neuropathy (DADS) have been proposed 
(27). Whether these variants need specifi c treatment is yet largely unknown. An excepti on 
is pure motor neuropathy in which intravenous immunoglobulin is eff ecti ve and steroids 
may induce clear deteriorati on; a feature that previously has been described in multi focal 
motor neuropathy (MMN) (26). 
Treatment trials
CIDP is a treatable disorder, but most pati ents need long-term treatment. Previous trials 
showed that pati ents with CIDP might improve aft er steroids, intravenous immunoglobulin 
or plasma exchange. Treatment trials are described and the most up-to-date treatment 
opti ons are discussed.
Corti costeroids
Dyck et al. (28) have conducted the only randomised controlled open study of prednison, 
and concluded that steroids are eff ecti ve in CIDP. Several non-randomised studies 
suggest that steroids are benefi cial in CIDP. A Cochrane review concluded that the single 
randomised controlled trial provided weak evidence to support the common opinion 
from non-randomised studies that oral corti costeroids reduce impairment in CIDP (6). 
The advantages of steroids are their availability and low initi al costs, but side eff ects can 
be very serious. The best steroid regimen to start with is not known. If we start with 
prednison, we generally start with 60 mg daily. Others start oral prednison 1.5 mg/kg on 
alternate days in a single morning dose (5). Since most pati ents will need steroids for a 
long-term it is advocated to start osteoporosis prophylaxes at the same ti me, especially 
in elderly pati ents (5). Pati ents with a pure motor form may deteriorate within days aft er 
treatment with steroids (29) (table 1 and 2).
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Plasma exchange
Plasma exchange is shown to be eff ecti ve in CIDP (30,31). A clear disadvantage of plasma 
exchange is its availability, high costs and the relati ve invasiveness of the procedure. 
Pati ents treated with plasma exchange may improve rapidly, but need regular treatment 
to avoid clinical deteriorati on (table 1 and 2).
Table 1 | Proven eff ecti ve treatment for CIDP
Treatment Cochrane 
review
eff ect side-eff ects 
(potenti al)
availability direct-costs
prednison (28,41) (6) + severe very good low
PE (30,31) - + minor rather good high
IVIg (32-35) (4) + minor/none good high
Table 2 | Therapeuti c regimes for CIDP
Proven eff ecti ve treatments Regimen
Prednison Inducti on: 60 mg prednison daily or 1.5 mg/kg on alternate 
days in a single morning dose
Maintenance: slowly tapering over months-years
Intravenous immunoglobulin (IVIg) Inducti on: 2 g/kg, divided over 2/5 days
Maintenance: 0.4/1 g/kg each 2/6 weeks 
Plasma exchange (PE) Inducti on: 3/5 PE sessions (2/2.5 l/session)
Maintenance: 1 PE session/ 1/3 weeks
Not-proven eff ecti ve treatments
IV Methylprednisolon Inducti on: 500 mg daily for 5 days, or 1 g daily for 3 days 
Maintenance: not determined
Azathioprine 1.5/3 mg/kg/day
Mycophenolate mofeti l 1.0/2.0 g/day divided into 2 doses PO
Cyclosporin 2.5/5.0 mg/kg/day divided into 2 doses PO
Methotrexate 7.5/15 mg once a week PO; see (11*)
Other treatments see (13*)
Intravenous immunoglobulin 
In placebo-controlled studies it was found that intravenous immunoglobulin is an eff ecti ve 
treatment for CIDP (31,32-34). A recent Cochrane study confi rmed the favourable eff ect of 
intravenous immunoglobulin (4,36). If pati ents improve aft er intravenous immunoglobulin, 
the improvement starts within 2 weeks. The majority of pati ents need intermitt ent 
treatment during many months or several years to maintain the improved conditi on (37). 
This is a problem because intravenous immunoglobulin is very expensive (table 1 and 2). 
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Intravenous immunoglobulin in general is well tolerated and has no or few mild infusion-
related reacti ons. Serious adverse eff ects are rare and can include thromboembolic events, 
renal failure (mainly in pati ents with pre-existi ng renal failure), anaphylaxis (especially in 
pati ents with IgA defi ciency), or asepti c meningiti s (38). A very useful paper on the use 
and working mechanisms of intravenous immunoglobulin in autoimmune neuromuscular 
diseases was published recently (39).
Comparison between steroids, plasma exchange and intravenous immuno-globulin
Intravenous immunoglobulin was equal to plasma exchange in a single-blind, controlled 
crossover trial of Pati ents with CIDP assigned to a 6-week course of plasma exchange 
or intravenous immunoglobulin, 0.2-0.4 g/kg administered weekly (40). A randomised 
double-blind crossover trial showed that intravenous immunoglobulin (2 g/kg given over 
1 or 2 days) is not signifi cantly bett er compared to oral prednisolon during a treatment 
period of 6 weeks (tapered from 60 to 10 mg daily during that period) (41). This is the only 
trial comparing intravenous immunoglobulin with steroids, but the treatment durati on 
was too short to judge any diff erences in side-eff ects. 
New randomised controlled trials 
No randomised controlled trial on treatment of CIDP has been published over the last year. 
New potenti ally eff ecti ve agents, non-randomised trials
Over the years smaller non-controlled studies reported a positi ve eff ect of immuno-
suppressive agents, such as azathioprine, cyclosporin or mycophenolate. The problem is 
not only the open fashion, but also the selecti on of pati ents since most are refractory to 
standard treatments. Such a negati ve selected populati on makes it even more diffi  cult to 
judge about possible effi  cacy of a new potenti ally eff ecti ve drug.
Mycophenolate
This drug is successfully applied in organ transplantati on pati ents. Recently, favourable 
results of mycophenolate have been reported in a small series of immune-mediated 
neuromuscular disorders including in two pati ents with CIDP (42). Another study reported 
on fi ve consecuti ve treatment-resistant pati ents with CIDP or MMN who were treated 
with mycophenolate. None showed clinical signifi cant benefi t and two of them had side 
eff ects severe enough to stop mycophenolate (43). Another report expresses personal 
experience with mycophenolate, that are not that encouraging (10). We have treated a few 
pati ents with CIDP who did not extremely well on intravenous immunoglobulin or other 
immunosuppressive treatment, in which it is suggested that mycophenolate might be of 
help (P.A. van Doorn, unpublished observati ons). Whether mycophenolate is an att racti ve 
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low-toxicity immunosuppressive agent for treatment of CIDP needs to be evaluated in a 
randomised controlled trial.
Azathioprine
One parallel group open study of azathioprine for 9 months involving 27 parti cipants did 
not show a positi ve eff ect (44). The drug, however, is frequently prescribed because it 
might reduce the steroid dosage. 
Etanercept
Etanercept is a tumour necrosis factor-α antagonist that has demonstrated effi  cacy in 
rheumatoid and psoriati c arthriti s. Ten CIDP and/or variant pati ents who were refractory 
or intolerant of standard therapies were treated with etanercept, subcutaneously, 25 mg 
twice a week. From this uncontrolled, retrospecti ve study it was concluded that three 
pati ents had clear improvement and three others had possible improvement. None of the 
pati ents had adverse eff ects. It was suggested from this study that anti - tumour necrosis 
factor-α agents might be useful in the treatment of some pati ents with CIDP, parti cularly 
in those who are refractory to or are intolerant of standard therapies (45*).
Interferon-β
Interferons are naturally occurring cytokines. A recent prospecti ve, open-label study 
described 20 treatment-resistant (at least a failure of intravenous immunoglobulin) 
pati ents with CIDP who were treated with intramuscular interferon-β-1a 30 μg once a 
week for 6 months. Seven pati ents (35%) showed clinical improvement, 10 (50%) had 
stable disease, the other three pati ents conti nued to deteriorate. This study indicates that 
some pati ents with CIDP may benefi t of this treatment (46). Another study in ten pati ents 
with CIDP failed to demonstrate clinical improvement aft er subcutaneous interferon-β-1a 
(47). Unti l we have no results from a randomised controlled trial no further conclusions 
about the effi  cacy of interferon-β can be drawn. 
 Interferon-β has been tried in CIDP presumably because effi  cacy has been shown in 
multi ple sclerosis. The eff ect of interferon-β however could be diff erent in pati ents with 
demyelinati on of the central or the peripheral nervous system. This was illustrated by a 
publicati on on three children with multi ple sclerosis who were treated with interferon-β 
and who developed CIDP, suggesti ng that interferon-β did not prevent development of 
CIDP. In these pati ents, intravenous immunoglobulin improved the features of CIDP, but 
not of the central demyelinati ng disease (48). A recent overview on the pathogenesis CIDP 
makes comparisons between CIDP and multi ple sclerosis and discusses a rati onale to use 
interferon-β in CIDP (49).
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Cochrane review on cytotoxic drugs and interferons
Since there are only limited studies, it was concluded in a recent Cochrane review that 
the evidence is inadequate to decide whether azathioprine, interferon-β or any other 
immunosuppressive drug is benefi cial in CIDP (50).
Combinati on of treatments
No new trials appeared that studied combinati ons of treatment that may act synergisti cally 
in CIDP. One case-report described two pati ents with CIDP who initi ally improved aft er 
intravenous immunoglobulin but thereaft er deteriorated despite regular intravenous 
immunoglobulin infusions. Various other immunosuppressive drugs did not improve 
these pati ents. However, treatment with plasma exchange immediately followed by 
intravenous immunoglobulin treatment induced a rapid reducti on of weakness (51). 
Intravenous immunoglobulin and steroids are both eff ecti ve in CIDP. The combinati on of 
intravenous immunoglobulin and steroids has not been studied systemati cally in CIDP, but 
is has in GBS. Recently the second randomised controlled trial of the Dutch GBS study 
group was published (52). This trial compares one course of intravenous immunoglobulin 
(0.4 g/kg for 5 days) and methylprednisolon (500 mg/day for 5 days) with intravenous 
immunoglobulin and placebo. There were borderline signifi cant results that became 
signifi cant aft er adjustment for well-known (not study-driven) prognosti c factors favouring 
the combinati on of intravenous immunoglobulin and steroids. Whether a combinati on of 
intravenous immunoglobulin and steroids can be helpful in the treatment of pati ents with 
CIDP has not been investi gated systemati cally . 
Chronic infl ammatory demyelinati ng poly(radiculo)neuropathy and 
diabetes
Reports indicate that 12-18% of pati ents with diabetes meet the electrophysiological 
criteria for CIDP, and that the risk of CIDP is 11 ti mes greater in pati ents with type 2 
diabetes than in those without (53). One study showed that pati ents with diabetes 
and electrophysiological features compati ble with demyelinati on might improve aft er 
immunomodulatory treatment (54). It is not completely clear from this study whether 
these pati ents had a clinical course of progression like idiopathic CIDP. The study indicates 
that pati ents with diabetes having an unexpected course of their neuropathy should be 
evaluated for whether this is CIDP. A controlled trial is needed to establish the safety and 
effi  cacy of intravenous immunoglobulin in diabetes-associated CIDP (39).
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Chronic infl ammatory demyelinati ng poly(radiculo)neuropathy with 
lesions of the central nervous system
The combinati on of CIDP and central nervous system white matt er lesions has been 
described before (48). A recent study reported that resoluti on of clinical and radiographic 
fi ndings of central-nervous-system lesions aft er intravenous immunoglobulin treatment 
(55).
Chronic infl ammatory demyelinati ng poly(radiculo)neuropathy and 
hereditary neuropathy
Seven pati ents with Charcot-Marie-Tooth type 1A (CMT1A) and one with X-linked 
disease (CMTX) were described who had acute or subacute deteriorati on (56). Seven had 
neuropathic pain. The fi ve pati ents who were treated with steroids and/or intravenous 
immunoglobulin had a variable response. It was esti mated that the associati on was more 
frequent than would be expected by chance, suggesti ng that CMT pati ents are predisposed 
to superimposed infl ammati on. The study stressed the importance of looking out for 
unexpected clinical deteriorati on in CMT1A pati ents, because immunotherapy may relieve 
these exacerbati ons (56).
 
Assessment of the eff ect of treatment
Improvement can be assessed at various levels: impairment, disability, handicap and 
quality of life. In order to assess a relevant eff ect of treatment in immune-mediated 
neuropathies, appropriate scales should be applied. An outcome measure needs to be 
relati vely simple, valid and reliable. Additi onally, a scale needs to be responsive which 
makes it suitable to study the eff ect of treatment during the course of disease. Thirteen 
pati ents with CIDP on treatment were regularly examined during a period of 52 weeks. In 
order to detect clinical relevant changes over ti me, a wide range of assessment scales was 
applied during this period. The infl ammatory neuropathy cause and treatment (INCAT) 
disability sumscore, the Medical Research Council (MRC) sumscore, and the Vigori hand-
held dynamometer were among the best responsive scales. It was suggested to use these 
measurements in studies of immune-mediated polyneuropathies (57).
Prognosti c factors related to improvement
A bett er outcome is reported to be related with younger age at onset, relapsing-remitti  ng 
course and absence of axonal damage (16). We have recently reviewed our series of over 
90 pati ents with CIDP and found that all pati ents with a relapsing course improved aft er 
intravenous immunoglobulin treatment (P.A. van Doorn, unpublished observati ons). As has 
been described previously, pati ents with pure motor weakness, irrespecti ve of whether 
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they have MMN or pure motor demyelinati ng neuropathy with symmetric involvement, 
may deteriorate aft er treatment with steroids (26). 
When should one start treatment?
Once the diagnosis of CIDP is clear, treatment should be initi ated when the pati ent exceeds 
a certain level of disability. Some pati ents only have minor symptoms, and especially in 
those pati ents a spontaneous improvement might be awaited since steroids can induce 
severe side eff ects and intravenous immunoglobulin and plasma exchange are very 
expensive. Most studies suggest that axonal degenerati on is a worse prognosti c factor 
for improvement aft er immunomodulatory treatment. It has not been studied whether 
intravenous immunoglobulin or steroids can miti gate the long-term axonal degenerati on 
that typically accompanies disease progression.
Cost-uti lity analysis
Intravenous immunoglobulin is a very expensive therapy and steroids may induce severe 
side eff ects. Cost-uti lity analysis studies would be very helpful for making decisions. A 
recent study was executed to calculate cost-uti lity for the pati ents with CIDP who were 
randomised in the intravenous immunoglobulin/steroids trial (41,58). The main outcome 
measure in the economic evaluati on was the number of quality-adjusted life years gained, 
using an 11-point disability scale to measure clinical outcome. As expected during a 6-week 
period no economic diff erences could be detected favouring intravenous immunoglobulin. 
The methods and data reported in this study could be used in future studies aiming to 
compare various costs, side eff ects and quality of life during long-term treatment.
Managing of residual symptoms
Over recent years, more att enti on has been paid to rehabilitati on of pati ents including 
management of symptoms such as foot drop, but also fati gue and pain (59,60). A recent 
study indicates that a well-structured physical training programme, three ti mes weekly for 
12 consecuti ve weeks can help to reduce severe fati gue and improve quality of life (61).
CONCLUSION
Intravenous immunoglobulin, steroids and plasma exchange are all eff ecti ve in about 70-
80% of pati ents with CIDP. Recent studies indicate that CIDP is a heterogeneous disorder, 
which could be a reason why not all pati ents improve aft er one of these treatments. 
At present there is inadequate evidence to decide whether azathioprine, interferon-β 
or any other immunosuppressive drug is benefi cial in CIDP. Because CIDP is a chronic 
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disorder, new studies should in parti cular evaluate long-term treatment with intravenous 
immunoglobulin and steroids. Many pati ents with CIDP have residual symptoms like 
fati gue, and although their nature is presently obscure it seems that a structured training 
program can be helpful. 
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CHAPTER 4.1
DETERMINATION OF PAIN AND 
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IN GUILLAINͳBARRÉ SYNDROME
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ABSTRACT
Introducti on: Pain can be a serious problem in pati ents with Guillain-Barré syndrome (GBS). 
Diff erent pain symptoms and the eff ect of methylprednisolone on pain are evaluated.
Methods: GBS pati ents were recruited from a randomised placebo-controlled study 
comparing intravenous immunoglobulin (IVIg) + methylprednisolone (500 mg for 5 
days) versus IVIg + placebo. Presence and severity of pain were prospecti vely scored at 
randomizati on and aft er 4 weeks. Effi  cacy of methylprednisolone was evaluated using 
endpoints: percentage of pati ents with pain and percentage of pati ents improving in pain-
severity level. Medical records of the subgroup of pati ents treated in the Erasmus MC 
were screened retrospecti vely for diff erent pain symptoms and course. Pain was scored 
at diff erent ti me intervals: within 4 weeks before randomizati on and 0-2, 2-4, 4-24, 24-52 
weeks aft er randomizati on. 
Results: 123 (55%) of 223 pati ents had pain at randomizati on. In 70%, pain already 
started before onset of weakness. Methylprednisolone did not show a positi ve eff ect 
on the presence and reducti on of pain. In the subgroup of 39 pati ents, backache (33%), 
interscapular (28%), muscle (24%), radicular pain (18%) and painful par-/dysaesthesiae 
(18%) were most frequently present within the period of 4 weeks before randomizati on. 
Twenty-six percent had extreme pain 0-2 weeks aft er randomizati on. Most symptoms of 
pain decreased aft er this period, but painful par-/dysaesthesiae and muscle pain oft en 
remained present during at least 6 months. 
Conclusions: Pain frequently occurs, oft en starts before onset of weakness and may cause 
severe complaints. Especially painful par-/dysaesthesiae and muscle pain may persist for 
months. Methylprednisolone seems to have no signifi cant eff ect on the presence and 
intensity of pain.
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INTRODUCTION
The most striking and alarming feature in pati ents with Guillain-Barré Syndrome (GBS) 
is progressive paralysis. Generally, less att enti on has been paid to pain, which may be a 
common and severe symptom in pati ents with GBS. Recogniti on of pain is very important, 
especially in pati ents unable to communicate due to intubati on, because treatment 
against pain can be off ered. Pain as a presenti ng symptom of GBS before the onset of 
weakness may be misleading in making the diagnosis of GBS and therefore can cause a 
delay in starti ng treatment for GBS. 
 Pain has been described in 3-89% of pati ents with GBS (1,6,9,14). Diff erent symptoms 
of pain associated with GBS have been disti nguished: par-/dysaesthesiae, backache / 
root pain, meningism, muscle pain, joint pain, visceral pain and other types (12). One 
larger study in 55 GBS pati ents subdivided the diff erent symptoms of pain as reported 
on admission into the following: low back pain with radiati on (67.3%), dysaestheti c 
extremity pain (20%) and myalgic-rheumati c extremity pain (9.1%) (9). During the further 
non subdivided period of six months, low back pain with radiati on (61.8%), dysaestheti c 
extremity pain (49.1%) and myalgic-rheumati c extremity pain (34.5%) were noted (9). As 
far as we know, there are no publicati ons on the more detailed course and level of severity 
of the diff erent pain symptoms during the fi rst year aft er onset of GBS. 
 Pain in GBS can be very severe, and treatment is oft en far from successful. In some cases 
however a positi ve eff ect of treatment of pain in the acute phase has been described 
using corti costeroids (8, 16). The pathophysiology of pain is likely multi factorial. Increased 
endoneurial fl uid pressure in nerve trunks possessing the epi- and perineurium may play a 
role (2). A possible cause of a salutary eff ect of corti costeroids could be a reducti on of the 
perineurial and endoneurial infl ammatory reacti on in GBS. 
 Most reports on the eff ect of medicati on to relieve pain in GBS are based on limited 
numbers of pati ents. When measuring a treatment eff ect, oft en all types of pain are 
lumped together (4,8,10,11,15-17). Because it is likely that diff erent pathophysiological 
mechanisms are related to these symptoms, a more detailed classifi cati on of diff erent pain 
symptoms associated with GBS can be of help to study the eff ect of drugs. 
 This study focuses on the frequency, characteristi cs, severity and course of various 
symptoms of pain during the course of GBS and on the eff ect of methylprednisolone as 
was administered in a large placebo-controlled study.
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METHODS
Prospecti ve study
All GBS pati ents were recruited from a double-blind, randomised placebo-controlled, 
multi centre study comparing IVIg + methylprednisolone (500 mg for fi ve days) versus IVIg 
+ placebo (18). A pati ent was eligible for this trial when the onset of weakness was within 
2 weeks before the date of randomizati on and the pati ent was unable to walk 10 meters 
across an open space without assistance (GBS disability score ≥. 3). Presence and severity 
of pain were collected prospecti vely at randomizati on and aft er 4 weeks. Pain severity 
was judged as: none, mild (pain but no real complaints), moderate (complaints, but no 
analgesics necessary) or severe (analgesics necessary). 
Retrospecti ve study 
Medical records of the subgroup of GBS pati ents who entered the trial and were 
admitt ed to the Erasmus MC (the coordinati ng centre) were retrospecti vely screened for 
diff erent pain symptoms. These symptoms were divided in nine diff erent pain symptoms 
as described before (12). In this subgroup of pati ents, severity of pain was judged as: 
none, severe (analgesics necessary in a way the complaints were acceptable) or extreme 
(severe complaints despite analgesics; defi ned as feeling uncomfortable due to pain, not 
well sleeping due to pain). In the Erasmus MC, treatment of pain in the acute phase of 
GBS is standardized following the WHO’s pain ladder. When a GBS pati ent aft er a few 
weeks suff ers from pain resembling neuropathic pain, we generally start amitriptyline 
followed by anti -convulsants. The diff erent pain syndromes and their severity were scored 
at diff erent ti me-intervals: within 4 weeks before randomizati on and 0-2, 2-4, 4-24, 24-52 
weeks aft er randomizati on. The ti me points 0 and 4 weeks were fi xed visits, during the 
other intervals we asked the pati ent at least once for pain at that moment and pain since 
the last visit. Three pati ents had to be excluded from the analysis for the ti me-interval 24-
52 weeks aft er randomizati on because of lost to follow-up aft er 24 weeks.
Stati sti cs
Percentage of pati ents with pain and percentage of pati ents improving in level of pain-
severity in independent groups were compared by the χ2 test. All calculati ons were 
performed using Stata/SE 8.2 for Windows 2000 (Stata Stati sti cal Soft ware, College Stati on, 
TX 77845, USA). A p-value <. 0.05 was considered to be signifi cant. 
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RESULTS 
Prospecti ve study
225 GBS pati ents were included in the prospecti ve study, 2 pati ents were excluded due to 
missing data on the presence of pain. Base-line characteristi cs, including the presence of 
pain at randomizati on between the two treatment groups, was not signifi cantly diff erent 
(table 1). Pain was reported by 123 (55%) of the 223 pati ents at randomizati on, 48 (22%) 
of these pati ents had severe pain. Of the 123 pati ents with pain, 86 (70%) indicated that 
the pain preceded the onset of weakness (median 3 days, range 1–36 days). In 84% of 
the pati ents starti ng with pain, weakness started within one week aft er the onset of pain 
(fi gure 1).
Table 1 | Baseline characteristi cs of treatment groups at randomizati on
IVIg/Placebo group 
(n=112)
IVIg/MP group 
(n=111)
Sex distributi on, n (%)
  Male 56 (50) 73 (66)
Age, median 50 51 
F-score, n (%)
  3
  4
  5
32 (29)
80 (71)
 0 (0)
26 (23)
76 (68)
 9 (8)
Pain, n (%)
  No
  Yes
  Mild 
  Moderate 
  Severe
45 (40)
67 (60)
24 (21)
17 (15)
26 (23)
55 (50)
56 (50)
17 (15)
17 (15)
22 (20)
MP = methylprednisolone
Figure 1 | Occurrence of pain before onset of weakness in 86 GBS pati ents
Legend: Pain = one or more pain symptoms, 86/223 GBS pati ents started with pain before onset of weakness
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 4 weeks aft er randomizati on, 58 pati ents (57%) in the IVIg/placebo group and 51 
(49%) in the IVIg/methylprednisolone group reported pain (no signifi cant diff erence). In 
individual pati ents with pain, there also was no signifi cant diff erence between the IVIg/
methylprednisolone and IVIg/placebo group in decrease or increase of pain severity 4 
weeks aft er randomizati on (Table 2). 
Table 2 | Presence and severity of pain at randomizati on and 4 weeks later
IVIg/Placebo group 
(n=112)
IVIg/MP group 
(n=111)
Pati ents with pain, n (%)
  Randomizati on
  4 weeks aft er randomizati on 
67 (60)
58 (57)
56 (50)
51 (49)
Pati ents with a decrease in pain severity, n (%)
  4 weeks aft er randomizati on 34 (34) 32 (31)
Pati ents with an increase in pain severity, n (%)
  4 weeks aft er randomizati on 26 (26) 22 (21)
MP = methylprednisolone
Retrospecti ve study
Of the 39 retrospecti vely analysed pati ents, 26 pati ents (67%) described one or more 
symptoms of pain within the 4 weeks before randomizati on (fi gure 2). 0-2 weeks aft er 
randomizati on, the prevalence rate increased to 79%, where aft er it decreased. Within the 
fi rst 2 weeks aft er randomizati on, 26% had extreme pain.
Figure 2 | Prevalence rate of pain over ti me in 39 pati ents with GBS 
Legend: Pain = one or more pain symptoms, Extreme pain = severe complaints due to one or more pain symptoms 
despite analgesics; defi ned as feeling uncomfortable due to pain, not well sleeping due to pain; Time-interval 24-
52: n=36 pati ents
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 Backache, radicular, interscapular painful par-/dysaesthesiae and muscle pain most 
frequently occurred in the beginning of the disease (table 3). Most pain symptoms 
decreased within 2 weeks. However, painful par-/dysaesthesiae and muscle pain remained 
rather constantly present during at least 6 months. 
Table 3 | Prevalence of pain symptoms during course of GBS in 39 pati ents
Number of weeks related to randomizati on
Pain symptoms [12] Before Aft er
(-4-0)
n (%)
0-2
n (%)
2-4
n (%)
4-24
n (%)
24-52*
n (%)
  Backache 13 (33) 11 (28) 1 (3)  2 (5) 0 (0)
  Interscapular pain 11 (28)  5 (13) 0 (0)  0 (0) 0 (0)
  Muscle pain / cramps  9 (24)  6 (15) 6 (15)  6 (15) 1 (3)
  Painful par-/dysaesthesiae  7 (18)  7 (18) 8 (21) 11 (28) 5 (14)
  Radicular pain  7 (18)  8 (21) 1 (3)  2 (5) 1 (3)
  Others  6 (15) 12 (31) 7 (18)  3 (8) 0 (0)
  Joint pain  2 (5)  2 (5) 2 (5)  5 (13) 0 (0)
  Visceral pain  2 (5)  4 (10) 4 (10)  3 (8) 0 (0)
  Meningism  0 (0)  2 (5) 0 (0)  0 (0) 0 (0)
* n=36 pati ents
DISCUSSION
In this study, we prospecti vely investi gated the frequency of pain and the eff ect of 
methylprednisolone on pain in a large group of GBS pati ents included in a randomised 
controlled trial. Retrospecti vely we investi gated the frequency and course of the diff erent 
symptoms of pain in more detail in a subgroup admitt ed to the coordinati ng center.
 Pain appeared to be highly prevalent in this large, well documented group of GBS 
pati ents. 55% of these pati ents had pain at randomizati on. In other studies, the incidence 
of pain during the acute phase varies between 3% and 86% (median value 50%) (1,5-7,9, 
13,14,19,20). This variati on mainly seems to be caused by the rather limited number of 
pati ents included in most studies. 
 It is remarkable that 70% of the pati ents reporti ng pain at randomizati on already 
had this pain prior to the onset of weakness. Pain as presenti ng symptom can lead to 
diagnosti c diffi  culti es (3). When pain initi ally is the only symptom, considering GBS as a 
possible diagnosis is not always so likely. So pain in the early phase can be confusing and 
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later on may cause a delay in diagnosing and starti ng specifi c treatment for GBS. This is 
important to realize, because a delay in diagnosing GBS is potenti ally life threatening and 
may hamper recovery. 
 In the subgroup of pati ents that we investi gated retrospecti vely in more detail, a 
somewhat higher percentage of pati ents (79%) reported pain in the acute phase compared 
to the whole group (55%). This is most likely due to the use of a ti me-interval of 2 weeks 
aft er randomizati on in stead of the fi xed point in ti me at randomizati on. 
 In the randomised controlled trial, methylprednisolone was primarily evaluated in 
relati on to the eff ect on disability of GBS (18). We did not use a clinimetrically validated 
scale to assess the level of severity of pain. Therefore the results of the eff ect of 
methylprednisolone on pain have to be interpreted with some cauti on. In the retrospecti ve 
part of the study, we were able to assess the level of pain in more detail. We did this in 
relati on to the use of analgesics. Because both treatment of GBS pati ents and treatment 
of pain is standardized in our center, it is likely that the prescripti on of analgesics is 
rather uniform and reported in a standardized way. This makes it rather well possible to 
judge about pain severity at a very global level in a retrospecti ve way. It appeared that 
approximately a quarter of the GBS pati ents in this study reported extreme pain in the 
acute phase indicati ng that pain is not only a common but also a severe symptom.
 Backache, interscapular and radicular pain were most frequently present in the acute 
phase. However, painful par-/dysaesthesiae remained rather constantly present during 
at least one year (Table 3). This trend is comparable to fi ndings in another larger study in 
which the diff erent pain symptoms were noted on admission and during one further non 
subdivided period of 24 weeks (9). The pathophysiological explanati on of pain in GBS is 
diverse. It seems that pain in the acute phase is predominantly nocicepti ve pain, due to 
infl ammati on of the nerve roots and peripheral nerves which may acti vate nociceptors. 
Later on, many GBS pati ents have neuropathic pain. This neuropathic pain is a non-
nocicepti ve pain that doesn’t arise from pain receptors but results from degenerati on and 
perhaps even regenerati on of nerves and is oft en encountered in pati ents with chronic 
neuropathies. The persistence of muscle pain on the other hand may be related to more 
mechanical factors due to limitati on of physical acti viti es.
 Previous case-reports suggest that corti costeroids might be an eff ecti ve treatment for 
pain, possibly due to its anti -infl ammatory eff ect (8,16). This is the fi rst study that evaluated 
the eff ect of methylprednisolone on pain in a placebo-controlled way. We did not fi nd a 
signifi cant decrease in the presence and severity of pain in the methylprednisolone treated 
group. This indicates that methylprednisolone for pain in general does not seem to have 
a positi ve eff ect. However, there are many symptoms of pain. In previous case reports, 
corti costeroids were reported to have a positi ve eff ect on radicular pain. In our series 10 
out of 39 pati ents had radicular pain. All 5 pati ents treated with methylprednisolone, but 
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also 4 out of 5 pati ents treated with placebo, had a decrease in severity of radicular pain 
aft er 4 weeks. The number of pati ents with radicular pain is too small to conclude about a 
possible favourable eff ect of methylprednisolone on this type of pain in GBS.
  In conclusion, pain frequently occurs and may cause severe complaints in pati ents 
with GBS. It oft en starts before onset of weakness and therefore can lead to diagnosti c 
diffi  culti es. Most pain symptoms decrease within 2 weeks, but painful par-/dysaesthesiae 
and muscle pain may persist for months. Methylprednisolone seems to have no positi ve 
eff ect on the development and reducti on of pain during the acute phase of GBS. 
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INTRODUCTION
In Guillain-Barré Syndrome (GBS), pain is frequently present and can even be misleading 
in making the diagnosis (1-4). Clinicians generally associate pain with aff ected sensory 
nerves and not with a pure motor neuropathy. We investi gated whether pain also occurs 
in the pure motor variant of GBS in a large group of GBS pati ents from Europe and Curaçao 
because this could increase awareness and ulti mately improve insight into mechanisms of 
pain in GBS. 
METHODS
The European pati ents with GBS (predominantly Dutch; GBS disability score ≥3) were 
recruited from a double-blind, placebo-controlled randomised, multi centre study between 
1994 and 2000 (5). The presence and severity of pain were prospecti vely collected. In 
Curaçao, where we previously described the predominant occurrence of pure motor GBS, 
we retrospecti vely screened the medical records of all GBS cases that had been admitt ed 
to the island’s only neurological department between 1987 and 2006 (6). In all cases, the 
presence of pain had been collected from the period ranging from hospital admission 
unti l 4 weeks later. The clinical diff erenti ati on between the motor and sensory-motor 
variant was made on the presence of sensory signs or symptoms by standard neurological 
examinati on. On the basis of electromyographic (EMG) studies, performed within 4 weeks 
aft er admission, we also tried to classify the pati ents as demyelinati ng [acute infl ammatory 
demyelinati ng polyneuropathy (AIDP)] or axonal [acute motor axonal neuropathy (AMAN)] 
(7,8). When the EMG was not conclusive, the pati ent was classifi ed as ’not conclusive’. 
Because we were primarily interested whether pain occurs in pati ents with GBS with pure 
motor neuropathy, only the clinical pure motor and AMAN pati ents were further specifi ed 
in this study.
RESULTS
We studied 225 European and 83 GBS pati ents from Curaçao. Age, sex, maximum GBS 
disability score, and the percentage of pati ents reporti ng pain were not signifi cantly 
diff erent between the two groups (table 1). The percentage of pati ents with a clinically 
pure motor neuropathy (72% vs. 8%) and AMAN based on the available EMG data (16% 
vs. 2%) was higher in the GBS populati on from Curaçao comparable with an earlier 
study, suggesti ng a probable relati onship with an increased percentage of preceding 
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gastroenteriti s (6). Also in the present study, the percentage of preceding diarrhea was 
higher in the pati ents with GBS from Curaçao. Of the total group of 77 pati ents from 
Europe and Curaçao with a clinically pure motor neuropathy, 38 (49%) reported to have 
pain, which was mostly located in the extremiti es. Some of these pati ents even reported 
to have severe pain. Unfortunately, no specifi c scale has been used to further specify 
the precise intensity of pain. There was no clear relati on between the presence of pain 
and the severity of disease. However, all pati ents studied, except 6 pati ents with GBS 
from Curaçao, had a severe variety of GBS with a maximum GBS disability score ≥3. Two 
out of these six mildly aff ected pati ents, all with a maximum GBS disability score of 2, 
reported pain. The pure motor GBS pati ents from Europe reported a higher percentage 
of pain compared to the pure motor GBS pati ents from Curaçao, which could probably be 
explained by the diff erent way of collecti ng the data. 
Table 1 | Characteristi cs of GBS pati ents from Europe and from Curaçao 
GBS pati ents form 
Europe 
(n=225)
GBS pati ents from 
Curaçao 
(n=83)
Sex distributi on, n (%)
  Male 130 (58) 50 (60)
Age, median (90% intercenti le range), y  55 (20-74) 44 (6-71)
Max GBS disability score, n (%)**
  ≥ 3 (able to walk 10 meters with a walker or support) 100 (100)* 70 (92) 
Pain, n (%)**
  Admission / randomizati on
  In the fi rst 2 weeks aft er admission
  4 weeks aft er randomizati on 
Diarrhoea, n (%)
123 (55) 
109 (53)
 60 (27)
39 (47)
40 (48) 
Pure motor, n (%)
Clinically
  Pain (n)
  Diarrhoea
EMG (AMAN)**
  Pain (n)
 17 (8) 
 12
  9
  4 (2)
  2
60 (72)
26 
30
12 (16)
 8
Clinical pure motor = no sensory signs or symptoms, GBS = Guillain-Barré syndrome, EMG = Electromyogram, AIDP 
= Acute infl ammatory demyelinati ng polyneuropathy, AMAN = Acute motor axonal neuropathy, * GBS disability 
score ≥3 was an inclusion criterion in the IVIg/MP study 9, ** data not available from all pati ents
 We found that a high percentage of GBS pati ents with pure motor neuropathy reported 
pain. Although not all EMG data could be classifi ed as AMAN or AIDP, due to missing or 
non-conclusive data, this study shows that pain during the initi al phase of GBS seems not 
to be dependent on the presence of sensory symptoms or electrophysiological signs of 
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demyelinati on. Neuropathic pain is not expected to be relevant in pure motor GBS because 
this type of pain results from degenerati on or regenerati on of sensory nerve fi bres, and 
these pati ents did not have clinical or electrophysiological signs or symptoms of sensory 
nerve involvement. Therefore, pain in the acute phase of pure motor GBS is likely to be of 
nocicepti ve origin, probably due to acti vati on of the nervi nervorum by infl ammati on or 
infl ammatory mediators, but this needs further explorati on (9). 
CONCLUSION
Pain can also accompany pure motor GBS. Recogniti on of pain is important because 
treatment can be off ered. Further studies are necessary to give more detailed clinical 
informati on about the character and intensity of the pain in GBS subgroups. 
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ABSTRACT 
Background: Pain in GBS may be pronounced and is oft en overlooked.
Objecti ves: To obtain detailed informati on about pain in GBS and its clinical variants. 
Methods: Prospecti ve cohort study in 156 pati ents with GBS (including 18 cases with 
MFS). Assessment of the locati on, type, and intensity of pain using questi onnaires at 
standard ti me points during a one year follow-up. Pain data were compared to other 
clinical features and serology. 
Results: Pain was reported in the two weeks preceding weakness in 36% of pati ents, 66% 
reported pain in the acute phase (fi rst 3 weeks aft er inclusion) and 38% aft er one year. 
In the majority of pati ents the intensity of pain was moderate to severe. Longitudinal 
analysis showed high mean pain intensity scores during enti re follow-up. Pain occurred 
in the whole spectrum of GBS. The mean pain intensity was predominantly high in GBS 
pati ents (non-MFS), pati ents with sensory disturbances and in severely aff ected pati ents. 
Only during later stages of disease, severity of weakness and disability were signifi cantly 
correlated with intensity of pain.
Conclusions: Pain is a common and oft en severe symptom in the whole spectrum of GBS 
(including MFS, mildly aff ected and pure motor pati ents). As it frequently occurs as fi rst 
symptom, but may even last for at least one year, also pain in GBS requires full att enti on. 
It is likely that sensory nerve fi bre involvement results in more severe pain. 
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INTRODUCTION
Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy 
comprising a broad spectrum of clinical variants (1). Pain is oft en overlooked because most 
att enti on is given to progression of weakness. Various types of pain have been described 
in GBS (2). The pathophysiology of pain is poorly understood. The reported frequency of 
pain in GBS is highly variable, and most studies determined pain only in the acute phase of 
GBS (table 1) (3-11). Two studies performed a longer follow-up and reported an increase 
of pain intensity in ti me, and one-third of pati ent may even have pain aft er two years (4,8). 
Previously we showed that the character of pain may change during the clinical course of 
GBS (10). Pain has also been reported in pati ents with the Miller Fisher syndrome (MFS), 
acute motor axonal neuropathy (AMAN) and even mild forms of GBS (12-14). Pain may 
therefore be a severe and chronic problem in a considerable proporti on of GBS pati ents. 
 The frequency and nature of the pain in GBS, however, needs to be further defi ned. 
All studies conducted so far included only a relati vely small number of cases with a 
limited set of clinical, electrophysiological and serological data. Moreover, neither the 
diff erent types nor the diff erent locati ons of pain were systemati cally analysed. Here we 
report a prospecti ve study defi ning the character, locati on, and intensity of pain in GBS 
during a follow-up of one year. In additi on, detailed informati on regarding the clinical, 
electrophysiological and serological phenotype was obtained to be able to relate the pain 
to the spectrum of GBS variants. 
MATERIALS AND METHODS
Pati ents
170 pati ents fulfi lling the diagnosti c criteria for GBS were prospecti vely included in the 
GRAPH study (GBS Research about Pain and Heterogeneity) (15,16).  Exclusion criteria were: 
age below twelve and signifi cant co-morbidity with a worse prognosis (predicted survival 
less than 1 year). Pati ents with Bickerstaff  encephaliti s and pati ents who developed A-CIDP 
(acute onset chronic infl ammatory demyelinati ng polyneuropathy) were also excluded. 
Study design
Pati ents were included in the GRAPH study in 55 parti cipati ng Dutch centres between 
February 2005 and October 2008. The protocol was approved by the ethics committ ee of 
the parti cipati ng centres. Clinical data, biological materials and electrophysiological data 
were collected systemati cally during 1 year follow-up, aft er obtaining writt en informed 
consent. 
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 Questi onnaires were fi lled in by the neurologist weekly during hospital stay and once 
aft er 6 months. The fi rst three weeks aft er inclusion was determined as the acute phase, 
because all included pati ents had their nadir of weakness within 3 weeks aft er inclusion. 
When the pati ent was discharged from hospital, additi onally questi onnaires were fi lled 
in by the pati ent at 3, 6, 9 and 12 months aft er inclusion. If questi onnaires or answers to 
some questi ons appeared to be lacking one week, our research coordinator phoned the 
pati ents and asked the pati ent to complete and return the questi onnaires if possible. If the 
pati ent was not able to fi ll in the questi onnaires, we asked relati ves for help. Pati ents who 
have sent back their questi onnaires where some answers were missing were not excluded 
from the analyses. 
Questi onnaires
Baseline characteristi cs and data about medical history were obtained. Medical history 
also included questi ons about the presence of chronic pain within 3 months before 
onset of GBS. If so, we asked for the type of pain and the daily use of analgesics. The 
fi rst questi onnaire also contained identi cal questi ons about pain in the two weeks period 
before onset of weakness and pain since the onset of weakness. In all subsequent 
questi onnaires we asked about the presence of pain in the past week. Data about locati on 
((low)back, interscapular, neck, extremiti es, trunk) and type of pain (radicular pain, painful 
par- and dysaesthesiae, joint pain, muscle pain, meningism and ‘other’ type of pain (2)) 
were also obtained. The reported pain had to be new or diff erent from the pain felt in 
medical history. Intensity of pain was determined using an 11-point numerical rati ng scale 
(NRS), in which 0 represents no pain and 10 represents extreme pain (17). The character of 
pain was obtained based on the simplifi ed version of the Dutch McGill Pain Questi onnaire 
(18,19). The mean NRS of the severest pain in the past week was questi oned. Additi onally, 
pain intensity was classifi ed into mild (NRS 0-4), moderate (NRS 5-7), and severe pain 
(NRS 8-10) (20,21). The use of daily analgesics was obtained and categorized based on 
the WHO’s pain ladder in: none; paracetamol or nonsteroidal anti -infl ammatory drugs 
(NSAIDs); opioids; anti -depressants or anti -convulsants. 
 Besides informati on about pain, neurological symptoms and signs, impairment scales 
(MRC sumscore -ranging from 0 ‘quadriplegic’ to 60 ‘normal strength’(22)) and ‘INCAT’ 
sensory sumscore (23,24)) and disability scales (GBS disability score -ranging from 0 ‘no 
symptoms or signs’ to 6 ‘dead’- (25) and overall disability sumscore (ODSS) -ranging from 
0 ‘no signs of disability’ to 12 ‘most severe disability score’- (24,26)), treatment and course 
of disease were obtained from the questi onnaires fi lled in by neurologist during hospital 
stay and aft er 6 months. Regarding the INCAT sensory sumscore we used the pinprick 
sensati on score and vibrati on sensati on score without the 2-point discriminati on score, 
because this score was oft en missing (23,24).
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 Aft er hospital discharge, pain symptoms, Fati gue Severity Scale (FSS, ranging from 1 ‘no 
signs of fati gue’ to 7 ‘most disabling fati gue’) (27,28), disability scales (GBS disability score, 
ODSS) and course of disease were obtained from the questi onnaires fi lled in by pati ent. 
 Clinical autonomic functi ons were obtained over the period of the last 7 days. Clinical 
autonomic dysfuncti on parameters were defi ned prior to study onset: hypertension 
(systolic >140 and/or diastolic >90 mmHg), hypotension (systolic <90 mmHg), tachycardia 
(heart rate >100 bpm), bradycardia (heart rate <60 bpm), gastrointesti nal dysfuncti on 
(diarrhoea, consti pati on, or inconti nence) and bladder dysfuncti on (urine retenti on or 
inconti nence).
 We defi ned pati ents as GBS (non-MFS) or MFS when they fulfi lled the diagnosti c criteria 
(15,16). The ‘pure motor’ variant was defi ned as having GBS without sensory defi cits 
(normal pinprick and vibrati on sense). The GBS disability scale was used to indicate the 
severity of disease at nadir: mildly aff ected = able to walk unaided = GBS disability score 
≤ 2; severely aff ected = unable to walk unaided = GBS disability score ≥ 3. 
Preceding infecti ons
Clinical manifestati ons of infecti ons within three weeks of onset of weakness were classifi ed 
as: infl uenza-, infl uenza-like illness or respiratory tract infecti on and gastro-enteriti s or 
diarrhoea when these met the criteria of the Center of Disease Control (CDC) defi niti ons 
for nosocomial infecti ons (29). Baseline serum samples were tested to determine recent 
infecti on with Campylobacter jejuni as described (30).
Anti -ganglioside anti bodies
Pre-treatment sera obtained aft er inclusion were tested for the presence of IgG and IgM 
anti bodies against the gangliosides GM1, GM2, GD1a and GQ1b using ELISA as described 
(31,32).
Electromyographic studies
Electrophysiological investi gati ons were scheduled within three weeks aft er inclusion. 
Investi gati ons were executed according to local setti  ngs of the parti cipati ng hospitals. Age 
and sex matched reference values were used (33). Electrophysiological investi gati ons were 
classifi ed as demyelinati ng, axonal, inexcitable, equivocal or normal (34).
Stati sti cs
Percentages were compared between groups using the chi-square test or Fisher’s exact 
test if appropriate. Longitudinal analysis of pain intensity scores, allowing for occasional 
missing data at some ti me points, was performed using repeated-measurement-analysis 
of variance in the total group and in subgroups using data from 2 weeks before onset 
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weakness, the acute phase (inclusion day, 1, 2 and 3 weeks aft er inclusion) and from the 
chronic phase (week 13, 26, 39, and 52 aft er inclusion). For the acute phase we used the 
weekly data from the questi onnaires unti l 3 weeks, because all pati ents had their nadir 
within 3 weeks aft er inclusion and aft er 3 weeks many pati ents had been discharged from 
hospital resulti ng in too small number of pati ents. The populati on of pati ents was divided 
into diff erent subgroups like GBS (non-MFS) or MFS and by age (using the median value 
as cut-off ), sex, severity according to GBS disability scale (mildly or severely aff ected), 
sensory signs (ab)normal pinprick and vibrati on sense, being treated with intravenous 
immunoglobulin (IVIg) with or without methylprednisolone (MP), electrophysiological 
classifi cati on (demyelinati ng or axonal) and by diff erent infecti ons. When there was no 
signifi cant diff erence in the profi le of mean values of the pain intensity score during the 
whole follow-up between the subgroups, we calculated the mean diff erence with 95% CI 
between the subgroups from ti me before weakness ti ll 52 weeks. Correlati on between 
impairment (MRC sumscore, INCAT sensory sumscore), disability (GBS disability score, 
ODSS) and fati gue (FSS) versus pain intensity (NRS) was analysed using Spearman’s Rank 
correlati on test (rs). For the relati on between fati gue (FSS) and pain intensity (NRS), 
changes from the previous measurement were also evaluated using rs. All calculati ons 
were performed using SPSS for Windows 2000 (version 15.0 SPSS, Chicago). A two-sided 
p-value < 0.05 was considered to be signifi cant.
RESULTS 
Pati ents
Between February 2005 and October 2008, 170 pati ents with GBS were enrolled in the 
GRAPH study. During follow-up some pati ents fi nally turned out to have another diagnosis 
(n=3), Bickerstaff  encephaliti s (n=2), an accompanying myeliti s (n=1) or A-CIDP (n=8) (35). 
These 14 pati ents were excluded from the analysis. Of the remaining 156 pati ents (61% 
male), 138 (88%) fulfi lled the diagnosti c criteria for GBS (non-MFS) and 18 (12%) had MFS 
(15,16). 
Pati ent characteristi cs
Baseline and clinical characteristi cs, electrophysiological classifi cati on, infecti ons and 
results of laboratory tests in the acute phase are listed in table 2. All pati ents had their 
nadir of weakness within three weeks aft er inclusion, and within four weeks aft er onset 
of weakness. At nadir, 81% of the pati ents (83% of GBS (non-MFS) and 67% of MFS) were 
unable to walk independently (severely aff ected). Aft er 6 months 11% of pati ents (12% of 
GBS (non-MFS) and 6% of MFS) were sti ll unable to walk independently. 
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Table 2 | Baseline and clinical characteristi cs, electrophysiological classifi cati on, infecti ons and 
anti -ganglioside anti bodies in the acute phase in 156 pati ents
Baseline, n (%)
  Male  95 (61)
  Age, median (IQR), y  50 (35 - 63) 
  GBS (non-MFS)
  MFS
138 (88)
 18 (12)
Acute phase,* n (%)
  Signs & symptoms, n (%)
  Cranial nerve involvement (n=153)
  Sensory symptoms (n=152)
  Sensory disturbances (n=150)
 81 (53)
132 (87)
 98 (65)
Severity at nadir, n (%) 
  Severely aff ected (unable to walk unaided)
  Respiratory support
126 (81)
 28 (18)
Autonomic functi ons, n (%) 
  Tachycardia
  Bradycardia
  Hypertension 
  Hypotension
  Gastro-intesti nal dysfuncti on
  Bladder dysfuncti on
 60 (38)
 14 (9)
107 (69)
 17 (11)
 70 (45)
 30 (19)
GBS medical treatment, n (%) 
  IVIg only
  IVIg + methylprednisolone
  None 
 91 (58)
 39 (25)
 26 (17)
E lectrophysiological classifi cati on (n=140), n (%) 
  Demyelinati ng
  Axonal
  Equivocal
  Inexcitable
  Normal
 65 (46)
  8 (6)
 61 (44)
  2 (1)
  4 (3)
Infecti ons, n (%)
  Clinical gastro-enteriti s / diarrhoea (n=153)
  Clinical respiratory tract / infl uenza (-like) (n=152)
  Positi ve C serology (n=148)
 52 (34)
 56 (37)
 33 (22)
Anti -ganglioside anti bodies (n=148), n (%)
  IgM reacti vity against GM1, GM2, GD1a, GD1b or GQ1b
  IgG reacti vity against GM1, GM2, GD1a, GD1b or GQ1b
 24 (16)
 44 (30)
Given percentages are based on number of pati ents with returned, fi lled in questi onnaires, serum or 
electrophysiological data. When the number of pati ents diff ers from 156, it is indicated between brackets, 
GBS=Guillain-Barré syndrome, MFS=Miller Fisher syndrome, Sensory disturbances=abnormal vibrati on sense / 
pinprick, Severely aff ected = Unable to walk unaided = GBS disability scale ≥ 3, IVIg=Intravenous immunoglobulin, 
* = First 3 weeks aft er inclusion
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Pain
Prevalence, locati on, type and intens ity of pain in the acute phase and during follow-up 
are listed in table 3. 22% of pati ents had chronic pain in medical history (mostly joint and 
backache, both 35%; nearly half of them (47%) used daily analgesics). 66% of pati ents 
(69% of GBS (non-MFS) and 44% of MFS; p<0.05) had pain in the acute phase. Aft er the 
acute phase, the prevalence of pain between GBS (non-MFS) and MFS was not signifi cantly 
diff erent. 36% of pati ents already had pain in the two weeks before the onset of weakness 
(40% of GBS (non-MFS) and 6% of MFS; p<0.01; median 5 days, IQR 1 – 13). The prevalence 
of pain during the enti re follow-up was signifi cantly higher in pati ents with sensory 
disturbances compared to pati ents with the clinical pure motor form (t=0: 62% versus 
43%; t=6months: 56% versus 34%; p<0.05). In the fi rst six months the prevalence of pain 
in mildly and severely aff ected pati ents was comparable; hereaft er the prevalence of pain 
was signifi cantly higher in the severely aff ected pati ents (t=39 weeks: 45% versus 17%, 
p<0.01; t=52 weeks: 42% versus 21%, p=<0.05). For the enti re group, the prevalence of 
pati ents with pain aft er 3, 6 and 9 months was signifi cantly higher in pati ents with pain in 
the acute phase compared to pati ents without pain in the acute phase (p<0.05). There was 
no signifi cant diff erence in the prevalence of pain during the whole follow-up between the 
pati ents with or without chronic pain in medical history. From the pati ents having pain in 
the acute phase, 86% reported a moderate to severe pain despite using analgesics. Mean 
pain intensity is shown in fi gure 1. 
Figure 1 | Mean pain intensity over ti me for the enti re group of GBS pati ents (n=156)
Legend: Data shown are means (+/-SE) from ANOVA. The means are based on number of pati ents (indicated 
between brackets) with returned questi onnaires and fi lled in NRS (numerical rati ng scale) score. Before weakness 
= maximum of 2 weeks before onset of weakness
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 In the acute phase and during the enti re period of follow-up, pain was most frequently 
present in the extremiti es. (Low-)back pain was notably present in the acute phase. Oft en, 
the pati ent indicated diff erent types of pain at more than one locati on and the neurologist 
oft en indicated more than one interpretati on (from the pati ents having pain, 61% reported 
pain at more than one locati on in the acute phase and 51% aft er 6 months; 53% had more 
than one interpretati on for the pain in the acute phase and 31% aft er 6 months). 
 The mean pain intensity was higher in the acute and follow-up phase in females and GBS 
(non-MFS) pati ents, in pati ents with sensory disturbances, preceding gastro-enteriti s or 
diarrhoea and in severely aff ected pati ents (fi gure 2). No associati on was found between 
pain intensity and age, additi onal treatment with MP, the presence of anti -gangliosides 
and demyelinati ng versus axonal GBS. When we excluded the MFS pati ents to evaluate 
diff erences in the mean pain intensity between subgroups, the results were comparable 
(see legend fi gure 2). Pati ents without pain before onset of weakness and pati ents without 
pain in the acute phase (n=43) had a lower mean pain intensity in the beginning of the 
follow-up (week 13: mean diff erence -1.4 [-2.6, -0.2] p<0.05; week 26: mean diff erence 
-1.3 [-2.6, -0.1] p<0.05) compared to pati ents with pain during that period. This signifi cant 
diff erence disappeared aft er 26 weeks.
 The correlati on between disability, impairment and fati gue versus pain intensity is listed 
in table 4. Summarized, pain intensity is associated with level of weakness, functi onal 
disability and fati gue, not in the acute but during later stages of GBS. Sensory involvement 
is associated with the intensity of pain during the acute and later stage of GBS.
DISCUSSION 
This is the fi rst large prospecti ve follow-up study on the diff erent aspects of pain in GBS 
in relati on to the spectrum of GBS. As shown in this study, pain appeared to be a very 
common symptom in the acute phase and during the later stage of GBS and it also occurs 
in the whole spectrum of GBS variants, like MFS, pure motor and mildly aff ected pati ents.
By far the most frequent locati on of pain during the enti re follow-up was in the extremiti es, 
followed by (low)-back pain and oft en more than one locati on was indicated. In MFS 
pati ents, neck pain occurred most frequent in the acute phase and also headache was 
regularly reported as ‘other’ type of pain, which is also described in another study (13). 
This indicates that pain in GBS may aff ect various parts of the body. And comparing GBS 
(non-MFS) with MFS, the distributi on of weakness seems to contribute to the distributi on 
of pain. 
Despite the use of analgesics, nearly half of the pati ents with pain reported moderate 
and one third even severe pain. This emphasizes the magnitude of the clinical problem of 
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pain in GBS. In a study in 55 GBS pati ents, a similar mean pain intensity was found in the 
acute phase, but a lower mean pain intensity was found in the period unti l 24 weeks (8). 
Table 4 | Correlati ons between impairment, disability, and fati gue versus pain intensity. 
t=0 Week 13 Week 26 Week 39 Week 52
Impairment
  Muscle strength 
(MRCsumscore)
-0.06
(n=131)
n.e. -0.25**
(n=136)
n.e. n.e.
  Sensory involvement 0.28*
(n=128)
n.e.  0.41***
(n=125)
n.e. n.e.
Disability
  Disability (GBS disability score) 0.00
(n=138)
0.40 ***
(n=141)
045***
(n=147)
0.51***
(n=146)
0.43***
(n=146)
  Disability score (ODSS score) -0.04
(n=135)
0.55 ***
(n=140)
0.51***
(n=147)
0.54***
(n=147)
0.46***
(n=143)
Fati gue (FSS score) n.e. 0.43***
(n=137)
0.52***
(n=142)
0.51***
(n=144)
0.37***
(n=145)
Data given are spearmen correlati on coeffi  cients (rs) between disability, impairment and fati gue on one hand 
versus pain intensity (NRS score) on the other hand for the enti re group. For the relati on between fati gue and 
pain intensity, changes from the previous measurement were also evaluated (week 13-26: rs=0.14; week 26-39: rs 
=0.30***; week 39-52: rs =0.23**). ***p<0.001; **p<0.01; *p<0.05; n.e.= not evaluated
 We have asked for the presence of pain within three months before onset of weakness 
retrospecti vely, therefore recall bias may have aff ected this part of the results of our study. 
In the questi onnaires, we emphasized that the reported pain during GBS had to be new or 
diff erent from the pain felt in medical history. We have to menti on however that it can be 
diffi  cult for pati ents to diff erenti ate between pre-existent and new pain. 
 To identi fy factors that are associated with pain, we related pain to clinical features. 
As shown in this study, pain intensity is associated with level of weakness, functi onal 
disability and fati gue, not in the acute but during later stages of GBS. Whether pain causes 
part of disability or disability contributes to pain cannot be concluded from our study. In 
another follow-up study, no signifi cant correlati on between disability and pain intensity 
was found (8). However several years aft er GBS, an interacti on between fati gue, pain, 
and muscle weakness has been described (36). In this study, they found a higher risk of 
pain and muscle weakness in individuals with pronounced fati gue. Both symptoms may 
infl uence each other and need to be registered. Depression or anxiety may also infl uence 
pain in GBS. Depression or anxiety was not specifi cally assessed in our study and needs 
further att enti on in forthcoming studies. Our results indicate that involvement of sensory 
nerves does play a role in the occurrence and intensity of pain during the acute and later 
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stage of GBS. It has been described that years aft er GBS muscle aches and cramps occur 
especially in pati ents with residual sensory disturbances (37). It was remarkable that in 
our study pati ents with previous diarrhoea had a signifi cantly higher mean pain intensity 
score compared to pati ents without diarrhoea. The fact that in this study the number of 
pure motor pati ents or severely aff ected pati ents was not signifi cantly diff erent in the 
group with and without diarrhoea does not explain the diff erence. Possibly diff erent 
immunological factors generated by an infecti on may play a role in pain. 
 The pathophysiology of pain in GBS is largely unknown and this study indicates the 
complexicity of studying pain in GBS. Aff ected nerve roots may explain the occurrence of 
radicular nocicepti ve nerve pain aff ecti ng (low-) back with radiati on to extremiti es or trunk 
(5). Infl ammatory factors generati ng pain via the nervi nervorum may also play a role in 
the pathophysiology of pain, but has not been studied yet. In our study, the prevalence of 
back pain was higher than the prevalence of radicular pain, indicati ng that other types of 
pain like muscle pain or arthralgia possibly due to immobilisati on may also contribute to 
back pain in GBS. Neuropathic pain due to spontaneous or abnormal acti vity from large 
myelinated sensory aff erents may explain the occurrence of painful paraesthesias and 
dysaesthesias in the extremiti es. However, considering the high prevalence of pain in the 
extremiti es also other types of pain may play a role. Small nerve fi bres can also be aff ected 
in GBS (38). Aff ected small nerve fi bres in GBS may play a role in pain and autonomic 
dysfuncti on and needs additi onal studies.
 Nevertheless, two diff erent combinati ons of pain symptoms may be disti nguished. One 
combinati on starts before onset of weakness unti l hospital discharge, is mostly located in 
the extremiti es and contains especially radicular pain, painful paraesthesiae and muscle 
pain; the other combinati on is predominantly present aft er hospital discharge during 
rehabilitati on, is also mostly located in the extremiti es and contains especially painful 
paraesthesiae, muscle pain and arthralgia. The intensity of pain is severe during the 
course of disease, but is most severe in the acute phase. Pain symptoms are associated 
with sensory disturbances and severe pain symptoms later in the stage of disease are 
associated with a higher level of weakness and disability. Pati ents suff ering from acute 
pain symptoms have a higher change on the occurrence of the pain symptoms in the later 
stage. In case reports, the analgesic eff ect of corti costeroids for lumbar and leg pain has 
been described (39,40). In this study there appeared to be no diff erence in pain between 
pati ents treated with MP or not, which is in line with a previous study on the additi onal 
eff ect of MP in GBS (10). 
 In conclusion, pain is very common and severe in the whole spectrum of GBS during 
the acute and later stages of disease. Therefore it requires full att enti on. Sensory nerve 
fi bre involvement is associated with severe pain, but this seems no prerequisite, because 
pati ents with pure motor symptoms may also have pain. It is important to realize that only 
binnenwerk l ruts.indd   148 31-3-2010   11:55:01
GBS and pain 149
in the later stage of disease the intensity of pain is related to the extent of weakness and 
disability. 
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CHAPTER 5
GBS AND SMALL FIBRE NEUROPATHY
GuillainͳBarré syndrome: a correlati on study of skin biopsy and clinical features
L. Ruts, P.A. van Doorn, R. Lombardi, E.D. Haasdijk, F. Camozzi, J.H.M. Tulen, R.J. Hempel, 
A.H. van den Meiracker, G. Lauria 
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ABSTRACT 
Objecti ve: To correlate skin biopsy fi ndings, clinical features, and outcome in pati ents with 
Guillain-Barré (GBS) and its variants.
Methods: A cohort of pati ents included into the ‘GBS Research about Pain and 
Heterogeneity’ Study underwent skin biopsy at distal leg and lumbar site, pain, and 
autonomic assessment. Data were collected in the acute phase and at 6-month follow-
up. Intraepidermal nerve fi bre density (IENFD) was compared to age and gender-matched 
healthy subjects and normati ve reference values. Quality and intensity of pain were 
evaluated using a questi onnaire and the 11-point numerical rati ng scale. Severity of GBS 
and outcome were assessed using the GBS disability scale. 
Results: Prospecti ve data were available from 32 pati ents. IENFD declined in the fi rst 
three weeks from onset (rs -0.389; p=0.027) and was lower at distal leg (median 3.9, 
IQR 2.4-6.3; p=0.004) and lumbar site (median 10.5, IQR 7.4-16.1; p=0.004) compared to 
controls (distal leg: median 5.6, IQR 4.9-7.2; lumbar site: median 15.2, IQR 12.0-19.5) and 
normati ve values. Distal leg IENFD correlated with pain (p=0.003) and NRS score (p=0.003), 
but did not predict pain at 6 months. Worse outcome at 6 months correlated with lower 
lumbar IENFD (p=0.04), GBS score at nadir (p=0.03), and clinically probable dysautonomia 
(p=0.004). At 6 months, pati ents had signifi cantly lower IENFD at both sites. 
Interpretati on: Small nerve fi bres are aff ected in GBS pati ents since the early phase of 
disease. Their loss in the fi rst three weeks from onset is associated with the severity of 
pain and autonomic dysfuncti on, and may predict long term disability. 
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INTRODUCTION 
Guillain-Barré syndrome (GBS) is an acute immune-mediated disorder of the peripheral 
nervous system. Its clinical spectrum in the acute phase as well as its outcome is highly 
variable. GBS mainly aff ects large diameter fi bres carrying motor functi ons, vibratory, 
and touch sensati on. Their dysfuncti on refl ect the main clinical features, namely rapidly 
progressive weakness of the limbs, with or without involvement of respiratory or cranial 
nerve innervated muscles and sensory disturbances (1,2). 
 Dysautonomia occurs in approximately two-third of GBS pati ents (3) and can lead to 
life threatening dysfuncti ons (4). Dysautonomia has been described also in Miller-Fisher 
syndrome (MFS), the cranial nerve variant of GBS (5,6).
 Pain symptoms have been described in up to 89% of pati ents with GBS and MFS (7-
13). Pain intensity can be very severe, parti cularly in the acute phase of the disease. We 
recently observed that 49% of pati ents with acute motor axonal neuropathy (AMAN) 
also complain of pain (14). The pathophysiological processes causing and maintaining 
pain in GBS pati ents are uncertain and probably more complex than in chronic painful 
neuropathies. Damage to small nerve fi bres has been suggested to play a role (15).
 Skin biopsy is an accepted tool to investi gate small nerve fi bres (16,17). Intraepidermal 
nerve fi bres (IENF) are unmyelinated axons with functi ons of thermal and nocicepti ve 
transducers (18). Their density is a measure of axonal degenerati on in painful and non-
painful neuropathies (14,15,19-28). Studies in peripheral neuropathies of diff erent 
eti ology suggested that reduced intraepidermal nerve fi bre density (IENFD) increases the 
risk to develop neuropathic pain (29) , whereas its recovery corresponds to decreased pain 
intensity (30-33). 
 The only previous study in GBS, based on a cross-secti onal design, reported a inverse 
correlati on between IENFD, dysautonomia, and poor outcome. The observati on that IENFD 
may be used as a predicti ve biomarker in GBS needed to be confi rmed by a prospecti ve 
study. We addressed this issue through a prospecti ve, multi ple locati on study designed to 
investi gate the relati onship between IENF loss, dysautonomia, pain, and poor outcome in 
pati ents with GBS and its variants, with the aim to identi fy subgroups of pati ents at higher 
risk to develop these complicati ons. 
MATERIALS AND METHODS
Pati ents 
Between February 2005 and October 2008, 170 pati ents diagnosed with GBS or MFS and 
admitt ed to one of the parti cipati ng Dutch centers were evaluated for inclusion into the 
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GRAPH study (GBS Research about Pain and Heterogeneity). Data were systemati cally 
collected over a 6-month follow-up aft er writt en informed consent was obtained. Only 
pati ents admitt ed to one of the hospitals in the region of Rott erdam were considered 
for undergoing skin biopsies. Exclusion criteria for skin biopsy study were age below 18 
years, previous diagnosis of neuropathy, diabetes mellitus, or other conditi ons at risk for 
neuropathy. Pati ents included in the skin biopsy study and admitt ed to the Erasmus MC 
underwent also autonomic cardiovascular evaluati on. The protocol was approved by the 
Ethic Committ ee of every parti cipati ng centre. 
 GBS was diagnosed according to published criteria (1). During follow-up, some pati ents 
initi ally diagnosed with GBS eventually turned to have relapsing and remitti  ng course and 
were defi ned as acute onset chronic infl ammatory polyneuropathy (A-CIDP) (34). MFS was 
defi ned according to diagnosti c criteria (35). Pati ents were diagnosed with the pure motor 
variant when they had weakness without sensory symptoms and signs (normal light touch, 
pinprick, and vibratory sensati on). 
Timing of assessments
The fi rst 3 weeks aft er inclusion were considered the acute phase (as all pati ents had 
reached their maximal weakness). During this period, we obtained the skin biopsies and 
assessed pain, autonomic functi ons, and severity of GBS. 
 The visit at 6-month follow-up was considered as the chronic phase. At that ti me we 
obtained skin biopsies, and assessed pain and residual disability.
Severity and disability assessment 
The GBS disability scale score (range 0 ‘no symptoms or signs’ to 6 ‘dead’) (36) was 
obtained weekly during the acute phase and at 6-month follow-up to indicate the severity 
of disease and the outcome. Score was dichotomized as follows: mildly aff ected = able to 
walk unaided = GBS score ≤ 2; severely aff ected = unable to walk unaided = GBS score ≥ 3.
Pain assessment
Pain was assessed using a questi onnaire that included questi ons about type(s) of pain 
(opti ons to mark: radicular pain, paraesthesiae, dysaesthesiae, joint pain, muscle pain, 
meningism, and other pain) and site of pain (opti ons to mark: back, lowback, interscapular, 
neck, extremiti es, and trunk) (10).
 All pati ents were asked to report on the presence of pain in the past week aft er inclusion. 
It was emphasized that it had to be a newly developed pain. Pati ents complaining of 
muscle or joint pain alone were excluded. The intensity of pain was assessed using the 
11-point numerical rati ng scale (NRS), with 0 representi ng no pain and 10 the worst pain 
(37). Pati ents were asked to report weekly the mean NRS score in the last 7 days. The 
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intensity of pain in the acute phase was defi ned as the highest mean NRS score reported 
in the fi rst 3 weeks aft er inclusion. 
Skin biopsies
Skin biopsies were taken using a 3-mm disposable punch, aft er local anesthesia with 2% 
lidocaine under sterile technique, from the distal leg (10 cm above the lateral malleolus) 
and lumbar site (3 cm besides the third/fourth lumbar vertebra) in the acute phase and at 
6-month visit. Follow-up biopsies were performed close to the scars of the former ones. 
For comparison, distal leg (n=24) and lumbar site (n=23; 1 lost) skin biopsies from age 
and gender-matched healthy subjects were performed aft er obtaining writt en informed 
consent. 
 All biopsies were fi xed for 24 hours at 4°C, cryoprotected, coded, and shipped to 
the Skin Biopsy Laboratory at the ‘Carlo Besta’ Neurological Insti tute of Milan to be 
processed. Skin biopsy examiners (R.L., F.C., G.L.) received only the coded specimens and 
were blinded to subject conditi on (diseased or healthy subjects) and site of biopsy. Three 
secti ons randomly chosen from each biopsy were immunoassayed with polyclonal anti -
PGP 9.5 anti bodies (Biogenesis Ltd, Poole, UK; 1:1000) using the free-fl oati ng protocol for 
bright-fi eld immunohistochemistry previously described (38). The linear density of IENF 
(IENFD=IENF/mm) was calculated following the rules reported by the guidelines of the 
European Federati on of the Neurological Societi es (39). 
 IENFD values at distal leg in pati ents were compared with healthy controls recruited in 
the present study and with available age and gender strati fi ed normati ve reference values 
(40). Similar normati ve reference values are not available for the lumbar site, therefore we 
sampled age and gender strati fi ed skin biopsies from normal individuals at this site.
Autonomic functi ons assessment
Clinical autonomic functi ons were assessed weekly in the acute period and defi ned as 
follows: hypertension (systolic >140 and/or diastolic >90 mmHg), hypotension (systolic 
<90 mmHg), tachycardia (>100 bpm), bradycardia (<60 bpm), gastrointesti nal dysfuncti on, 
bladder dysfuncti on or other symptoms of autonomic dysfuncti on (e.g., excessive sweati ng, 
Horner’s syndrome, pupil dilatati on). Clinical autonomic dysfuncti on was considered 
’defi nite’ in the presence of at least three abnormal parameters, and ‘probable’ when two 
abnormal parameters were scored in at least two of the weekly questi onnaires. 
Autonomic cardiovascular measurement 
Spectral analysis of heart rate (HR) and blood pressure (BP) variability (41-44) was applied 
the same day of skin biopsy. HR variability in the high frequency band (HF: 0.15-0.50 
Hz) is related to respiratory variati ons (respiratory sinus arrhythmia) and refl ects vagal 
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(parasympatheti c) modulati on. BP variability in the low frequency band (LF: 0.07-0.14 
Hz) refl ects alterati ons in peripheral vasomotor tone related to barorefl ex-mediated 
and predominantly sympatheti c control. The interbeat interval (IBI) ti me series (transfer 
functi on between LF-systolic BP [SBP] and LF-R-R interval), is a measure of barorefl ex 
sensiti vity (BRS) (45). 
 Electrocardiogram (ECG), BP (2300 Finapres TM blood pressure monitor; Ohmeda, 
Englewood CO, USA), and respirati on were conti nuously recorded during a 10-minute 
period of supine rest. R-R intervals were transposed to HR series and SBP and DBP were 
defi ned per R-R interval of ECG. Periods of stati onary signals with a length of 5 minutes 
were selected from the 10 minute recording period and corrected for technical and 
physiological artefacts in the HR, SBP, DBP and respirati on ti me series. 
 Fourier transformati on was applied to 5-minute HR and BP ti me series segments (46), to 
yield power spectra of the oscillati ons over a frequency range of 0.02 to 0.50 Hz. Spectral 
power data were transformed into natural logarithmic values to obtain normal distributi on. 
The BRS index (gain in the LF band between SBP and IBI ti me series) was computed based 
on frequency points within the frequency range with a coherence ≥ 0.35 (47).Twenty-fi ve 
age and gender-matched healthy subjects were recorded. 
Stati sti cs
Normality was examined using Shapiro-Wilk test. Pati ents and controls were compared 
using unpaired t-tests or χ2 tests. Fisher exact test or the Mann-Whitney U test was used 
when appropriate. IENFD was compared within the same pati ent using the paired t-test. 
Data were expressed as mean±SD or median and interquanti le range (IQR). The correlati on 
between GBS disability score at 6 months, IENFD, presence and intensity of pain, GBS 
disability score at onset, and clinical dysautonomia was analysed using the Spearman’s 
Rank correlati on test. IENFD in acute and chronic phase, and autonomic measurements 
were analysed using the Pearson correlati on test. Analysis of variance (ANOVA) and linear 
multi ple regression analysis were used to assess the predicti ve value of variables. Analyses 
were performed using the SPSS for Windows 2000 (version 15.0 SPSS, Chicago). P values 
<0.05 were considered signifi cant.
RESULTS
Pati ents
Between February 2005 and October 2008, 138 pati ents with GBS, 18 pati ents with MFS, 
and 8 pati ents with A-CIDP (n=8) were enrolled in the GRAPH study. The skin biopsy study 
involved pati ents admitt ed to the hospitals in the region of Rott erdam. Three pati ents 
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younger than 18 years and 4 pati ents with signifi cant comorbidity were excluded. Nine 
pati ents did not give their consent to the study. One pati ent died one month aft er inclusion 
due to severe sepsis. Eventually, 32 pati ents (26 GBS and 6 MFS) were included, along 
with 3 pati ents later diagnosed with A-CIDP (all males, mean age 62 years). Their clinical 
features are presented in table 1. 
Table 1 | Baseline characteristi cs, signs, symptoms and severity during the acute phase and 
aft er 6 months in GBS (non-MFS) and MFS pati ents included in the skin biopsy study
GBS (non-MFS) 
n=26
MFS
 n=6
Age at onset, mean, (SD), y 52 (15) 54 (17)
Male, n (%) 14 (54)  5 (83)
Cranial nerve dysfuncti on, n (%) 10 (39)  6 (100)
Pure motor, n (%)  7 (27)  3 (50)
Neuropathic pain, n (%) 
  Acute phase
  Aft er 6 months
13 (50) 
 6 (23)
 1(17) 
 0 (0)
Autonomic functi on acute phase, n (%)
  Tachycardia
  Bradycardia
  Hypertension
  Hypotension
  Gastro-intesti nal dysfuncti on
  Bladder dysfuncti on 
  Other 
Defi nite clinical dysautonomia
Probable clinical dysautonomia 
16 (62)
 2 (8)
19 (73)
 4 (15)
13 (50)
 3 (12)
 2 (8)
 7 (27)
12 (46)
 3 (50)
 1 (17)
 6 (100)
 1 (17)
 3 (50)
 1 (17)
 1 (17)
 1 (17)
 2 (33)
Severity, n (%)
  Mild at nadir (able to walk independently)
  Need for arti fi cial respirati on
  Worse outcome aft er 6 months (unable to walk 
independently)
 5 (19)
 9 (35)
 4 (15)
 2 (33)
 1 (17) 
 1 (17)
 In the acute phase, skin biopsies were obtained within one week from onset in 44% of 
pati ents, within two weeks in 34% of pati ents, and within 3 weeks in 22% of pati ents. Two 
pati ents had only distal skin biopsies. Five pati ents were not available for 6-month follow-
up biopsies. 
 Autonomic cardiovascular measurement wa s performed in 19 pati ents (13 GBS, 5 MFS, 
and 1 A-CIDP). Eight pati ents were excluded from the analyses (2 pati ents for unreliable 
BP recording, 3 pati ents for arrhythmia, and 3 pati ents because SBP-IBI ti me series was 
<0.35). 
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Skin biopsy fi ndings
In the acute phase, IENFD at distal leg signifi cantly declined over the fi rst three weeks 
from onset (rs -0.389; p=0.027), whereas there was no correlati on between ti ming of the 
biopsy and IENFD at lumbar site. Compared to normati ve reference values strati fi ed per 
age decade and gender (40), IENFD in the acute phase was reduced in 15 (40.6%) pati ents 
(13 GBS, 2 MFS) at distal leg and in 22 (73.3%) pati ents (18 GBS, 4 MFS) at lumbar site. 
Compared to controls recruited in the study (distal leg: median 5.6, IQR 4.9-7.2; lumbar 
site: median 15.2, IQR 12.0-19.5) IENFD was signifi cantly lower both at distal leg (median 
3.9, IQR 2.4 -6.3; p=0.004) and lumbar site (median 10.5, IQR 7.4-16.1; p=0.004) (fi gure 1 
and table 2). Notably, 3 of 7 pati ents with the pure motor form of GBS had lower IENFD 
values at the distal leg compared both to controls and strati fi ed normati ve value (40) 
whereas 5 of them had reduced values at the lumbar site. 
 At 6-month follow-up, IENFD remained signifi cantly lower both at distal leg (median 4.3, 
IQR 3.2-6.7; p 0.024) and lumbar site (median 10.4, IQR 8.7-15.7; p=0.005) compared to 
controls (fi gure 1 and table 2). Nine of 15 (60%) pati ents with reduced distal leg IENFD and 
13 of 21 (61.9%) pati ents with reduced lumbar IENFD in the acute phase showed values 
lower than strati fi ed normati ve values (40) at 6-month follow-up (table 2). 
 Pati ents with A-CIDP showed signifi cantly lower IENFD at distal leg in the acute (median 
3.3; p=0.021) and chronic phase (median 2.5; p=0.005), whereas we did not fi nd signifi cant 
diff erences at the lumbar site (fi gure 1). 
Correlati on between skin biopsy, neuropathic pain, autonomic dysfuncti on, 
severity and outcome
Neuropathic pain
In the acute phase, pati ents with neuropathic pain showed a signifi cantly lower distal 
leg IENFD than those without neuropathic pain (median 2.8, IQR 1.5-3.8 versus median 
5.5, IQR 3.7-6.9; p<0.001). Moreover, distal leg IENFD was inversely correlated with pain 
intensity (rs -0.506; p=0.003), whereas IENFD at lumbar site did not. Distal leg and lumbar 
site IENFD in the acute phase did not predict either occurrence or intensity of pain at 6 
months. 
Autonomic dysfuncti on
Defi nite clinical dysautonomia was present in 8 GBS (25%) and 1 MFS (16%) pati ents, and 
probable dysautonomia in 14 GBS (44%) and 2 MFS (33%) pati ents (table 2). IENFD at any 
site was not related with clinically defi nite or probable autonomic dysfuncti on at onset 
and 6-month follow-up. However, GBS pati ents showed signifi cantly higher mean levels 
of HR, SBP, and lower levels of LFHR power and BRS index compared to controls (table 3). 
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There was a positi ve correlati on between distal leg IENFD in  the acute phase and HFHR 
(r=0.52; p<0.05) and with BRS (r=0.61; p<0.05).
Figure 1 | Distal leg and lumbar site IENFD of GBS (non-MFS), MFS and A-CIDP pati ents in the 
acute and chronic (6-month follow-up) phase compared to healthy controls 
Legend: Bars are median values. Diff erences were tested with the Mann-Whitney U test. P-values <0.05 are shown.
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Table 3 | Autonomic cardiovascular measurements in GBS pati ents (n=13 GBS (non-MFS) and 
n=5 MFS) and controls
  GBS 
(n=18)
Controls 
(n=26)
p
Male, n (%)     11 (61)      14 (54) 0.76
Age, mean (SD), y     55 (14)     52 (4) 0.22
Autonomic measures acute phase
  SBP, mmHg 
  DBP, mmHg
  HR, beats/minute
  LFSBP, ln values
  LFHR, ln values
  HFHR, ln values
  BRS, ms/mmHg
   139 (124-155)‡
    62 (58-85)‡ 
     80 (77-93)
  5.5 (4.7-6.5)*
  4.6 (4.3-6.3)§
  5.1 (4.2-6.1)§
     4 (1.8-7.6)*
   122 (109-139)
     66(60-72)
    66 (60-73)
  5.5 (4.9-6.1)
  6.1 (5.6-6.8)
  5.8 (5.3-6.2)
  9.1 (5.8-12.1)
0.04
0.83
0.00
0.80
0.02
0.19
0.00
Shown are data (median + IQR) from the autonomic functi on test. Due to technical problems, BP data of 2 pati ents 
were rejected. In additi on, spectral data of 3 pati ents were excluded from further analyses because of frequently 
occurring cardiac arrhythmia’s, and the BRS could not be computed in 3 pati ents because the coherence between 
the SBP and IBI ti me series was below 0.35 (‡ n=16, § n=15, * n=13)
Table 4 | Correlati on between IENFD and severity of disease in the acute phase and aft er 6 
months in 32 GBS pati ents (n=26 GBS (non-MFS) and n=6 MFS) 
GBS including MFS GBS (non-MFS) 
GBS disability score GBS disability score 
IEFD rs p rs p rs p rs p 
Acute phase Nadir Aft er 6 months Nadir Aft er 6 months
  Distal leg -0.19  0.31  0.08 0.67 -0.16 0.42 0.14 0.51  
  Lumbar site -0.20*  0.29 -0.38* 0.04 -0.09** 0.69 -0.30** 0.16 
Aft er 6 months  Aft er 6 months Aft er 6 months
  Distal leg -0.26‡ 0.21 -0.26 0.28∆  
  Lumbar site  0.04** 0.84 0.11 0.67**
Data given are spearmen correlati on coeffi  cients (rs) between distal leg and lumbar site IENFD versus GBS disability 
score at nadir and aft er 6 months (8 n=18, ∆ n=20, * n=30, ** n=24, ‡ n=26). For the relati on between IENFD and 
severity of GBS, the regenerati on of IENFD (diff erence in IEFD between the acute phase and aft er 6 months) versus 
recovery in GBS disability score was also evaluated. 
Severity and outcome 
Poor GBS disability score at 6 months correlated with lower lumbar IENFD in the acute 
phase (rs -0.376; p=0.04), GBS score at nadir (rs -0.50; p=0.03), and clinically probable 
dysautonomia (rs 0.491; p=0.004). Linear multi ple regression analysis, including age, 
diarrhea, GBS disability score (T0=onset, T1=one week aft er inclusion, T2=two weeks at 
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nadir), distal leg and lumbar IENFD in the acute phase, demonstrated that age (p=0.022) 
and lumbar IENFD (p=0.034) were the best predictor of worse outcome (GBS disability 
score ≥3) at 6 months (table 4). 
DISCUSSION
Our prospecti ve study confi rmed that small nerve fi bres are aff ected in pati ents with GBS 
and MFS since the acute phase of the disease. We showed that the decrease of IENFD is 
associated with a higher risk and severity of pain and in part with cardiovascular autonomic 
dysfuncti on, and that it may predict a poorer outcome at 6 months.
Small fi bre neuropathy in the course of GBS
IENFD at distal leg and lumbar site was signifi cantly reduced, in a non length-dependent 
patt ern, in the acute phase of GBS and MFS, as well as in A-CIDP pati ents, confi rming 
previous fi ndings (15,48). Intriguingly, we found that IENF can be aff ected also in pati ents 
with the pure motor form of GBS.
 The course of small fi bre neuropathy and the ability of IENF to regenerate has been 
previously described in pati ents with pure small fi bre neuropathy and diabeti c neuropathy 
(20,30,32,49), but it has never been investi gated in immune-mediated neuropathies. Most 
pati ents showed a further decrease of lumbar IENFD over ti me, suggesti ng either a slower 
regenerati on rate of IENF at proximal than distal sites or, more likely, a relati onship with 
the ti ming of skin biopsy. Indeed, the decrease of IENFD at the distal leg correlated with 
the ti ming of skin biopsy in the fi rst three weeks aft er the onset. Since most biopsies were 
taken in the fi rst week aft er onset and most pati ents showed a further decrease of lumbar 
IENFD at 6 months follow-up, we speculate that the degenerati on of IENF conti nued with 
a course corresponding to the ascending character of GBS. 
Small fi bre neuropathy and neuropathic pain
We demonstrated that lower values of IENFD at distal leg were associated with the 
occurrence of pain. Conversely, Pan and colleagues did not fi nd any diff erence in distal 
IENFD values between GBS pati ents with and without painful symptoms (15). This 
diff erence could be related to the defi niti on of pain used. Indeed, we strived to select only 
those pati ents with neuropathic pain. We also observed that distal leg IENFD inversely 
correlated with the severity of pain, diff erently from what has been recently observed in 
small fi bre neuropathy (20). 
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Small fi bre neuropathy and autonomic dysfuncti on
IENF are unmyelinated axons with exclusive somati c functi on. The previous observati on 
that reduced IENFD at distal leg was associated with dysautonomia (15) was not completely 
confi rmed by our results. Indeed, we did not fi nd a correlati on between IENFD at any site 
and clinical features of dysautonomia. However, there was a correlati on between IENFD 
at distal leg, BRS, and HF power of HR, refl ecti ng changes in parasympatheti c cardiac vagal 
tone. Like for pain, results could be infl uenced by the relati ve small number of pati ents 
and events. 
Small fi bre neuropathy, disability, and outcome 
We did not confi rm the correlati on between IENFD and disability at nadir as previously 
reported (15). Conversely, our fi ndings suggest that lumbar IENFD in the acute phase, 
along with age, may be an independent predictor of worse outcome at 6 months in GBS 
and MFS. However, this issue needs further investi gati ons before being considered a 
prognosti c factor.
CONCLUSIONS
We demonstrated that somati c IENF can be aff ected in the whole spectrum of GBS, 
including in pati ents with the pure motor variant. The density of IENF inversely correlated 
with occurrence and intensity of pain, and with measures of autonomic dysfuncti on in 
the early phase of the disease. Lower IENFD at lumbar site predicted a worse outcome 
at 6 months follow-up. The pathophysiology of IENF degenerati on in GBS and its variants 
remains unaddressed. Possibly, the immune-mediated process causes a diff use damage 
to peripheral nerves, including small nerve fi bres. Whether this is caused by specifi c 
anti bodies, complement acti vati on, infl ammatory cytokines or other factors need focused 
studies. 
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GENERAL DISCUSSION 
According to the general accepted criteria, rapidly progressive symmetrical weakness 
is the main clinical symptom for the Guillain-Barré syndrome (GBS) and the course is 
monophasic (1). Time to reach nadir is within four weeks whereaft er the pati ent improves. 
However, the extent and distributi on of clinical symptoms, course of disease and outcome 
largely varies between individuals with GBS. Some GBS pati ents have fl uctuati ng course. 
This oft en raises doubt about the diagnosis. Some ‘GBS pati ents’ eventually may develop 
chronic infl ammatory demyelinati ng polyneuropathy (CIDP) with acute onset (A-CIDP). 
For the treatment strategy and prognosis it is relevant to disti nguish between GBS with 
a fl uctuati ng course and A-CIDP as soon as possible. Besides weakness, pain can be a 
prominent symptom and is oft en overlooked, because progressive paralysis is the most 
striking and alarming symptom of GBS. Autonomic dysfuncti on also frequently occurs and 
this can be life threatening. In the studies described in my thesis I have focused on the 
aforementi oned issues. The aim was to provide more insight in the course of disease, 
the presence and severity of residual fi ndings and the frequency and nature of pain 
and autonomic dysfuncti on in GBS and fi nally to delineate factors that are related to a 
fl uctuati ng course, pain and autonomic dysfuncti on. In this chapter, the main fi ndings of 
the retrospecti ve studies and the results of the prospecti ve GRAPH (GBS Research about 
Pain and Heterogeneity) study will be discussed. Clinical practi cal suggesti ons will be 
provided and suggesti ons for future studies are made. 
RESIDUAL FINDINGS AND COURSE OF DISEASE 
In the GRAPH cohort we found that even one year aft er onset of GBS, residual symp-
toms appear to be very common, also in mildly aff ected as well as in pati ents with Miller 
Fisher syndrome (MFS) (chapter 3.1). Besides functi onal disability, fati gue and pain are 
also frequently present in the whole spectrum of GBS even aft er one year (chapter 3.1). 
Residual fi ndings, especially arm-hand functi on and mobility in mildly aff ected pati ents 
are comparable with those in a retrospecti ve Dutch study describing that a considerable 
proporti on of mildly pati ents do have residual disabiliti es aft er 6 months (2). Randomised 
controlled trials (RCTs) that have assessed the eff ect of intravenous immunoglobulins 
(IVIg) have not studied the eff ect in mildly aff ected pati ents (3). One trial has described a 
positi ve eff ect of plasma exchange (PE) in mildly aff ected pati ents (4). 
 The presence of residual in pati ents with MFS (chapter 3.1) are not fully in line with other 
studies describing fast and excellent recovery (5,6). The GBS disability score – fi ndings 
not validated for pati ents with MFS –, the presence of pain and the level of fati gue have 
not been evaluated in these studies. Additi onally it was not menti oned that symptoms of 
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prolonged double vision or ataxia for several months could clearly limit pati ent’s acti vity 
and social life. This might explain the diff erence in conclusion about residual signs in MFS. 
No RCTs have studied the eff ect of PE or IVIg in pati ents with MFS (7). 
Clinical practi cal suggesti ons
  Inform also mildly aff ected GBS pati ents and MFS pati ents and their caregivers about possible 
long-term residual symptoms (functi onal disability, pain, fati gue) when they are discharged 
from the hospital (based on this thesis). 
  When GBS pati ents (including mildly aff ected and MFS pati ents) are admitt ed to a rehabilitati on 
centre or visit the outpati ent clinic aft er hospital discharge, pay serious att enti on to residual 
symptoms (functi onal disability, pain, fati gue) (based on this thesis). 
  In expectati on of a possible RCT to the eff ect of IVIg in mildly aff ected pati ents, and based 
upon this thesis and the results and outcome of our additi onal studies evaluati ng mildly 
aff ected GBS pati ents, treat also mildly aff ected GBS pati ents with IVIg, especially 1) when 
they have considerable defi cit otherwise (such as severe cranial nerve dysfuncti on, autonomic 
dysfuncti on or severe pain) especially when this can not be fully substanti ated using the 
GBS disability scale (pati ent is sti ll able to walk); or 2) when the pati ent shows rapid clinical 
deteriorati on and it is to be expected that walking will be impossible or arti fi cial venti lati on 
will be needed shortly (based on this thesis). 
  In expectati on of a possible RCT to the eff ect of IVIg in pati ents with MFS, it is suggested 
to treat at least MFS pati ents having severe opthalmoplegia and/or ataxia, especially when 
there is a GBS-MFS overlap syndrome (general suggesti on).
 In the literature the following variants in course of disease are described: subacute 
infl ammatory demyelinati ng polyneuropathy (SIDP) (8,9), GBS with treatment related 
fl uctuati ons (GBS-TRF) (10-12), A-CIDP (13), and recurrent GBS (14,15). The disti ncti on 
between these diff erent types of infl ammatory polyradiculoneuropathy perhaps is 
arbitrary, and these variants likely form a spectrum. However, because treatment 
strategies and prognosis diff er, it is important to have early indicators to disti nct between 
these diff erent types of infl ammatory polyradiculoneuropathy. 
 GBS and CIDP are both immune-mediated disorders for which criteria are defi ned (1,16), 
however their precise pathogenesis is sti ll unclear. GBS and CIDP are mainly disti nguished 
based on the severity and durati on of progressive weakness. There are currently no 
specifi c biomarkers known to disti nguish between GBS and CIDP. The pathogenesis of 
GBS and CIDP variants or overlap syndromes is therefore even more speculati ve. In this 
thesis we have provided criteria that help to disti nguish between GBS-TRF and A-CIDP in 
individual pati ents already in the early phase of disease (chapter 3.2 and 3.3). 
 Our studies are the fi rst in which GBS-TRF and A-CIDP are compared. These results are 
helpful in clinical practi ce for guiding treatment and to determine the course of disease. 
Because treatment strategy and prognosis for GBS-TRF and A-CIDP diff er considerably, 
it is relevant to disti nguish between these two variants early in the course of disease. 
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Based on the criteria described in our studies, A-CIDP now can be diagnosed earlier. 
It is to be expected that this will lead to a bett er and more effi  cient pati ent tailored 
treatment. 
Clinical practi cal suggesti on
  The diagnosis of A-CIDP has to be considered when ‘a pati ent with GBS’ deteriorates again 
aft er eight weeks from onset, or when deteriorati on occurs three ti mes or more. Especially 
when the pati ent remains able to walk independently, has no cranial nerve dysfuncti on, 
and electrophysiological features are more likely to be compati ble with demyelinati on, 
maintenance treatment for CIDP has to be considered (based on this thesis). 
 In chapter 3.2 the results of a retrospecti ve study are described. Chapter 3.3 focusses on 
part of the results of the GRAPH study. In this study pati ents were prospecti vely followed. 
Classifying into GBS-TRF or A-CIDP was done retrospecti vely based on the clinical course 
over a period of ti me. Although the relati vely small number of GBS-TRF and A-CIDP pati ents 
in both studies, the ti me to reach deteriorati on(s) and the number of deteriorati ons in 
GBS-TRF and A-CIDP are signifi cantly diff erent. The results from both studies are very 
much comparable. In our prospecti ve study comparing GBS-TRF and A-CIDP, additi onal 
factors about preceding infecti ons and immunological data have been added (chapter 3.3). 
We have not found diff erences in preceding infecti ons and anti -ganglioside anti bodies. 
However, the small number of pati ents with GBS-TRF and A-CIDP makes it diffi  cult to be 
conclusive about these topics. It is recommended using the provided criteria from now on 
in individual pati ents with a fl uctuati ng course to disti nguish as soon as possible between 
GBS-TRF and A-CIDP. This will result in the right treatment as soon as possible and the right 
indicati on of the prognosis. 
 We have also described some clinical diff erences between GBS pati ents with and without 
TRFs to bett er understand the pathogenesis of TRFs. It appeared that especially the more 
severely aff ected GBS pati ents with sensory disturbances are at risk for developing TRFs 
(chapter 3.3). A more severe or prolonged immune-att ack in individual pati ents, inducing 
the need for prolonged- or repeated IVIg treatment, could possibly form the basis of these 
TRF’s. 
 Several other studies have been published comparing A-CIDP versus acute infl ammatory 
demyelinati ng polyneuropathy (AIDP) (17), GBS versus GBS-TRF (18), A-CIDP versus CIDP 
(19), and GBS versus recurrent GBS (20) to generate indicators to diff erenti ate and to 
bett er understand the pathogenesis (fi gure 1). Summarised the following diff erences are 
known: 1) A retrospecti ve study has compared A-CIDP versus AIDP (17). More sensory 
signs in A-CIDP and less autonomic nervous system involvement, facial weakness, 
preceding infecti ous illnesses, or need for mechanical venti lati on were observed in the 
A-CIDP group compared to AIDP pati ents. No electrophysiological diff erences were found. 
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2) Another study has compared GBS without TRFs and with TRFs (18). None of the GBS 
pati ents with preceding gastro-intesti nal illness, initi al predominant distal weakness, acute 
motor neuropathy, or anti -GM1 anti bodies showed TRFs. EMG data showed signifi cantly 
lower sensory nerve acti on potenti als in the TRF group. 3) In a electrophysiological study, 
A-CIDP pati ents were reported to show a longer distal motor latency and a lower terminal 
latency index (TLi), when compared to CIDP pati ents with a more chronic onset of disease 
(19), suggesti ng accentuated pathology in the distal nerve segments in A-CIDP pati ents. 
4) A retrospecti ve study has compared GBS with pati ents experiencing recurrent GBS 
(20). Recurrent GBS pati ents were younger, and more oft en had MFS or milder symptoms 
compared to the pati ents without recurrent GBS. Geneti c and immunological host factors 
seem to play a role in recurrences, since similar neurological symptoms can occur during a 
recurrence aft er diff erent infecti ons. 
Figure 1 | Diff erences between A-CIDP, GBS, GBS-TRF and CIDP (studies described in this thesis, 
17-19) 
■ deterioraon aer 8 weeks
■ deterioraon occurs three mes or more
■ mildly affected
■ cranial nerve dysfuncon
■ features of demyelinaon (EMG)
■ severely affected
■ acute motor neuropathy
■ sensory signs
■ predominant distal weakness
■ autonomic nervous system involvement
■ facial weakness
■ preceding infecon
■ preceding gastro-intesnal infecon
■ need for mechanical venlaon
■ an-GM1 anbodies
■ decreaseed sensory acon potenals
■ longer distal motor latency
■ lower terminal latency index
GBS-TRF A-CIDP
GBS-TRF GBS / AIDP A-CIDP CIDP
 So, both GBS and CIDP comprise several subtypes in course of disease and these 
syndromes may parti al overlap and probably form a conti nuum. The diff erences between 
the subtypes suggest a variati on of the pathogenesis. In the literature unti l now, especially 
clinical and electrophysiological diff erences between GBS, GBS-TRF, recurrent GBS, AIDP, 
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A-CIDP, and CIDP are described. In clinical practi ce this can be used to guide treatment. 
At this ti me the pathogenic mechanism underlying these diff erent courses is largely 
unknown. A relati vely prolonged immune response as an explanati on for TRFs has been 
suggested (18). Since more severely aff ected GBS pati ents are at risk for developing 
TRFs (chapter 3.3) this seems in line with this possible explanati on. Pathogenic cellular 
or humoral immune reacti ons can conti nue beyond the durati on of the eff ect of IVIg 
treatment. Anti bodies to diff erent gangliosides have been found in about half of GBS 
pati ents (21). Anti bodies to gangliosides have been reported in fewer than 10% in CIDP 
pati ents (22;23). Titers of anti -ganglioside anti bodies have been studied in a GBS-TRF 
pati ent (24). The conclusion was that the clinical TRF was not due to changes in the ti ters 
of anti -ganglioside anti bodies. In the same case a long-lasti ng elevati on of cerebrospinal 
fl uid (CSF) protein was found which could possibly be related with long-term infl ammati on 
of nerve roots. A recent study showed that GBS pati ents with limited increase in serum 
IgG levels aft er IVIg treatment had a more severe clinical course and poor outcome (25). 
A possible explanati on for the occurrence of TRFs could be explained by a too low dosage 
of IVIg for these individual pati ents. In our study GBS-TRF also had a worse prognosis at 
6 months compared to GBS without TRFs. It is likely that further research will allow us to 
design tailor-made treatments for individual pati ents or groups of pati ents. 
Directi on for future research
Studying residual signs and courses of disease in subgroups of pati ents may determine 
clues about recovery which can help to design new treatment studies. Since mildly aff ected 
GBS pati ents also had considerable residual symptoms aft er one-year follow-up (chapter 
3.1), new treatment studies should focus on IVIg treatment in mildly aff ected pati ents. 
Also part of the MFS had considerable residual  symptoms during follow-up (chapter 3.1). 
Therefore, investi gati on of the eff ect of IVIg in MFS pati ents is also indicated. 
 Overall, most of the GBS pati ents experienced residual symptoms, like functi onal 
disability, pain and fati gue aft er one year. IVIg studies mainly have focussed on the 
eff ect of disability (GBS disability scale) aft er 4 weeks. Therefore it is important that new 
treatment studies include a long-term follow-up in order to evaluate the treatment eff ect 
in the acute phase but also in the chronic phase, one or maybe two years aft er onset of 
disease. New treatment studies should also focus on the additi onal therapeuti c benefi t 
of a higher dosage or second course of IVIg on disability but also on arti fi cial respirati on 
and the just menti oned residual fi ndings. However, it needs to be stressed that residual 
fi ndings could also be due to axonal degenerati on in the early phase of disease. In this 
case, a higher dosage or second course of IVIg would likely not benefi t the pati ent, unless 
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it will be applied very early in the course of disease when nerve degenerati on is sti ll likely 
to be reversible.
 It is evident that some GBS or CIDP pati ents respond bett er to immunotherapy than 
others. Diff erent responses to standard therapy might also suggest that not only humoral 
factors but also other mechanisms or other factors are relevant. These factors could be 
the occurrence and extent of complement acti vati on, ongoing and specifi c infecti ons, 
variati on in IVIg kineti cs, the extent of axonal degenerati on otherwise or a variati on 
in geneti c background (immune response gene polymorphisms). Additi onal detailed 
informati on about preceding and ongoing infecti ons before any deteriorati on and ti ters 
of anti -gangliosides anti bodies during the enti re course of disease could give more 
detailed informati on about the role of infecti ons and anti -gangliosides anti bodies in these 
subgroups of pati ents. 
 Measuring of IgG levels in GBS-TRF pati ents pre-treatment and regularly during the 
course of disease (for example every two days) could possibly answer the questi on if 
the dosage of IVIg for these individual pati ents is too low. A controlled trial is needed to 
demonstrate the additi onal therapeuti c benefi t of a higher dosage or second course of 
IVIg in these GBS-TRF pati ents. A new RCT investi gati ng the eff ect of a second dose IVIg 
versus placebo in GBS pati ents (SID-GBS study) with a poor prognosis is now carried out in 
the Netherlands by the Dutch GBS studygroup. An internati onal-SID GBS study is expected 
to start soon. 
PAIN AND SMALL FIBRE NEUROPATHY
In chapter 4 we extensively describe the frequency, intensity, locati on and interpretati on 
of pain in the fi rst year aft er onset of GBS and we have related these aspects of pain to 
the spectrum of GBS variants. We have shown that pain is a common and severe problem 
in about two thirds of the GBS pati ents and that it also occurs in mildly aff ected, MFS and 
pure motor pati ents. For some pati ents pain can be a very traumati c experience and one 
of the most severe symptoms of GBS. Even aft er one year, one third of the GBS pati ents 
has to deal with pain. Probably the results in chapter 4 are underesti mated, because most 
of the GBS pati ents included in our studies used analgesics. This underscores the problem 
of pain even more. It also indicates the diffi  culty of treati ng pain in GBS. 
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Clinical practi cal suggesti ons
  Pain can be severe in the various phases of GBS. Daily ask for the presence and intensity of 
pain in every GBS pati ent during hospital stay (based on this thesis). 
  Be aware that pain can also be severe during the rehabilitati on phase (based on this thesis). 
  The NRS scale can easily be used to evaluate the severity of pain (27) (general suggesti on).
  For pati ents who are intubated, it is essenti al to create a uniform manner for communicati on 
and to ask for pain (general suggesti on).
 We did not include a control group in our studies on pain in GBS. It is known from the 
literature that pain is a common problem in mechanically venti lated criti cal ill pati ents in 
general (26). 18% from the GBS pati ents included in the GRAPH study had to be venti lated. 
Especially procedures like mobilisati on or endotracheal sucti oning are described to 
be very painful in mechanically venti lated criti cal ill pati ents (26). Therefore, also pain 
symptoms, likely not primary GBS related, have infl uenced our results. For the practi cal 
approach dealing with pain in GBS, the cause of the pain doesn’t really matt er, for the 
pathophysiology of pain in GBS it does. 
 The pathophysiology of pain in GBS is largely unknown. In general two types of pain can 
be disti nguished: nocicepti ve and neuropathic pain. Sti mulati on of a nociceptor may cause 
nocicepti ve pain. Damage to the nervous system itself may cause neuropathic pain (27). 
In chapter 4.3 we describe the interpretati on of pain fi lled in on the questi onnaires by 
the neurologists. In one third of the pati ents with pain in the acute phase, the nature was 
interpretated as radicular pain. Aff ected nerve roots in the acute phase may likely explain 
the occurrence of nocicepti ve nerve pain aff ecti ng (low-)back with radiati on to extremiti es 
or trunk. The origin of radicular pain is unclear. Root enhancement in GBS pati ents with 
pain has been described in a prospecti ve MRI study (28). Probably infl ammatory factors 
or peripheral nerve ischemia generate radicular pain via the nervi nervorum (nocicepti ve 
neuropathic pain). In our study, the prevalence of (low-)back pain was higher than the 
prevalence of radicular pain, this suggests that other factors like muscle or facet joint 
pain also contribute to (low-)back with radiati on in the acute phase of GBS. About one 
third of the pain in the acute and chronic phase was interpreted as painful paraesthesias 
and dysaesthesias. Pain due to spontaneous or abnormal acti vity from the aff ected large 
myelinated sensory aff erents in GBS may explain the occurrence of this neuropathic pain. 
This is in line with the result that sensory nerve fi bre involvement is related with more 
severe pain during the enti re follow-up (chapter 4.3). A small number of pati ents with 
pain in the acute phase, had meningism and some of these pati ents had an increased 
cell count in the CSF. CSF pleiocytosis suggests meningeal irritati on due to infl ammatory 
factors in these GBS pati ents. CSF pleiocytosis and meningeal infl ammati on have been 
described before (29). One retrospecti ve study showed that pain in the neck, usually with 
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meningism, occurred in around one third of severely aff ected pati ents (30). The prevalence 
of neck pain was higher than the prevalence of meningism, suggesti ng that other factors 
like muscle or facet joint pain may contribute to neck pain in the acute phase of GBS. 
The most common type of pain during the enti re follow-up in our study was muscle pain 
(chapter 4.3). This suggests overuse of (weak) muscles. Due to overuse, muscle lesions 
can occur which results in acti vati on of the muscle nociceptor, local oedema and ischemia. 
Possibly muscle nociceptors can also be sti mulated otherwise in GBS, a mechanism we 
don’t know yet. In our study an elevated CK level, a measure for muscle lysis, was found in 
a quarter of the GBS pati ents in the acute phase. In a previous report, elevated CK levels 
in GBS were associated with the presence, but not the severity of pain (31). We have not 
found an associati on with neither the presence, nor the intensity of (muscle) pain and 
CK levels. Also within the GBS pati ents with muscle pain, where an elevated CK could 
be expected, we have not found a higher CK level compared to pati ents without muscle 
pain suggesti ng that muscle lysis in GBS is not the main factor in muscle pain in GBS. The 
presence of joint pain increased during follow-up (chapter 4.3). This suggests that joint 
sti ff ness and contractures due to immobilisati on (32,33), but possibly also too intensive 
passive stretch movements, result in local joint problems which results in nocicepti ve joint 
pain. Damage to small nerve fi bres, which has been already shown in one study in GBS 
pati ents (34) and which is also described in chapter 5, could also trigger pain in GBS. We 
demonstrated in chapter 5 that lower values of distal leg IENFD were associated with the 
presence of neuropathic pain and correlated with its intensity. 
 Taking these results together, it can be concluded that the pathophysiological processes 
causing the initi ati on and the maintenance of pain in GBS pati ents are likely more complex 
than in other chronic and painful polyneuropathies (35). In chapter 4.3 we also describe 
that oft en a combinati on of diff erent types and locati ons of pain is present. Distributi on 
and characteristi cs of pain in GBS refl ect the presence of both nocicepti ve pain, and 
neuropathic pain, during diff erent phases of disease. It seems that pain in the acute phase 
is predominantly nocicepti ve pain, due to infl ammati on of the nerve roots and peripheral 
nerves which may acti vate nociceptors. Later on, many GBS pati ents have neuropathic pain. 
This neuropathic pain is a non-nocicepti ve pain that doesn’t arise from pain receptors but 
results from degenerati on and perhaps even regenerati on of nerves, oft en encountered 
in pati ents with chronic neuropathies. Which analgesics are most eff ecti ve in the whole 
spectrum of GBS is not known. In chapter 4.1 we describe that methylprednisolone did 
not show a positi ve eff ect on the presence and reducti on of pain in 225 severely aff ected 
GBS pati ents (36). Previous case-reports suggest that corti costeroids might be an eff ecti ve 
treatment for pain, possibly due to its anti -infl ammatory eff ect (37,38). However, there 
are many symptoms of pain. In previous case reports, corti costeroids were reported 
to have a positi ve eff ect on radicular pain. Theoreti cally, methylprednisolone could be 
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eff ecti ve because it could reduce swelling of the nerve roots. In our study, the number of 
pati ents with radicular pain was too small to conclude about a possible favourable eff ect 
of methylprednisolone on this type of pain in GBS. 
 Besides this study there are some other studies about pain treatment in GBS, however 
most are based on limited numbers of severely aff ected pati ents. Summarised there is: 
1) A randomised, double-blind, cross-over trial involving 18 GBS pati ents admitt ed to the 
intensive care unit (ICU) who required assisted venti lati on. Gabapenti n or placebo was 
given for 7 days before switching to the alternate treatment (39). There was a signifi cant 
relief of pain intensity and reducti on in the need for rescue medicati on in the gabapenti n 
group. 2) In a similar study of 12 pati ents, a signifi cant relief of pain intensity and reducti on 
in the need for rescue medicati on was obtained from carbamazepine for 3 days compared 
to placebo (40). 3) In a randomised, double-blind study in 36 GBS pati ents admitt ed to 
the ICU who required assisted venti lati on, the eff ects of gabapenti n and carbamazepine 
were compared (41). The pati ents in the gabapenti n group had signifi cantly lower pain 
intensity scores. 4) Relief of severe pain by epidural infusions of opioids has been reported 
in two case-reports about mechanically venti lated GBS pati ents (42,43). 5) Pain relief aft er 
treatment with corti costeroids via oral or intravenous routes has also been described in a 
few cases (37,38). 
 In conclusion, only small and mostly non-controlled studies about pain treatment in 
GBS are available. In the small randomised trials only ICU admitt ed venti lated pati ents are 
included and the eff ect on pain is only studied for a very short period. Further studies, how 
to treat pain in GBS are needed. Herefore it is important to assess pain in the right way. 
Assessment of pain in pati ents with GBS can be regarded as a ti me-consuming process, 
especially when pati ents are nearly unable to express themselves because they are 
paralysed and intubated. 
 As described above, the origin of pain just aft er onset of disease will likely to be 
nocicepti ve. In the course of ti me, spontaneous or abnormal acti vity from sensory 
aff erents may explain the occurrence of neuropathic pain. Although not validated for 
GBS pati ents separately, the Neuropathic Pain Symptom Inventory (NPSI) can be used to 
diagnose neuropathic pain (44). 
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Clinical practi cal suggesti ons
  Because of the limited studies about pain treatment in GBS and the probable nocicepti ve 
origin in the acute phase, treat pain in the acute phase according the WHO pain ladder (non 
opioids (aspirin, paracetamol); then, if necessary, mild opioids (codeine); then strong opioids 
such as morphine, unti l the pati ent is free of pain). Be aware of consti pati on as side-eff ect of 
opiods which can be more severe due to autonomic dysfuncti on. To calm fears and anxiety, 
additi onal drugs, adjuvants like anti depressants, anti convulsants, steroids, muscle relaxants, 
exercise and psychological support could be used (general suggesti on). 
  Try to make a disti ncti on between pain during procedures or acti viti es and pain in rest. In the 
fi rst situati on a pain treatment can be given before the procedure or acti vity, in the other 
situati on analgesics have to be given ‘by the clock’ (that is e.g. every 3-6 hours) to maintain 
freedom from pain in stead of as-need basis (general suggesti on). 
  The eff ect of pain treatment in the acute phase should be evaluated every day (general 
suggesti on). 
  Treat neuropathic pain with tricyclic anti depressant (TCA), gabapenti n, pregabalin or other 
anti -epilepti c agents according studies to neuropathic pain in general and the CBO guideline 
‘Polyneuropthie’ (45,46) (general suggesti on). 
Directi on for future research
As described in this thesis, pain is major problem in GBS. The cause of pain in GBS is 
largely unknown. Only limited studies about pain treatment are done. Probably various 
subtypes and causes of pain exist in GBS. Clinical discriminati on between the diff erent 
types of pain like radicular pain, meningism, painful par/dysaesthesiae, muscle pain and 
joint pain is rather possible. However, studying the course of the diff erent types of pain 
and the eff ect of pain treatment is diffi  cult especially because diff erent types of pain 
oft en occur simultaneously. Therefore it is recommended to focus future research on 
exploring the pathophysiological processes of diff erent types of pain in GBS (47). Finally, 
this might guide the development of new therapeuti c strategies. Infl ammati on likely plays 
an important role in the origin of pain in the acute phase of GBS. Pain is mediated by 
several diff erent classes of nocicepti ve aff erent fi bres. Numerous chemical substances play 
a part in generati ng nocicepti ve impulses (e.g. histamine, serotonin, prostaglandins) and 
the pathogeneti c role of infl ammatory cytokines such as TNF-α and neuropepti des such as 
CGRP and substance P are interesti ng to explore in relati on to pain. Pharmacological and 
physiological studies argue that pro-infl ammatory cytokines such as TNF- α are strongly 
involved in the generati on and maintenance of neuropathic pain (48). Elevated serum 
concentrati ons of TNF- α show a positi ve correlati on with severity of neuropathy in pati ents 
with GBS (49). Furthermore, the role of neuropepti des, such as CGRP and substance P, 
has clearly been demonstrated in the acti vati on of early neurogenic infl ammati on. In 
diabeti c neuropathy, where nocicepti ve aff erent fi bres could also be aff ected, a marked 
reducti on of CGRP and substance P immunoreacti vity has been described (50;51). TRPV1 
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is expressed in the central and the peripheral nervous system and is essenti al for selecti ve 
modaliti es of pain sensati on and for thermal hyperalgesia induced by ti ssue infl ammati on 
(52). Whether TRPV1 has a role in maintaining pain in GBS is not known. Notably, previous 
studies in painful diabeti c neuropathy have shown a diff use loss of TPRV1 positi ve axons 
both in the sural nerve and in the skin (53). Moreover, intraepidermal nerve fi bres express 
TPRV1, which shows that they are nociceptors (53). To further investi gate pain in the 
acute phase of GBS and during recovery, anti bodies against 1) neuropepti des and 2) pain 
receptors as indicated above should be used in further studies. For this, skin biopsies can 
be used. 
AUTONOMIC DYSFUNCTION AND SMALL FIBRE NEUROPATHY
Abnormal autonomic functi ons frequently occur in GBS, including in MFS and mildly 
aff ected pati ents (chapter 3.1). Severely aff ected GBS pati ents more oft en showed 
abnormal autonomic functi ons (tachycardia, hypertension, gastro-intesti nal, and bladder 
dysfuncti on) than in the mildly aff ected group (chapter 3.1). The frequency of clinical 
autonomic dysfuncti on described in GBS is highly variable (54). This already suggests the 
diffi  culty in assessing autonomic neuropathy in clinical setti  ng. 
 Some remarks about our assessment of abnormal autonomic functi ons must be made. 
A control group was lacking, and we were not well informed about autonomic functi ons in 
medical history, therefore we could not assess autonomic dysfuncti on purely due to GBS. 
Unlike severely aff ected pati ents, serious bradycardias did not occur in the acute phase 
in mildly aff ected pati ents (chapter 3.1). In the literature it has been described in a small 
study that serious bradyarrhythmias spontaneously or aft er eyeball pressure testi ng was 
also present in mild-to-moderately disabled pati ents (55-56). On the other hand, it has 
been described that mechanically venti lated pati ents have the greatest risk of developing 
serious bradyarrhythmias (57). In our study bradycardias did not occur more frequently in 
mechanically venti lated pati ents compared to not mechanically venti lated pati ents. 
 Several techniques have been devised for assessment of autonomic functi ons. 
Examples available to assess the sympatheti c and parasympatheti c nervous system are: 
cardiovascular refl ex testi ng by Valsalva manoeuvre, blood pressure response to standing 
or ti lt and measuring the heart rate variati on during deep breathing and during the 
Valsalva manoeuvre. However, at least part of the severely aff ected GBS pati ents are 
unable to perform standardised tests of autonomic functi on in an appropriate fashion 
(57). Therefore we choose a non-invasive and easy applicable autonomic cardiovascular 
measurement (blood pressure (BP), heart rate (HR), and spectral analysis of their variability 
measured during 10 minutes supine rest) in a subgroup of GBS pati ents in the fi rst week 
binnenwerk l ruts.indd   182 31-3-2010   11:55:28
General discussion 183
aft er inclusion under uniform circumstances (chapter 5). We did realise that these 
measurements are not always related to clinically autonomic dysfuncti on. GBS pati ents 
showed signifi cantly higher mean levels of HR, systolic blood pressure (SBP), and lower 
levels of low frequency heart rate (LFHR) power and barorefl ex sensiti vity (BRS) index as 
compared to controls. A high GBS disability score (severely aff ected) was associated with a 
high HR. It is likely that associated problems that may occur especially in severely aff ected 
pati ents, like ICU related stress and pneumoniae, may also play a role in this associati on. 
For all the other autonomic parameters there was no correlati on with severity of disease. 
 AIDP pati ents (based on the electrophysiological classifi cati on) more frequently showed 
abnormal autonomic functi ons in the acute phase compared to acute motor axonal 
neuropathy (AMAN), however this was, except for the gastro-intesti nal dysfuncti on, not 
signifi cant and could be related to the relati ve small number of AMAN pati ents included 
in the GRAPH study. In one other study it was concluded that AMAN was not necessarily 
associated with marked autonomic dysfuncti on except for the sudomotor hypofuncti on 
seen in pati ents with severe neurological defi cits (58).
Clinical practi cal suggesti ons 
  Be aware that abnormal autonomic functi ons frequently occur in GBS, including in mildly 
aff ected and MFS pati ents (based on this thesis). 
  Regularly (every 3 to 4 hours) assess the autonomic functi ons in the acute phase in the whole 
spectrum of GBS including MFS and mildy aff ected GBS pati ents. Especially cardiovascular 
autonomic functi ons (BP and HR) have to be asessed, because those can be life-treathening 
(general suggesti on). 
Directi on for future research
In a further study to autonomic dysfuncti on in GBS, discriminati on between diff erences in 
abnormal autonomic functi ons and autonomic neuropathy due to GBS needs to be made. 
To make conclusions about clinical abnormal autonomic functi ons, a control group needs 
to be included. However, defi ning and fi nding an otherwise comparable (non-GBS) control 
group admitt ed to a hospital or ICU that is not likely to develop abnormal autonomic 
functi ons is diffi  cult. Regarding autonomic functi on tests, part of the severely aff ected 
pati ents are unable to perform tests of autonomic functi on in an appropriate fashion (57).
The non-invasive and early applicable autonomic cardiovascular measurement (BP, HR, and 
spectral analysis of their variability) measured during 10 minutes is a usable tool, however 
it does not always correlate with clinical autonomic dysfuncti on. Additi onally spectral 
analysis is not always and everywhere available and the interpretati on might be diffi  cult. 
Before using this measurement clinically, further study is needed in a large group of GBS 
pati ents to interpretate the clinical relevance for the individual GBS pati ent. 
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 Another way to further study autonomic dysfuncti on in GBS is to obtain informati on 
about the involvement of autonomic nerve fi bres in GBS. With PGP 9.5, the non-specifi c 
panaxonal marker, we studied the unmyelinated small fi bres in the epidermis. Distal leg 
density of the unmyelinated small fi bres in the epidermis in the acute phase showed 
a signifi cantly positi ve correlati on with part of the cardiovascular autonomic functi ons 
(chapter 5). To investi gate autonomic nerve fi bre involvement during the acute phase 
and during recovery, anti bodies against cholinergic sympatheti c receptors on sudomotor 
fi bres innervati ng sweat glands and adrenergic sympatheti c receptors on non-sudomotor 
fi bres like anti bodies against vaso intesti nal pepti de (VIP), neuropepti de Y and tyrosine 
hydroxylase can be used. Immunohistochemical analysis could identi fy the type of fi bres 
predominatly involved in autonomic dysfuncti on in GBS.  
OUTCOME OF DISEASE AND SMALL FIBRE NEUROPATHY
Small nerve fi bres are aff ected in the whole spectrum of GBS at distal but also lumbar 
sites already from the early phase of the disease and their loss is associated with the 
occurrence of acute neuropathic pain and autonomic dysfuncti on but may also have a 
relati on with outcome (chapter 5). 
Clinical practi cal suggesti on 
  Skin biopsy and determinati on of intradermal nerve fi bre density (IENFD) oft en shows reduced 
number of fi bres not only in severe but also in mildly aff ected GBS pati ents. Reduced fi bre 
numbers are related with pain and autonomic dysfuncti on. Whether skin biopsies are helpful 
to determine the prognosis in GBS needs further studies. Currently skin biopsy investi gati on 
in GBS has to be considered as a research tool and is not indicated in clinical practi ce (based 
on this thesis). 
Directi on for future research
Long-term morbidity from GBS is presumably predominantly caused by axonal damage. 
Motor impairment dominates the clinical pictures also during the chronic phase of recovery, 
but there are some data on potenti al biomarkers useful to indicate an acti ve regenerati ng 
process at the neuropathological level. This informati on could be important for the 
overall prognosis of pati ents. A prospecti ve study demonstrated that the concentrati on 
of neurofi laments in the CSF was of prognosti c value in GBS. Pathologically high CSF 
neurofi lament levels predicted worse motor and functi onal outcome (59). As far as we 
know there are no studies available yet on cytoskeleton elements in skin biopsies from 
GBS pati ents. To investi gate the axonal structure during the acute phase of the disease 
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and during recovery, anti bodies against cytoskeleton elements like monoclonal anti bodies 
against unique β-tubulin (TuJ1), nonphosphorylated microtubule associated protein-1B 
(MAP1B), neurofi lament (NF) and phosphorylated neurofi lament (SMI 312) could be used.
 Myelinated nerve fi bres, a primary target of disease in GBS (AIDP), can be investi gated 
in the skin using specifi c anti bodies against myelin basic protein (MBP) and peripheral 
myelin protein (PMP 22). Myelinated fi bres of the skin haven’t been studied before in GBS 
pati ents. It seems possible to study it in GBS since it is possible to quanti tate and to study 
morphology of myelinated fi bres in other immune-mediated demyelinati ng neuropathies 
(60). It would be interesti ng to study whether the demyelinati ng proces and/or axonal 
damage present in large fi bres is refl ected in the small fi bres, and whether skin biopsies 
can act as a model to study the disease process.
 Finally, GBS is associated with anti bodies to several gangliosides or ganglioside complexes 
(61), and complement acti vati on and membrane att ack complexes (MAC) play a prominent 
role (62). Therefore it would be interesti ng to study these factors also in skin biopsies.
GENERAL CONCLUSION
GBS is a heterogeneous disorder regarding the severity, course of disease, residual 
symptoms, the presence and severity of pain, and autonomic dysfuncti on. Infecti ons, 
cross-reacti ve anti -ganglioside anti bodies, and electrophysiological fi ndings may at least 
parti ally determine the severity of disease. The studies described in this thesis have 
provided more insights in the course of disease and the presence of residual fi ndings. 
These studies have also contributed to delineate factors that play a role in a fl uctuati ng 
course that eventually may lead to CIDP, the presence and severity of pain and the presence 
of autonomic dysfuncti on within the spectrum of GBS. The ‘clinical practi cal suggesti ons’ 
are expected to be helpful to opti mize medical treatment and care for pati ents with GBS. 
 The prognosis of individual GBS pati ents is sti ll diffi  cult to determine. Recently our 
GBS study group has published two prognosti c models based upon severely aff ected GBS 
pati ents (63,64). These models, in combinati on with the results of this thesis, may help to 
determine additi onal prognosti c factors that may be relevant for a broad spectrum of GBS 
pati ents. It would be helpful not only to identi fy factors that predict functi onal disability, 
but also to add factors that predict pain or autonomic dysfuncti on, which needs further 
research. 
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SUMMARY 
 
In this thesis, studies concerning the heterogeneity in clinical symptoms and course of 
disease of the Guillain-Barré syndrome (GBS) are presented. GBS is an acute immune-
mediated polyneuropathy characterised by rapidly progressive and relati vely symmetrical 
limb muscle weakness and loss of tendon refl exes with or without sensory disturbances, 
cranial nerve involvement and respiratory dysfuncti on. In most pati ents, GBS is a post-
infecti ous disorder with a monophasic course of disease. Time to reach nadir is within four 
weeks where aft er the pati ent gradually improves. There are some underexposed issues in 
GBS that we have studied and discussed in this thesis: 1) Residual fi ndings. The presence 
and severity of residual fi ndings in GBS largely varies between individuals. Most treatment 
trials and the majority of other larger studies have focussed on severely disabled GBS 
pati ents (pati ents who are unable to walk). In this thesis, we have also focussed on the 
presence and severity of residual fi ndings in subgroups of GBS pati ents, in parti cular 
mildly aff ected pati ents and pati ents with Miller Fisher syndrome (MFS). This informati on 
may help to guide whether these GBS subgroups also require medical treatment already 
during the progressive phase of disease. 2) Fluctuati ng course of disease. Some GBS 
pati ents have a fl uctuati ng course instead of a monophasic course. This oft en raises doubt 
about the diagnosis. Some ‘GBS pati ents’ eventually may develop chronic infl ammatory 
demyelinati ng polyneuropathy with acute onset (A-CIDP). For the opti mal treatment 
strategy and prognosis, it is relevant to disti nguish between GBS with a fl uctuati ng course 
and A-CIDP as soon as possible. 3) Pain. Besides weakness and sensory disturbances, 
pain can be a prominent symptom. Because progressive paralysis is the most striking and 
alarming symptom of GBS, pain is oft en overlooked. 4) Autonomic dysfuncti on. Autonomic 
dysfuncti on also frequently occurs and can be life threatening. In the studies presented 
in this thesis, we have focussed on the aforementi oned underexposed but important 
issues in GBS. The aim was to provide more insight in the presence and severity of 
residual fi ndings, course of disease, and the frequency and nature of pain and autonomic 
dysfuncti on, and fi nally to delineate factors that relate to a fl uctuati ng course, pain and 
autonomic dysfuncti on in GBS. To study these issues we have set up the Dutch prospecti ve 
‘GBS Research about Pain and Heterogeneity’ (GRAPH) study.
 Chapter 1 is the general introducti on of this thesis. Background informati on about 
clinical features, pathogenesis, and treatment of GBS is reviewed to provide an overview 
of the current knowledge about GBS. Additi onally, the rati onale for this thesis is described 
in relati on to several cases that illustrate some diffi  culti es physicians may be faced with 
when taking care for pati ents suff ering from GBS. The cases that are described are: 1) 
a mildly aff ected GBS pati ent having residual symptoms, 2) a pati ent with GBS having a 
fl uctuati ng course, 3) a pati ent having severe pain during the course of GBS, and 4) GBS 
pati ents with severe autonomic dysfuncti on.
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 In chapter 2 an overview of the GRAPH study design is given. The GRAPH study is a 
prospecti ve observati onal follow-up study with 55 parti cipati ng Dutch centres. In total 
170 pati ents were included. Clinical data, biological material (serum, CSF, throat and stool 
specimens, skin biopsies), an electromyographic study, and autonomic parameters were 
collected at standard ti me points during one-year follow-up. The results of the GRAPH 
study are described in chapter 3 to 5.
 In chapter 3, the clinical spectrum and the treatment of GBS and CIDP are described. 
Chapter 3.1 provides prospecti ve collected informati on about the diff erences in preceding 
infecti ons, autonomic dysfuncti on, course of disease and residual fi ndings in GBS (non-
MFS) versus MFS, and mildly versus severely aff ected GBS pati ents. We found that mildly 
aff ected GBS pati ents more oft en showed a preceding virological infecti on compared 
to severely aff ected GBS pati ents. This suggests that preceding infecti ons may at least 
parti ally determine symptoms and severity of disease. Severely aff ected GBS pati ents 
more oft en showed autonomic dysfuncti on compared to mildy aff ected pati ents. Residual 
symptoms like functi onal disability, pain and fati gue appeared to be very common, not 
only in severely aff ected GBS pati ents, but also in MFS and in mildly aff ected GBS pati ents. 
This raises the questi on if pati ents with MFS and mildly aff ected GBS pati ents also require 
treatment with intravenous immunoglobulin (IVIg). In chapter 3.2, the diff erences 
between GBS with treatment related fl uctuati ons (GBS-TRF) and A-CIDP are described 
based on a retrospecti ve study. It is relevant to disti nguish between these two variants 
as soon as possible because treatment strategy and prognosis diff er considerably. We 
compared thirteen A-CIDP pati ents with eleven GBS-TRF pati ents and for the fi rst ti me 
we identi fi ed factors that help to disti nguish between GBS-TRF and A-CIDP. In chapter 3.3, 
the diff erences between GBS-TRF and A-CIDP are described into more detail based on the 
GRAPH study. The diagnosis of A-CIDP indeed should be considered when ‘a pati ent with 
GBS’ deteriorates again aft er eight weeks from onset, or when deteriorati on occurs three 
ti mes or more. Especially when the pati ent remains able to walk independently during the 
most severe phase of disease, has no cranial nerve dysfuncti on and electrophysiological 
examinati on shows features of demyelinati on, it is likely that the pati ent has A-CIDP. In 
this case, maintenance treatment for CIDP should be considered. Chapter 3.4 reviews 
treatment of CIDP. IVIg, steroids and plasma exchange (PE) are shown to be eff ecti ve. 
It is suggested that some other immunomodulatory agents can also be eff ecti ve, but 
that randomised trials are needed to confi rm these benefi ts. Residual symptoms in CIDP, 
including pain and fati gue are also discussed (with the suggesti on to pay att enti on and 
manage these residual symptoms). Based upon the studies as described in this thesis, and 
at least from the more clinical point of view, it is likely that GBS, A-CIDP, and CIDP are all 
within one spectrum ranging from very acute GBS on one side to a slowly progressive form 
of CIDP on the other side. 
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 In chapter 4, the focus is on the occurrence, the diff erent types and locati ons, and 
the intensity of pain in GBS. In chapter 4.1, the presence of pain and the eff ect of 
methylprednisolone on pain is described in 225 severely aff ected GBS pati ents enrolled in 
a randomised controlled trial (RCT) studying the additi onal eff ect of methylprednisolone 
when added to standard treatment with IVIg with the aim to improve disability. Pain was 
reported by 55% of pati ents at randomisati on, 22% of these pati ents had severe pain. Of 
the pati ents with pain, surprisingly 70% indicated that the pain preceded the onset of 
weakness. Although this RCT was not designed to study the eff ect of methylprednisolone 
on pain reducti on in GBS, it could be concluded that there was no indicati on that 
methylprednisolone has a positi ve eff ect on the presence and reducti on of pain in GBS 
pati ents. A retrospecti ve analysis in a subgroup of pati ents showed that backache, 
interscapular -, muscle -, and radicular pain, together with painful par-/dysaesthesiae were 
most frequently present in the acute phase of disease. Most symptoms of pain decreased 
aft er this period, but painful par-/dysaesthesiae and muscle pain appeared to be present 
in a large number of pati ents even aft er 6 months. In chapter 4.2, we describe that pain 
rather surprisingly can also occur in pati ents with the pure motor form of GBS. Of a group 
of 77 GBS pati ents from Europe and Curaçao with a clinically pure motor neuropathy that 
we studied retrospecti vely, it appeared that 49% of the pati ents reported to have pain, 
which was mostly located in the extremiti es. Some of these pati ents even reported to 
have severe pain. In chapter 4.3, the presence and detailed aspects of pain are described 
based on the results of the GRAPH study in an unselected GBS populati on. Here we related 
pain symptoms also to other clinical symptoms of GBS. Pain was reported to occur already 
in the two weeks preceding weakness in 35% of the pati ents. In the acute phase 64% 
of the pati ents reported pain and 35% even had pain aft er one year. In the majority of 
pati ents, the intensity of pain was moderate to severe. The mean pain intensity in the 
whole cohort of GBS pati ents slowly decreased over ti me. Pain occurred in the whole 
spectrum of GBS (also pure motor, mildly aff ected and MFS pati ents). Pain symptoms 
were associated with sensory disturbances, and the presence of severe pain symptoms 
later in the stage of disease was associated with a higher level of weakness, disability 
and fati gue at that moment. Mainly radicular pain, painful par-/dysaesthesiae and muscle 
pain were described in the acute phase. Aft er 6 months, painful par-/dysaesthesiae and 
muscle pain were predominantly present. It could be concluded that pain is a common 
and oft en severe symptom in the whole spectrum of GBS and it is likely that sensory nerve 
fi bre involvement results in more severe pain. Overall, it can be concluded that pain in GBS 
requires full att enti on. 
 Small diameter nerve fi bres play a key role in pain conducti on and autonomic 
functi ons. These fi bres can easily be investi gated in skin biopsies by quanti fi cati on of 
the intraepidermal nerve fi bre density (IENFD). With the aim to get more informati on on 
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the presence and ulti mately also on pathophysiology of pain and autonomic dysfuncti on 
in GBS, we performed a skin biopsy study in part of the GBS pati ents enrolled in the 
GRAPH study. The results are described in chapter 5. In this chapter we investi gated the 
number of small diameter fi bres within the whole spectrum of GBS over ti me in both 
distal (ankle) and proximal (lumbar paraspinal) sites of the body. In GBS pati ents, distal 
and lumbar IENFD values were lower in the acute phase as compared to controls. IENFD 
remained lower also at 6-month follow-up. Loss of small nerve fi bres was associated with 
the presence and intensity of neuropathic pain, autonomic dysfuncti on, and ͵ to some 
extent ͵ with worse outcome. It could be concluded from this study that small diameter 
nerve fi bres are aff ected in the various subgroups of GBS at diff erent locati ons and over 
ti me. Furthermore, that research using skin biopsies may lead to more insight into the 
pathophysiology of features leading to pain and autonomic dysfuncti on in GBS. 
 Finally, in chapter 6 the results of the diff erent studies described in this thesis are 
discussed and suggesti ons for further research are given. 
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In dit proefschrift  is het onderzoek naar de heterogeniteit van klinische symptomen 
en het beloop van het Guillain-Barré syndroom (GBS) beschreven. GBS is een acute 
immuun-gemedieerde polyneuropathie. Klinisch wordt GBS gekenmerkt door een snel 
progressieve symmetrische zwakte van de armen en benen, verlaagde of afwezige 
spierrekkingsrefl exen, al dan niet gepaard gaand met gevoelsstoornissen, uitval van de 
hersenzenuwen en zwakte van de ademhalingsspieren. Bij de meeste pati ënten is er een 
voorafgaande infecti e geweest en heeft  de ziekte een monofasisch beloop. Het dieptepunt 
van de zwakte wordt bereikt binnen vier weken, waarna de pati ënt geleidelijk aan weer 
verbetert. In de klinische prakti jk, is een aantal onderwerpen rondom GBS onderbelicht. 
De volgende onderwerpen zijn bestudeerd in dit proefschrift : 1) Restverschijnselen. De 
aanwezigheid en de ernst van restverschijnselen van GBS varieert sterk tussen individuele 
pati ënten. De meeste gerandomiseerde trials en andere grotere studies zijn gericht op 
ernsti g aangedane GBS pati ënten (pati ënten die niet in staat zijn om te lopen). In dit 
proefschrift , hebben we ons gericht op de aanwezigheid en de ernst van restverschijnselen 
in subgroepen van GBS pati ënten, in het bijzonder de relati ef mild aangedane pati ënten 
en pati ënten met het Miller Fisher syndroom (MFS). Informati e over restverschijnselen 
kan meehelpen in de beslissing of deze GBS subgroepen wel of niet behandeld moeten 
worden met intraveneus immunoglobuline (IVIg). 2) Fluctuerend ziektebeloop. Sommige 
GBS pati ënten hebben een fl uctuerend ziektebeloop, in plaats van een monofasisch 
beloop. Dit resulteert vaak in twijfel over de juiste diagnose. Sommige ‘GBS pati ënten’ 
ontwikkelen namelijk uiteindelijk chronische infl ammatoire demyeliniserende 
polyneuropathie met een acuut begin (A-CIDP). Voor de juiste behandeling en de 
prognose, is het van belang om zo vroeg mogelijk onderscheid te maken tussen GBS met 
een fl uctuerend beloop en A-CIDP. 3) Pijn. Behalve zwakte en gevoelsstoornissen, kan pijn 
een belangrijke klacht zijn. Omdat de aandacht meestal uitgaat naar de progressie van 
de zwakte, wordt pijn vaak over het hoofd gezien. 4) Autonome dysfuncti e. Autonome 
dysfuncti e, wat ook vaak voorkomt bij GBS, kan levensbedreigend zijn. In het onderzoek 
wat beschreven is in dit proefschrift  hebben we ons gericht op de bovengenoemde 
onderbelichte, maar belangrijke onderwerpen bij GBS. Het doel was om meer inzicht te 
krijgen in de aanwezigheid en ernst van de restverschijnselen, het beloop van de ziekte 
en in de frequenti e en de aard van pijn en autonome dysfuncti e om vervolgens factoren 
te identi fi ceren die bij GBS pati ënten van invloed zijn op een fl uctuerend verloop, pijn en 
autonome dysfuncti e. Om dit te onderzoeken hebben wij de Nederlandse prospecti eve 
GRAPH studie opgezet. GRAPH staat voor ‘GBS Research about Pain and Heterogeneity’. 
 Hoofdstuk 1 is de algemene inleiding van dit proefschrift . Hierin wordt een overzicht 
gegeven van de huidige kennis over de klinische symptomen, pathogenese en behandeling 
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van GBS. Daarnaast wordt het doel van dit proefschrift  beschreven aan de hand van enkele 
pati ënten casussen die de moeilijkheden illustreren waar artsen mee te maken hebben 
ti jdens de zorg voor pati ënten die lijden aan GBS. De voorbeelden die worden beschreven 
zijn: 1) een mild aangedane GBS pati ënt met restverschijnselen, 2) een pati ënt met GBS 
met een fl uctuerend beloop, 3) een pati ënt met ernsti ge pijn ti jdens het doormaken van 
GBS, en 4) GBS pati ënten met ernsti ge autonome dysfuncti e. 
 In hoofdstuk 2 wordt de onderzoeksopzet van de GRAPH studie beschreven. De GRAPH 
studie is een prospecti eve observati onele follow-up studie waaraan 55 Nederlandse 
centra deelnamen. In totaal zijn er 170 pati ënten geïncludeerd. Klinische gegevens, 
biologisch materiaal (serum, liquor, faeces, sputum, huidbiopten), een EMG en autonome 
parameters werden verzameld op standaard ti jdsti ppen gedurende één jaar follow-up. De 
resultaten van de GRAPH studie worden beschreven in hoofdstuk 3 tot en met 5.
 In hoofdstuk 3 wordt het klinische spectrum en de behandeling van GBS en CIDP 
beschreven. Hoofdstuk 3.1 bevat prospecti ef verzamelde informati e over de verschillen in 
voorafgaande infecti es, autonome dysfuncti e, beloop van de ziekte en restverschijnselen in 
GBS (zonder MFS) versus pati ënten met MFS en mild aangedane versus ernsti g aangedane 
GBS pati ënten. We vonden dat mild aangedane pati ënten vaker een voorafgaande 
virologische infecti e hadden doorgemaakt in vergelijking met ernsti g aangedane GBS 
pati ënten. Dit suggereert dat een voorafgaande infecti e deels bepalend kan zijn voor 
de symptomen en de ernst van de ziekte. Ernsti g aangedane GBS pati ënten bleken 
vaker autonome dysfuncti e te vertonen in vergelijking met mild aangedane pati ënten. 
Restklachten zoals functi onele handicap, pijn en vermoeidheid kwamen frequent voor, 
niet alleen bij ernsti g aangedane GBS pati ënten, maar ook bij MFS en mild aangedane 
GBS pati ënten. Dit resulteert in de vraag of MFS en mild aangedane GBS pati ënten ook 
behandeld zouden moeten worden met IVIg. In hoofdstuk 3.2 zijn de verschillen tussen 
GBS pati ënten met treatment related fl uctuati on (GBS-TRF) en A-CIDP beschreven op basis 
van een retrospecti eve studie. Het is van belang om zo spoedig mogelijk onderscheid te 
maken tussen deze twee varianten, omdat de behandeling en de prognose aanzienlijk 
verschillen. We vergeleken derti en A-CIDP pati ënten met elf GBS-TRF pati ënten en voor 
het eerst identi fi ceerden we factoren die helpen onderscheid te maken tussen GBS-TRF en 
A-CIDP. In hoofdstuk 3.3 zijn de verschillen tussen GBS pati enten met treatment related 
fl uctuatGBS-TRF en A-CIDP beschreven in meer detail, gebaseerd op de GRAPH studie. 
De waarschijnlijkheidsdiagnose A-CIDP moet worden gesteld als ‘een pati ënt met GBS’ 
opnieuw verslechtert na acht weken na het begin van GBS, of wanneer er drie keer of meer 
een verslechtering optreedt. Vooral wanneer de pati ënt nog zelfstandig kan lopen ti jdens 
het dieptepunt van de ziekte, geen hersenzenuw uitval heeft  en het elektrofysiologische 
onderzoek kenmerken toont van demyelinisati e, is het waarschijnlijk dat de pati ënt 
A-CIDP heeft . In dat geval moet onderhoudsbehandeling voor CIDP worden overwogen. 
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Hoofdstuk 3.4 beschrijft  de behandeling van CIDP. IVIg, steroïden en plasmaferese zijn 
eff ecti ef gebleken. Gesuggereerd wordt dat sommige andere immunomodulerende 
middelen ook eff ecti ef zouden kunnen zijn. Gerandomiseerde studies zijn nodig om dit te 
bevesti gen. Restklachten in CIDP, zoals pijn en vermoeidheid, zijn eveneens beschreven 
met de opmerking om aandacht te besteden aan restverschijnselen bij deze pati ënten. Op 
basis van de studies zoals beschreven in dit proefschrift  en vanuit klinisch oogpunt, is het 
waarschijnlijk dat GBS, A-CIDP en CIDP allemaal onderdeel uitmaken van een spectrum met 
aan de ene kant de zeer acuut vorm, GBS en aan de andere kant de langzaam progressieve 
vorm, CIDP.
 In hoofdstuk 4 ligt de nadruk op pijn bij GBS. De prevalenti e, de verschillende 
soorten, lokalisati es en intensiteit van pijn worden beschreven. In hoofdstuk 4.1, is de 
aanwezigheid van pijn en het eff ect van methylprednisolon op de pijn beschreven onder 
225 ernsti g aangedane GBS pati ënten die geïncludeerd waren in een gerandomiseerde 
gecontroleerde trial (RCT) naar het additi onele eff ect van methylprednisolon op de 
snelheid van het verbeteren van de functi onele handicap wanneer dit toegevoegd 
werd aan de standaardbehandeling met IVIg. Pijn werd gerapporteerd door 55% 
van de pati ënten bij randomisati e, 22% van deze pati ënten had ernsti ge pijn. Van de 
pati ënten met pijn gaf 70% aan dat de pijn vóór aanvang van zwakte al was begonnen. 
Hoewel deze RCT niet was ontworpen om het eff ect van methylprednisolon op pijn in 
GBS te bestuderen, kan er worden geconcludeerd dat er geen aanwijzingen waren dat 
methylprednisolon een positi ef eff ect heeft  op de aanwezigheid en de vermindering van 
pijn bij GBS pati ënten. Uit een retrospecti eve analyse van een subgroep van pati ënten 
bleek dat rugpijn, interscapulaire -, spier -, en radiculaire pijn, samen met pijnlijke par-/
dysaesthesieën het meest aanwezig waren in de acute fase van de ziekte. De meeste 
pijnsymptomen namen af na deze periode, maar vooral pijnlijke par-/dysaesthesieën en 
spierpijn bleken in een groot aantal van de pati ënten zelfs na 6 maanden nog aanwezig 
te zijn. In hoofdstuk 4.2 wordt beschreven dat pijn opvallenderwijs ook kan optreden 
bij pati ënten met de puur motore vorm van GBS. In een groep van 77 GBS pati ënten uit 
Europa en Curaçao met de klinisch puur motore vorm die we retrospecti ef bestudeerd 
hebben, bleek dat 49% van de pati ënten pijn had, die voornamelijk was gelokaliseerd in 
de extremiteiten. Sommige van deze pati ënten gaven ook aan ernsti ge pijn te hebben. 
In hoofdstuk 4.3 wordt pijn bij GBS gedetailleerd beschreven in een niet-geselecteerde 
GBS populati e van het cohort van de GRAPH studie. Daarnaast is pijn gerelateerd aan 
andere klinische symptomen van GBS. 35% van de pati ënten had al pijn in de twee weken 
voorafgaand aan de zwakte. In de acute fase gaf 64% van de pati ënten aan pijn te hebben 
en 35% had zelfs pijn na één jaar. Bij de meerderheid van de pati ënten was de intensiteit 
van de pijn mati g tot ernsti g. De gemiddelde pijn intensiteit van het gehele GBS cohort 
nam langzaam af in de ti jd. Pijn kwam voor in het gehele spectrum van GBS (dus ook bij 
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de puur motore vorm, de mild aangedane en MFS pati ënten). De aanwezigheid van pijn 
was geassocieerd met de aanwezigheid van gevoelsstoornissen. Na de acute fase was de 
ernst van de pijn geassocieerd met de ernst van de zwakte, de ernst van de handicap en de 
ernst van vermoeidheid op dat moment. In de acute fase werden vooral radiculaire pijn, 
pijnlijke par-/dysaesthesieën en spierpijn beschreven. Na 6 maanden waren voornamelijk 
pijnlijke par-/dysaesthesieën en spierpijn aanwezig. Geconcludeerd kan worden dat pijn 
een veel voorkomend en vaak ernsti g symptoom is in het hele spectrum van GBS. Het is 
waarschijnlijk dat betrokkenheid van de sensibele zenuwvezels leidt tot ernsti gere pijn. 
Over het algemeen kan worden geconcludeerd dat pijn bij GBS veel aandacht behoeft . 
 Dunne zenuwvezels spelen een belangrijke rol in pijngeleiding en autonome functi es. 
Deze vezels kunnen eenvoudig worden onderzocht in huidbiopten door kwanti fi cering 
van de intraepidermale zenuwvezel dichtheid (IENFD). Met als doel om meer inzicht te 
krijgen in de pathophysiologie van pijn en autonome dysfuncti e bij GBS hebben we bij een 
deel van de GBS pati ënten geïncludeerd in de GRAPH studie huidbiopten afgenomen. De 
resultaten zijn beschreven in hoofdstuk 5. In dit hoofdstuk onderzochten we het aantal 
dunne zenuwvezels binnen het gehele spectrum van GBS na verloop van ti jd in distale 
(enkel) en proximale (paraspinaal lumbaal) delen van het lichaam. Bij GBS pati ënten waren 
de distale en lumbale IENFD waardes lager in de acute fase in vergelijking met de controle 
groep. IENFD was ook lager na 6 maanden follow-up. Verlies van kleine zenuwvezels was 
geassocieerd met de aanwezigheid van neuropathische pijn, autonome dysfuncti e, en 
͵ tot op zekere hoogte ͵ met een slechter herstel van de zwakte. Uit deze studie kan 
worden geconcludeerd dat de dunne zenuwvezels in de verschillende subgroepen van GBS 
op verschillende locati es en op verschillende ti jdsti ppen zijn aangedaan. Onderzoek van 
huidbiopten kan leiden tot een beter inzicht in de pathofysiologie van pijn en autonome 
dysfuncti e bij GBS.
 Tenslott e worden in hoofdstuk 6 de resultaten van de verschillende studies die in dit 
proefschrift  zijn beschreven besproken en worden er suggesti es voor verder onderzoek 
gegeven. 
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LIST OF ABBREVIATIONS 
A-CIDP = acute onset chronic infl ammatory demyelinati ng polyneuropathy 
AIDP = acute infl ammatory demyelinati ng polyneuropathy
AMAN = acute motor axonal neuropathy
AMSAN  = acute motor and sensory axonal neuropathy
BP  = blood pressure
BRS = barorefl ex sensiti vity 
CIDP  = chronic infl ammatory demyelinati ng polyneuropathy
CMV  = cytomegalovirus
CSF  = cerebrospinal fl uid 
dCMAP = distal compound muscle acti on potenti al
DML = distal motor latency
DBP  = diastolic blood pressure
DRG  = dorsal root ganglion
EBV = Epstein-Barr virus 
EMG = electromyography
GBS  = Guillain-Barré syndrome
GBS-TRF = Guillain-Barré syndrome with treatment related fl uctuati ons
GRAPH = GBS Research about Pain and Heterogeneity
hCoV  = human coronavirus 
HF  = high-frequency
HR  = heart rate
hMPV = human metapneumovirus 
HSV = herpes simplex virus
IBI  = interbit interval
ICU = intensive care unit
IENFD = intra epidermal nerve fi bre density
IENF  = intra epidermal nerve fi bre
IF  = immunofl uorescence
IVIg  = intravenous immunoglobulin 
LF  = low-frequency
LOS = lipo-oligosaccharide
MFS  = Miller Fisher syndrome 
mNCV = motor nerve conducti on velocity
MP = methylprednisolone
pCMAP  = proximal compound muscle acti on potenti al
PE  = plasma exchange 
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PGP 9.5 = protein gene product 9.5
RCT  = randomised controlled trial
RSV  = respiratory syncyti al virus 
TRF  = treatment related fl uctuati on
SBP  = systolic blood pressure
SIDP = subacute infl ammatory demyelinati ng polyneuropathy
SNAP = sensory nerve acti on potenti al
sNCV = sensory nerve conducti on velocity
TLi = terminal latency index
TRF = treatment related fl uctuati on
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Februari 2002, ik weet het nog goed, mijn begin als arts-assistent Neurologie op de 
afdeling 6 Noord in het Erasmus MC in Rott erdam. Naast Neuroloog worden, wilde ik ook 
graag onderzoek doen. Al snel had ik een goed gevoel bij de GBS onderzoeksgroep en 
het onderzoek wat daar mogelijk was. Dat gevoel bleek wederzijds. Nu, acht jaar later 
heb ik mijn promoti eonderzoek afgerond. In het vaak meest gelezen onderdeel van het 
proefschrift  wil ik vele pati ënten, familieleden, vrienden en collega’s bedanken. Want 
zonder hen was het niet mogelijk geweest het promoti eonderzoek tot een goed einde 
te brengen. Ik kan niet genoeg benadrukken hoe dankbaar ik hiervoor ben. Een aantal 
mensen wil ik graag persoonlijk noemen, waarbij ik me besef nooit volledig te kunnen zijn. 
Deelnemende Guillain-Barré pati ënten en controlepersonen
Op de eerste plaats wil ik alle pati ënten en controlepersonen bedanken voor hun deelname 
aan het GBS onderzoek. Dankzij hen is het mogelijk geweest het GBS onderzoek weer een 
stapje verder te brengen. Bij heel veel Rott erdamse GBS pati ënten heb ik wekelijks aan 
het bed gestaan om onder andere de vragenlijsten voor de GRAPH studie af te nemen. 
De plotselinge afh ankelijkheid, het machteloze gevoel, de pijn, de angst hoe het verdere 
beloop zou zijn, het verdriet en de frustrati es maakte ik hierdoor van dichtbij mee. Meer 
en meer respect kreeg ik voor jullie doorzetti  ngsvermogen. Jullie moti veerden me om 
meer te weten te komen over deze plotseling optredende ziekte met zijn diversiteit aan 
klachten en beloop. Dank jullie wel, jullie verhalen zullen me alti jd bijblijven! 
Deelnemende centra GRAPH studie
Zonder de neurologen en arts-assistenten uit de 55 deelnemende ziekenhuizen was de 
GRAPH studie nooit een succes geworden. Bedankt voor jullie inzet de afgelopen jaren. 
Daarnaast wil ik alle onderzoeksassistenten, verpleegkundigen en secretaressen die ons 
hierin hebben bijgestaan bedanken voor hun hulp.
Prof. dr. Pieter A. van Doorn | Promotor
Beste Pieter, in 2001 zat je in m’n sollicitati ecommissie, in 2010 ben je de promotor van 
m’n promoti ecommissie. Kort nadat ik deel uitmaakte van de GBS onderzoeksgroep, 
gingen we met de gehele GBS onderzoeksgroep op congres in Canada. Tijdens dat congres 
hebben we elkaar direct goed leren kennen. Het was voor mij een bevesti ging dat ik de 
juiste keus had gemaakt te starten met promoti eonderzoek onder jouw begeleiding. 
Jouw enthousiasme en betrokkenheid bij het GBS onderzoek hebben voor mij alti jd zeer 
moti verend gewerkt. Op wetenschappelijk gebied heb ik erg veel van je geleerd. Ook heb 
je me heel veel bijgebracht van de neurologie en in het bijzonder van de neuromusculaire 
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ziekten. Je stond steeds open voor ideeën en verleende ook alti jd alle medewerking, 
ondanks je vaak overvolle agenda. Naast promotor ben ik je enorm gaan waarderen als 
mens. Elke keer toon je oprechte interesse ook in het leven buiten het onderzoek. Het is 
erg pretti  g om op een informele en open manier met je te kunnen praten. We hebben ook 
veel gelachen. Eén van die hilarische momenten was dat we samen op krukken langs de 
pati ënten gingen. Je kracht om aan de ene kant wetenschappelijk het maximale uit me 
te halen en aan de andere kant even bij te praten over van alles en nog wat, maken jou 
in mijn ogen een hele unieke ‘baas’. Daarnaast heb ik bijzonder veel waardering voor de 
manier waarop jij meewerkt aan het groepsgevoel binnen de GBS onderzoeksgroep. Wat 
er ook ondernomen wordt binnen de groep, jij bent van de parti j. Sterker nog, jij neemt 
vaak ook het initi ati ef om er wederom een geslaagde dag, avond of nacht van te maken 
ti jdens congressen, ‘vergaderingen te water’ of andere uitjes. Bedankt en ik hoop je nog 
vaak te zien!
Bart Jacobs, Pieter van Doorn, Judith Drenthen, Marcel Garssen, Karin Geleijns, 
Rinske van Koningsveld, Mark Kuijf, Krista Kuitwaard, Ellen Maathuis, Sonia van 
Nes, Christa Walgaard, Marti ne Bos Eyssen | GBS onderzoeksgroep
GBS onderzoekers, jullie input en suggesti es bij de vele besprekingen en de gezamenlijke 
arti kelen die we hebben geschreven, hebben mede geleid tot dit proefschrift . Bart, jou 
wil ik hiervoor in het bijzonder bedanken. Jij wist elke keer weer tot de kern van te zaak 
te komen. Dat er met jou ook andere discussies te voeren waren, bijvoorbeeld over 
‘een berenbel’, was een plezierige afwisseling. Ik waardeer het zeer dat jij deel uitmaakt 
van m’n promoti ecommissie. Judith, Rinske, Mark, Krista, Sonia en Christa, ti jdens m’n 
vakanti es waren jullie alti jd bereid de GBS telefoon over te nemen en GBS pati ënten te 
includeren in de GRAPH studie, dank je wel. De koffi  e, taart, lunch en borrel-breaks op 
de 22e, zorgden alti jd voor de benodigde ontspanning. De congressen die we met elkaar 
bezocht hebben zal ik nooit vergeten. In het bijzonder heb ik mooie herinneringen aan 
de gletsjerbeklimming en het kanogevecht in Canada. In Barcelona zal ik de Carpe Diem 
Lounge Club nooit vergeten. Pisa, in het mooie Italië, wat hebben we gelachen. Na het 
congres in Utah gingen Karin, Sonia, Pieter en ik op pad richti ng de Rocky Mountains. De 
liedjes van Bruce onderweg, de zware beklimming in Bryce en de welverdiende afk oeling 
in Zion, stuk voor stuk onvergetelijke herinneringen. En tot slot niet te vergeten onze 
diverse avontuurlijke, culinaire zeiltochten. Bedankt voor alles en ik hoop jullie nog vaak 
tegen te komen!
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Dr. Giuseppe Lauria, Francesca Camozzi, Raff aella Lombardi | Nati onal Neurological 
Insti tute ‘Carlo Besta’ (Italië)
Dear Giuseppe, in 2005 we met at the PNS congress in Pisa and started to talk about 
Milan. What a coincidence that you knew some people I worked with during my training 
period in Milan in 1997. In Pisa the skin biopsy project for the GRAPH study started. As 
‘skin-biopsy hero’, you provided the knowledge and all faciliti es to set up the skin biopsy 
part in Rott erdam. Also you supported me with the arti cle and thesis. Aft er the congress 
in Pisa, many congresses followed. We have had a lot of fun and I greatly appreciate that 
you are member of my PhD committ ee. In 2006, I visited your lab in Milan. Francesca 
and Raff aella, you showed me the whole work-up from biopsy to density. Thanks for your 
explanati on, counti ng, fun and lovely espressos! Recent years, many frozen biopsies have 
travelled the road Rott erdam – Milano. Aft er visiti ng the lab and meeti ng you all, I know 
the biopsies are in good hands. Grazie!
Prof. dr. Gert J. van Dijk, Prof. dr. Rogier Q. Hintzen, Prof. dr. Peter A.E. Sillevis Smitt  
| Leden van de promoti ecommissie
Beste professor van Dijk, hartelijk dank voor het kriti sch doorlezen van mijn manuscript 
en het plaatsnemen in de kleine commissie. Beste Rogier, als MS-goeroe had jij vanuit 
een andere hoek input op de neuro-immunologie besprekingen. Dat zorgde vaak voor net 
weer even een andere kijk op de zaak. Daarnaast was het gewoon alti jd erg gezellig! Dank 
je wel dat je deel uitmaakt van m’n promoti ecommissie. Beste Peter, het grootste deel 
van m’n neurologie opleiding ben jij de opleider geweest. Ik heb veel van je geleerd in de 
kliniek waarvoor ik je wil bedanken. Eén van onze eerste en ook onze laatste gesprekken 
in het Erasmus MC gingen onder andere over een wereldreis. Ik ben je meer dan dankbaar 
dat je openstond om de mogelijkheden hiervoor te bekijken. Ook wil ik je bedanken voor 
de betrokkenheid bij m’n nieuwe baan in het Havenziekenhuis. Ik waardeer het zeer dat 
je deel uitmaakt van m’n promoti ecommissie, en dank dat je ook de secretaris wilde zijn 
van de kleine commissie. 
Rita de Kimpe | Research coördinator
Het opzett en en draaiende houden van de GRAPH studie was een hele klus. Mede dankzij 
jouw hulp liep de logisti ek uiteindelijk gesmeerd. Jij had het overzicht en zorgde ervoor 
dat alle gegevens binnenkwamen. Ik ben je heel erg dankbaar voor al het werk dat je 
me uit handen hebt genomen. Als jij ergens je tanden in zett e, ging je er ook voor. Ik 
zal nooit vergeten dat we onze, in jaren verzamelde, huidbiopten op luchtt ransport naar 
Milaan hadden gezet via Nederlands grootste postbedrijf. Wat bleek…, de doos met de 
ingevroren huidbiopten had het vliegtuig gemist. Waar ze nu dan waren en of ze niet 
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zouden ontdooien, was onbekend. Jij pakte de telefoon en zocht alles piekfi jn uit. Eind 
goed, al goed, bedankt!
Cisca Peters | Neuromusculair vepleegkundige 
Lieve Cisca, samen hebben we vele GBS pati ënten op de poli gezien. Het afnemen van de 
huidbiopten, de bloeddrukmeti ngen, jij stond alti jd klaar om te helpen en bleef vooral 
ook rusti g als we de bloeddrukmeter weer eens niet aan de praat kregen. Hiervoor wil 
ik je bedanken. Ook ben ik je dankbaar voor de mooie gesprekken die we hadden. Ik heb 
respect voor datgene wat je allemaal doet binnen, maar zeker ook buiten het Erasmus MC!
Anne Tio, Wouter van Rijs | Afdeling Immunologie
Beste Anne en Wouter, jullie wil ik bedanken voor de bepalingen en opslag van de 
honderden bloed- en liquormonsters. Jullie waren alti jd bereid mee te denken en de 
terugkoppeling wanneer er monsters misten, liep gesmeerd. Mede dankzij jullie was er 
zo’n hoge opbrengst, dank jullie wel!
Dr. Joost L. Jongen, Elize Haasdijk, Dr. Joan C. Holstege, Prof. dr. Chris I. de Zeeuw | 
Afdeling Neurologie en Neurowetenschappen
Beste Joost, met het pijnonderzoek had jij al heel wat ervaring op de afdeling 
Neurowetenschappen. Met veel enthousiasme was je alti jd bereid mee te denken over 
en input te leveren aan het pijnonderzoek bij GBS. Naast een goede ‘pijnraadgever’, vind 
ik je een fantasti sch skiër. We hebben veel plezier gehad ti jdens de vele Babinski-reisjes. 
In 2005 maakten Pieter en ik een afspraak met Chris en Joan, met de vraag of we konden 
samenwerken op het gebied van pijn en huidbiopten. Hartelijk dank dat dit mogelijk was.
Elize, jij was de reddende engel toen we het huidbiopten project daadwerkelijk wilden 
gaan starten in het Erasmus MC. Wij hadden de wens, jij de spullen en de techniek. Door 
jouw hulp is het gelukt. Alti jd was je vrolijk, behulpzaam en bereid medium klaar te zett en 
en de biopten op te slaan. Voor de diverse transporten naar Milaan, was jij degene die 
zorgde voor een goede verzendbox met alle biopten op droogijs. Bedankt voor alles!
Dr. Roelie J. Hempel, Dr. Hugo G. van Steenis, Dr. Joke H.M. Tulen | Afdeling Psychiatrie
Beste Joke, Hugo en Roelie, de bloeddrukmeti ng en de spectraal analyse, voor jullie 
dagelijkse kost, voor mij in het begin één groot raadsel. Jullie hebben me de afgelopen 
jaren op een zeer pretti  ge manier geholpen. Allereerst, de spullen die nodig waren voor 
de autonome meti ngen. Hartelijk dank voor het lenen. Daarnaast de uitleg en de hulp als 
ik het apparaat weer eens niet aan de praat kreeg. Jullie waren alti jd bereid mee te helpen 
en mee te denken. Tenslott e de analyses, Roelie heel erg bedankt dat je dit wilde doen. 
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Dr. Anton H. van den Meiracker, Arnold Birkenhager | Afdeling Interne
Beste Ton, dank je wel voor de mogelijkheid om de spullen voor de bloeddrukmeti ng 
te lenen en mij op weg te helpen in de autonome wereld. Je manier van uitleggen 
was erg pretti  g en verhelderend. Ik waardeer het zeer dat jij deel uitmaakt van m’n 
promoti ecommissie. Beste Arnold, ik hoefde maar te bellen of te mailen en ik kon de 
spullen voor de bloeddrukmeti ng ophalen. Heel erg fi jn. Ik vond het jammer te horen dat 
je uiteindelijk een andere weg bent ingeslagen. Ik hoop dat het goed met je gaat!
Dr. Gerhard H. Visser, Judith Drenthen, Ellen Maathuis, Jannie en Michiel de KNF 
laboranten, Magda en Monique van het secretariaat, Dr. Joseph C. Perumpillichira, Dr. 
Joleen H. Blok, Ruud Veldhuizen | Afdeling KNF
Beste Gerhard, hartelijk dank voor het mede mogelijk maken van de vele EMG’s op de 
afdeling KNF en de verhelderende overlegmomenten. Het bouwen van een EMG database 
was een hele klus, zeker als er ijs lag, maar het is gelukt! Gerhard, Joseph, Ellen en Judith, 
heel wat studiepati ënten hebben jullie gemeten, dank je wel. Judith in het bijzonder wil ik 
bedanken voor het (her)beoordelen van alle GRAPH EMGs en de pretti  ge samenwerking. 
De KNF laboranten, Jannie en Michiel, wil ik bedanken voor de gezellige meetsessies en 
het invoeren van de EMG data in de database. Het secretariaat van de KNF en Ruud wil 
ik bedanken voor het kunnen plannen (en vaak weer verzett en) van de GRAPH pati ënten. 
Prof. dr. Gerard J.J. van Doornum, Dr. Hubert P. Endtz, Dr. Peggy C.R. Godschalk, 
Rogier Louwen, Ad Luijendijk, Machteld van Rede, Cobi Kerkhof, Sandra Scherbeijn  | 
Afdeling Medische Microbiologie en Virologie
De baliemedewerkers van de afdeling Medische Microbiologie en Virologie wil ik 
bedanken voor het in ontvangst nemen en verwerken van de honderden kweekmonsters.
Beste Gerard, jij zorgde er samen met Sandra voor dat de virologische bepalingen en 
interpretati es op ti jd af waren, dank je wel! Je rusti ge manier van uitleggen, waardeerde 
ik zeer. Veel dank dat je deel uitmaakt van m’n promoti ecommissie. Beste Hubert, Peggy 
en Rogier, ook voor de GRAPH studie werd er weer gezocht naar de campy. Bedankt voor 
de pretti  ge samenwerking. Ad, bedankt voor het verzorgen van de talloze studiemapjes. 
Dr. Wim C.J. Hop | Stati sti cus
Beste Wim, met behulp van de repeated measurements wist jij alle data van de GRAPH 
studie te gebruiken. Hartelijk dank voor de pretti  ge overlegmomenten, je hulp en je uitleg. 
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Dr. Ingemar S.J. Merkies | Spaarne Ziekenhuis
Roberto E. Rico, Juan David Botero, secretariaat| Sint Elisabeth Hospitaal (Curaçao)
Izzy Gerstenbluth | GGD (Curaçao)
Beste Ingemar, dankzij jou was het mogelijk naar Curaçao te gaan voor het GBS onderzoek. 
Hier ben ik je erg dankbaar voor. Je lieve familie zorgde voor een warm welkom en 
onderkomen. Ook wil ik je bedanken voor je begeleiding in de beginti jd van m’n onderzoek. 
Beste Roberto, dank voor de mogelijkheid langs te komen en me opweg te helpen in 
het Sint Elisabeth Hospitaal om het GBS onderzoek voort te zett en. Het secretariaat 
hielp me de statussen bij elkaar te zoeken, hartelijk dank. Beste Juan, bedankt voor het 
meehelpen en nasturen van de GBS gegevens. Beste Izzy, bedankt voor je uitleg over de 
regenstati sti eken van het eiland en het nutti  ge werk wat je doet bij de GGD. Later heb je 
me nog allerlei GBS gegevens toegestuurd, dank je wel. Twee weken Curaçao waren twee 
onvergetelijke weken. 
Patricia Blomkwist, Eimbert van de Oet | Vereniging Spierziekten Nederland
Beste Patricia en Eimbert, als geen ander weten jullie wat GBS pati ënten doormaken en 
hoe ze een hart onder de riem te steken. Patricia, ik ben je heel erg dankbaar dat ik je elke 
keer weer kon bellen om de GBS pati ënten in het Eramus MC te bezoeken. Daarnaast heb 
ik grote waardering voor de jaarlijkse organisati e van de GBS pati ëntendag. 
Lourens van Briemen, Kris Sieradzan | Computerhelden
Beste Lourens, dankzij jouw hulp werkte mijn computer en had ik die programma’s die ik 
nodig had. Je was alti jd bereid om een handje te helpen, dank je wel! Beste Kris, uren en 
uren zijn erin gaan zitt en om al die vragenlijsten voor de GRAPH te ontwerpen in teleform. 
Heel wat discussies hebben we gevoerd of het nu zus of zo moest. Gelukkig was er alti jd 
die heerlijke espresso. Dank je wel.
Arjenne, Bett y, Caroline, Claudia, Elles, Erna, Isabel, Jacqueline, Joram, Legisa, 
Marja, Minah | Secretariaat 
Beste Arjenne, jou wil ik bedanken voor allerlei regeldingen. Je was elke keer bereid om 
even te helpen. Bij jou was het papierwerk in goede handen. Het ga je goed. Bett y wil ik 
bedanken voor het inplannen (en regelmati g ook weer verzett en) van de afspraken voor 
de GBS pati ënten. Even binnenlopen voor een vraag of een praatje, het kon alti jd. Beste 
Minah, jij deed alti jd weer de moeite om wensen voor onderzoeksti jd, congresbezoek en 
niet te vergeten vakanti es in te plannen. Dank je wel. Beste Erna, dank je wel voor je 
interesse en het doorsturen van de post. De secretaresses van de polikliniek neurologie wil 
ik bedanken voor het klaarzett en van de benodigde spullen, het opzoeken van de statussen 
en de pretti  ge werksfeer op de poli. 
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Alcidia, Alja, Chantale, Joyce, Magda, Marjolein, Nathalie | Doktersassistenten
De doktersassistenten wil ik bedanken voor het afnemen en wegbrengen van de vele 
buisjes bloed, het aanvullen van de benodigde spullen en de pretti  ge samenwerking. 
Verpleging van de afdeling Neurologie en Intensive Care
De verpleging wil ik bedanken voor de goede zorg voor de pati ënten, het afnemen en 
wegbrengen van de kweken en de fi jne werksfeer op de afdeling. 
Nadine van der Beek, Janet de Beukelaar, Eric van Breda, Maaike Dirks, Laura Donker 
Kaat, Puck Franssen, Mary-Lou van Goor, Marloes Hagemans, Heleen den Hartog, 
Ilse Hoppenbrouwers, Nagmeh Jafari, Immy Ketelslegers, Ladbon Khajeh, Alex 
Korsten, Lisett e Maasland, Bas ter Meulen, Karin ter Meulen, Rinze Neuteboom, 
Niels Prins, Sonia Rosso, Maaike Schuur, Harro Seelaar, Juna de Vries, Annemarie 
Wijnhoud, Marie-Claire de Wit | Overige collega’s uit ‘de witt e toren’
Alle collega’s van de hoogbouw wil ik hartelijk bedanken voor de goede ti jd op de 22e. 
Naast jullie interesse wil ik jullie bedanken voor de ontspannende koffi  e-breaks. Nadine, 
Janet, Ilse, Naghmeh, Immy, Rinze en Juna, heel wat nutti  ge, maar zeker ook gezellige 
neuro-immunologie besprekingen of avondjes hebben we de afgelopen jaren gehad samen 
met de GBS onderzoekers, dank jullie wel. Bas, samen begonnen we in 2002 op afdeling 
6 Noord en later ook op de 22e. Je was een fi jne collega. Niels, de salsa lessen zorgden 
voor een swingende ontspanning. Juna en Ladbon, wat leuk dat jullie uiteindelijk toch 
in Rott erdam zijn komen werken. Ilse en Bregje, ik hoop dat onze etentjes nog lang door 
blijven gaan. Harro, m’n kleine buurjongen van vroeger, leuk je weer te ontmoeten op de 
22e. Iedereen van de boekenclub, het waren mooie avonden. Marloes, jij hebt me wegwijs 
gemaakt in de repeated measurements, hartelijk dank hiervoor. Alle arts-assistenten en 
neurologen van de afdeling Neurologie die ik niet persoonlijk heb genoemd, bedankt voor 
de pretti  ge samenwerking en alles wat ik van jullie heb geleerd!
Maarten Liedorp, Sonia Rosso, Annemarie Wijnhoud en alle andere collega’s | 
Havenziekenhuis
1-1-2010 ben ik begonnen als Neuroloog in het Havenziekenhuis. Johan Dorresteijn 
en Ineke Leenders, dank voor jullie overtuigingskracht en aanstekelijk enthousiasme. 
Maarten en Sonia, het is toch heel bijzonder dat we allemaal zo ongeveer tegelijk gestart 
zijn in het Havenziekenhuis, we maken er iets moois van! Annemarie, heel veel succes in 
het IJsselland Ziekenhuis, we komen elkaar vast weer tegen. Collega’s van de poli, KNF en 
afdeling Neurologie, eerste hulp en alle andere afdelingen, dank voor de nu al pretti  ge 
samenwerking. Ik hoop nog vele jaren te werken in dit pretti  ge, pati ëntgerichte, zorgzame 
ziekenhuis! 
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Van Rott erdam tot Milaan | Mijn vrienden
Lieve vrienden, bedankt voor jullie vriendschap! Ook al hebben we elkaar niet veel gezien 
het afgelopen jaar, ik wist dat jullie er waren. Jullie zijn voor mij zeer waardevol! Iederéén 
bedanken is helaas niet mogelijk, toch ook een paar persoonlijke woorden van dank.
Ingrid, Lianne, Mirella, Saskia en Willeke, ieder via haar eigen weg begonnen we 
uiteindelijk samen aan de studie Geneeskunde in Utrecht. Onze gesprekken begonnen 
bij de koffi  eautomaat in het voormalige AZU. Door de jaren heen is onze band sterker en 
sterker geworden. Dank voor jullie vriendschap. Dat de bijzondere momenten met z’n 
allen nog heel lang mogen doorgaan! Lieve Lianne, we waren ook huisgenoten en zijn 
ongeveer tegelijk het promoti etraject ingestapt. Heel wat hebben we de afgelopen jaren 
gedeeld met elkaar. Samen door de dalen en samen naar ‘de top’. Dat we dit jaar elkaars 
paranimf zijn, vind ik erg bijzonder. Bedankt voor alles en ‘to be conti nued’! Annemieke, 
Els, Evelien, Ingrid en Janneke, deels op dezelfde middelbare school en vervolgens samen 
gaan studeren. Wat heerlijk dat jullie niet in de medische hoek zijn beland. Bedankt voor 
de mooie vriendschap. Dear Veronica, I will never forget our very special ti mes in Milano.
Stefan en Kathalijne, onze vriendschap begon in Rott erdam, inmiddels zijn jullie verhuisd 
en wonen jullie helaas niet meer in de buurt. Dank voor de mooie gesprekken over het 
leven en hoe deze zijn weg kan gaan. Stefan, fantasti sch dat je met ZZESTO mee wilde 
denken en werken aan het ontwerp voor de kaft  van dit boekje samen met je collega 
Hendrik. Het is prachti g geworden, dank jullie wel! Elise, Ilse en Bregje, met jullie heb ik 
heel wat gesport en vooral ook heerlijk gegeten. Dank voor de gezellige, relati verende 
ontspanning! Amanda, het is toch een giller hoe parallel onze levens lopen en onze wegen 
elkaar elke keer weer kruisen, leuk! Vrienden uit Brabant, ook al zal ik nooit een echte 
Brabander worden, het is alti jd erg gezellig om ‘onder de rivieren’ te zijn, bedankt!
 
Hennie, Toon, Meike, Jasper en Karin | Mijn ‘schoonfamilie’
Hennie en Toon, bedankt voor het alti jd welkom zijn op de Kivitslaan, jullie goede hulp 
om alles draaiende te houden in drukke ti jden en jullie inspanning om met regelmaat er 
op uit te gaan met z’n allen, erg fi jn! Meike, bedankt voor je gezelligheid, je vrolijkheid, je 
att entheid en je warmte. Te grappig dat jij mee ging helpen om Babinski te organiseren en 
dat ik samen met jou en m’n collega’s heb geskied. Dat skiën hebben we sowieso heel wat 
jaren gedaan. Jij ging alti jd sneller, maar dat mocht de pret niet drukken. Jasper en Karin, 
ti jdens de weekendjes en etentjes hebben we het alti jd erg naar ons zin, bedankt hiervoor. 
Papa, mama, Jan Willem en Charlott e | Mijn familie
Lieve papa en mama, Wat ben ik een gelukkig mens dat jullie mijn ouders zijn. Met 
onbeschrijfb aar veel liefde, geborgenheid, zorgzaamheid en vertouwen ben ik opgegroeid. 
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Alti jd hebben jullie mij gesteund in de keuzes die ik in mijn leven maakte. De adviezen die 
jullie mij daarin gaven waren: doe datgene waar je hart ligt en waar je lol in hebt. Dat heeft  
mij gebracht tot waar ik nu sta in mijn werk, maar zeker ook privé. Jullie bevonden je niet 
alti jd naast de deur. Maar waar ook ter wereld, voor mijn gevoel waren jullie alti jd dichtbij. 
Sowieso, en het laatste jaar in het bijzonder, hebben jullie klaar gestaan om te helpen. 
Zonder jullie hulp was het niet mogelijk de afronding van mijn proefschrift , mijn nieuwe 
baan als Neuroloog en het moeder zijn te combineren. Dank, dank, dank!  
Lieve Jan Willem, je bent een kanjer van een broer, van wie ik ongelofelijk veel hou. Ik vind 
het dan ook geweldig dat je mij terzijde wil staan ti jdens m’n promoti e. Ook ben je nauw 
betrokken geweest bij het Guillain-Barré onderzoek. Dagen heb je op de 22e vragenlijsten 
geprint voor de GRAPH studie. Toen ik voor het Guillain-Barré onderzoek naar Curaçao 
ging, kwam jij me opzoeken. Jij was 5, ik 15, toen we al het plan hadden gemaakt om 
ooit een keer samen naar Curaçao te gaan. Toen Pieter mij in 2005 vertelde dat ik voor 
het Guillain-Barré onderzoek naar Curaçao mocht gaan, was jij dan ook de eerste die ik 
belde om mee te gaan. Jij bent zelfs verknocht geraakt aan het eiland en woont er nu. 
Ook hebben we samen de huidbiopten naar Milaan gebracht. Op de terugweg sloegen 
we nog even rechtsaf om een weekendje te kunnen skiën. De weg Rott erdam – Milaan 
heb jij nog meerdere keren gereden met een box bevroren huidbiopten in de achterbak. 
Onder andere een keer met Charlott e, inmiddels je grote liefde. Lieve Charlott e, ik ben 
heel erg blij dat jij bij onze familie bent gekomen. Bedankt voor je gezelligheid, warmte 
en heerlijke koken. Nu samen met Jan Willem op Curaçao, fantasti sch dat jullie dit samen 
hebben ondernomen! 
Lieve familie, we go far, we see the world, but we don’t forget where we come from! Ik 
hou van jullie, grenzeloos veel.
Remko Sanders | Mijn grote liefde
Allerliefste Remko, ik ben je zo ongelofelijk dankbaar voor alles wat jij het afgelopen 
jaar op je hebt genomen om het promoveren te laten slagen. Kort nadat ons prachti g, 
lieve mannetje Abe geboren werd, begon de ‘eindsprint’ voor het proefschrift . Alles 
combineren leek een onmogelijke klus. Maar het was juist de combinati e die ervoor zorgde 
dat de wil er was de klus te klaren. Jij hebt hier een heel belangrijke rol in gespeeld. Ik heb 
heel veel bewondering voor hoe jij elke keer weer met je enthousiasme, zorgzaamheid, 
energie en liefde alles draaiende hield. Jij creëerde thuis enerzijds de rust en ti jd om te 
kunnen werken in de avonduren en weekenden, anderzijds zorgde je voor de ‘quality ti me’ 
met Abe en elkaar waardoor het lukte om ‘het schema’ vol te houden. Hiervoor heb je heel 
veel opzij gezet en gegeven. Ook fi etste je tussendoor nog even zes keer de Alpe d’Huez op 
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en neer in één dag voor het goede doel. Een klein voorbeeld om aan te geven hoe uniek ik 
je vind. Jij staat ergens voor, gaat ergens voor en leeft  bewust het leven! Jouw ‘zijn’, geeft  
ons balans. Onze balans, geeft  onze dromen. Onze dromen, geven ons leven. Lief, de reis 
door het leven met jou is prachti g mooi, en die mag van mij oneindig lang duren. Vanaf nu 
ook weer buiten de Wilhelminalaan!
ABE | Mijn alles 
Lieve Abe,  zo klein als je bent, zo groot is jouw rol geweest bij de afronding van dit proefschrift . 
Op de dag dat ik de inclusie voor de GRAPH studie stopzett e, vond jij het ti jd worden om 
geboren te worden. De clichés zijn waar: een wonder, een verrijking, een onvoorwaardelijk 
gevoel van liefde! Jouw tevredenheid, rust en regelmaat, zorgden voor mijn tevredenheid, 
rust en regelmaat. Je bent een heerlijk mannetje, voor wie ik de omvang van ‘houden van’ 
niet in woorden kan omschrijven. Wat is het toch fi jn dat jij er bent!
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